id	sid	tid	token	lemma	pos
ajcp-1612	1	1	pa	pa	PROPN
ajcp-1612	1	2	ge	ge	PROPN
ajcp-1612	1	3	1	1	NUM
ajcp-1612	1	4	pa	pa	PROPN
ajcp-1612	1	5	ge	ge	PROPN
ajcp-1612	1	6	9	9	NUM
ajcp-1612	1	7	american	american	PROPN
ajcp-1612	1	8	journal	journal	PROPN
ajcp-1612	1	9	of	of	ADP
ajcp-1612	1	10	chemistry	chemistry	NOUN
ajcp-1612	1	11	and	and	CCONJ
ajcp-1612	1	12	pharmacy	pharmacy	NOUN
ajcp-1612	1	13	(	(	PUNCT
ajcp-1612	1	14	ajcp	ajcp	NOUN
ajcp-1612	1	15	)	)	PUNCT
ajcp-1612	1	16	diabetes	diabetes	NOUN
ajcp-1612	1	17	mellitus	mellitus	NOUN
ajcp-1612	1	18	control	control	PROPN
ajcp-1612	1	19	and	and	CCONJ
ajcp-1612	1	20	chronic	chronic	ADJ
ajcp-1612	1	21	kidney	kidney	NOUN
ajcp-1612	1	22	disease	disease	NOUN
ajcp-1612	1	23	safaa	safaa	NOUN
ajcp-1612	1	24	mohamed	mohame	VERB
ajcp-1612	1	25	matarid1	matarid1	PROPN
ajcp-1612	1	26	*	*	PUNCT
ajcp-1612	1	27	volume	volume	NOUN
ajcp-1612	1	28	2	2	NUM
ajcp-1612	1	29	issue	issue	NOUN
ajcp-1612	1	30	2	2	NUM
ajcp-1612	1	31	,	,	PUNCT
ajcp-1612	1	32	year	year	NOUN
ajcp-1612	1	33	2023	2023	NUM
ajcp-1612	1	34	issn	issn	X
ajcp-1612	1	35	:	:	PUNCT
ajcp-1612	1	36	2834	2834	NUM
ajcp-1612	1	37	-	-	SYM
ajcp-1612	1	38	0116	0116	NUM
ajcp-1612	1	39	(	(	PUNCT
ajcp-1612	1	40	online	online	ADJ
ajcp-1612	1	41	)	)	PUNCT
ajcp-1612	1	42	doi	doi	NOUN
ajcp-1612	1	43	:	:	PUNCT
ajcp-1612	1	44	https://doi.org/10.54536/ajcp.v2i2.1612	https://doi.org/10.54536/ajcp.v2i2.1612	PROPN
ajcp-1612	1	45	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	1	46	article	article	NOUN
ajcp-1612	1	47	information	information	NOUN
ajcp-1612	1	48	abstract	abstract	ADV
ajcp-1612	1	49	received	receive	VERB
ajcp-1612	1	50	:	:	PUNCT
ajcp-1612	1	51	april	april	PROPN
ajcp-1612	1	52	16	16	NUM
ajcp-1612	1	53	,	,	PUNCT
ajcp-1612	1	54	2023	2023	NUM
ajcp-1612	1	55	accepted	accept	VERB
ajcp-1612	1	56	:	:	PUNCT
ajcp-1612	1	57	may	may	AUX
ajcp-1612	1	58	08	08	NUM
ajcp-1612	1	59	,	,	PUNCT
ajcp-1612	1	60	2023	2023	NUM
ajcp-1612	1	61	published	publish	VERB
ajcp-1612	1	62	:	:	PUNCT
ajcp-1612	1	63	may	may	AUX
ajcp-1612	1	64	13	13	NUM
ajcp-1612	1	65	,	,	PUNCT
ajcp-1612	1	66	2023	2023	NUM
ajcp-1612	1	67	chronic	chronic	ADJ
ajcp-1612	1	68	kidney	kidney	NOUN
ajcp-1612	1	69	disease	disease	NOUN
ajcp-1612	1	70	(	(	PUNCT
ajcp-1612	1	71	ckd	ckd	NOUN
ajcp-1612	1	72	)	)	PUNCT
ajcp-1612	1	73	is	be	AUX
ajcp-1612	1	74	the	the	DET
ajcp-1612	1	75	rampant	rampant	ADJ
ajcp-1612	1	76	onset	onset	NOUN
ajcp-1612	1	77	of	of	ADP
ajcp-1612	1	78	diabetes	diabetes	NOUN
ajcp-1612	1	79	and	and	CCONJ
ajcp-1612	1	80	related	related	ADJ
ajcp-1612	1	81	complications	complication	NOUN
ajcp-1612	1	82	;	;	PUNCT
ajcp-1612	1	83	chronic	chronic	ADJ
ajcp-1612	1	84	kidney	kidney	NOUN
ajcp-1612	1	85	disorders	disorder	NOUN
ajcp-1612	1	86	and	and	CCONJ
ajcp-1612	1	87	end	end	NOUN
ajcp-1612	1	88	-	-	PUNCT
ajcp-1612	1	89	stage	stage	NOUN
ajcp-1612	1	90	renal	renal	ADJ
ajcp-1612	1	91	disease	disease	NOUN
ajcp-1612	1	92	are	be	AUX
ajcp-1612	1	93	progressing	progress	VERB
ajcp-1612	1	94	in	in	ADP
ajcp-1612	1	95	more	more	ADJ
ajcp-1612	1	96	than	than	ADP
ajcp-1612	1	97	10	10	NUM
ajcp-1612	1	98	%	%	NOUN
ajcp-1612	1	99	of	of	ADP
ajcp-1612	1	100	the	the	DET
ajcp-1612	1	101	world	world	NOUN
ajcp-1612	1	102	population	population	NOUN
ajcp-1612	1	103	and	and	CCONJ
ajcp-1612	1	104	mostly	mostly	ADV
ajcp-1612	1	105	affect	affect	VERB
ajcp-1612	1	106	the	the	DET
ajcp-1612	1	107	elderly	elderly	ADJ
ajcp-1612	1	108	,	,	PUNCT
ajcp-1612	1	109	women	woman	NOUN
ajcp-1612	1	110	,	,	PUNCT
ajcp-1612	1	111	minorities	minority	NOUN
ajcp-1612	1	112	and	and	CCONJ
ajcp-1612	1	113	patients	patient	NOUN
ajcp-1612	1	114	with	with	ADP
ajcp-1612	1	115	diabetes	diabetes	NOUN
ajcp-1612	1	116	and	and	CCONJ
ajcp-1612	1	117	hypersensitivity	hypersensitivity	NOUN
ajcp-1612	1	118	.	.	PUNCT
ajcp-1612	2	1	the	the	DET
ajcp-1612	2	2	early	early	ADJ
ajcp-1612	2	3	stages	stage	NOUN
ajcp-1612	2	4	of	of	ADP
ajcp-1612	2	5	ckd	ckd	PROPN
ajcp-1612	2	6	are	be	AUX
ajcp-1612	2	7	typically	typically	ADV
ajcp-1612	2	8	quiet	quiet	ADJ
ajcp-1612	2	9	;	;	PUNCT
ajcp-1612	2	10	thus	thus	ADV
ajcp-1612	2	11	,	,	PUNCT
ajcp-1612	2	12	many	many	ADJ
ajcp-1612	2	13	people	people	NOUN
ajcp-1612	2	14	are	be	AUX
ajcp-1612	2	15	unaware	unaware	ADJ
ajcp-1612	2	16	they	they	PRON
ajcp-1612	2	17	have	have	VERB
ajcp-1612	2	18	the	the	DET
ajcp-1612	2	19	condition	condition	NOUN
ajcp-1612	2	20	.	.	PUNCT
ajcp-1612	3	1	data	datum	NOUN
ajcp-1612	3	2	for	for	ADP
ajcp-1612	3	3	this	this	DET
ajcp-1612	3	4	review	review	NOUN
ajcp-1612	3	5	was	be	AUX
ajcp-1612	3	6	gathered	gather	VERB
ajcp-1612	3	7	from	from	ADP
ajcp-1612	3	8	google	google	PROPN
ajcp-1612	3	9	scholar	scholar	NOUN
ajcp-1612	3	10	,	,	PUNCT
ajcp-1612	3	11	scopus	scopus	PROPN
ajcp-1612	3	12	,	,	PUNCT
ajcp-1612	3	13	pubmed	pubmed	PROPN
ajcp-1612	3	14	,	,	PUNCT
ajcp-1612	3	15	elsevier	elsevier	PROPN
ajcp-1612	3	16	,	,	PUNCT
ajcp-1612	3	17	cochrane	cochrane	PROPN
ajcp-1612	3	18	,	,	PUNCT
ajcp-1612	3	19	sage	sage	NOUN
ajcp-1612	3	20	,	,	PUNCT
ajcp-1612	3	21	medline	medline	NOUN
ajcp-1612	3	22	,	,	PUNCT
ajcp-1612	3	23	and	and	CCONJ
ajcp-1612	3	24	web	web	NOUN
ajcp-1612	3	25	of	of	ADP
ajcp-1612	3	26	science	science	NOUN
ajcp-1612	3	27	.	.	PUNCT
ajcp-1612	4	1	studies	study	NOUN
ajcp-1612	4	2	were	be	AUX
ajcp-1612	4	3	selected	select	VERB
ajcp-1612	4	4	from	from	ADP
ajcp-1612	4	5	2018	2018	NUM
ajcp-1612	4	6	-	-	SYM
ajcp-1612	4	7	2023	2023	NUM
ajcp-1612	4	8	,	,	PUNCT
ajcp-1612	4	9	using	use	VERB
ajcp-1612	4	10	keywords	keyword	NOUN
ajcp-1612	4	11	such	such	ADJ
ajcp-1612	4	12	as	as	ADP
ajcp-1612	4	13	diabetes	diabetes	NOUN
ajcp-1612	4	14	mellitus	mellitus	NOUN
ajcp-1612	4	15	management	management	PROPN
ajcp-1612	4	16	,	,	PUNCT
ajcp-1612	4	17	chronic	chronic	ADJ
ajcp-1612	4	18	kidney	kidney	NOUN
ajcp-1612	4	19	disease	disease	NOUN
ajcp-1612	4	20	,	,	PUNCT
ajcp-1612	4	21	microalbuminuria	microalbuminuria	NOUN
ajcp-1612	4	22	,	,	PUNCT
ajcp-1612	4	23	target	target	VERB
ajcp-1612	4	24	time	time	NOUN
ajcp-1612	4	25	in	in	ADP
ajcp-1612	4	26	range	range	NOUN
ajcp-1612	4	27	,	,	PUNCT
ajcp-1612	4	28	impaired	impaired	ADJ
ajcp-1612	4	29	fasting	fasting	NOUN
ajcp-1612	4	30	glucose	glucose	NOUN
ajcp-1612	4	31	,	,	PUNCT
ajcp-1612	4	32	management	management	NOUN
ajcp-1612	4	33	ways	way	NOUN
ajcp-1612	4	34	,	,	PUNCT
ajcp-1612	4	35	lifestyle	lifestyle	NOUN
ajcp-1612	4	36	modification	modification	NOUN
ajcp-1612	4	37	,	,	PUNCT
ajcp-1612	4	38	medication	medication	NOUN
ajcp-1612	4	39	treatment	treatment	NOUN
ajcp-1612	4	40	,	,	PUNCT
ajcp-1612	4	41	and	and	CCONJ
ajcp-1612	4	42	diet	diet	PROPN
ajcp-1612	4	43	control	control	NOUN
ajcp-1612	4	44	.	.	PUNCT
ajcp-1612	5	1	although	although	SCONJ
ajcp-1612	5	2	blood	blood	NOUN
ajcp-1612	5	3	glucose	glucose	NOUN
ajcp-1612	5	4	levels	level	NOUN
ajcp-1612	5	5	are	be	AUX
ajcp-1612	5	6	too	too	ADV
ajcp-1612	5	7	unpredictable	unpredictable	ADJ
ajcp-1612	5	8	to	to	PART
ajcp-1612	5	9	provide	provide	VERB
ajcp-1612	5	10	a	a	DET
ajcp-1612	5	11	reliable	reliable	ADJ
ajcp-1612	5	12	evaluation	evaluation	NOUN
ajcp-1612	5	13	,	,	PUNCT
ajcp-1612	5	14	measures	measure	NOUN
ajcp-1612	5	15	reflecting	reflect	VERB
ajcp-1612	5	16	long	long	ADJ
ajcp-1612	5	17	-	-	PUNCT
ajcp-1612	5	18	term	term	NOUN
ajcp-1612	5	19	glycemic	glycemic	ADJ
ajcp-1612	5	20	load	load	NOUN
ajcp-1612	5	21	are	be	AUX
ajcp-1612	5	22	used	use	VERB
ajcp-1612	5	23	instead	instead	ADV
ajcp-1612	5	24	.	.	PUNCT
ajcp-1612	6	1	the	the	DET
ajcp-1612	6	2	results	result	NOUN
ajcp-1612	6	3	gathered	gather	VERB
ajcp-1612	6	4	after	after	SCONJ
ajcp-1612	6	5	the	the	DET
ajcp-1612	6	6	review	review	NOUN
ajcp-1612	6	7	suggests	suggest	VERB
ajcp-1612	6	8	that	that	SCONJ
ajcp-1612	6	9	optimal	optimal	ADJ
ajcp-1612	6	10	glycemic	glycemic	ADJ
ajcp-1612	6	11	control	control	NOUN
ajcp-1612	6	12	along	along	ADP
ajcp-1612	6	13	with	with	ADP
ajcp-1612	6	14	lifestyle	lifestyle	NOUN
ajcp-1612	6	15	medication	medication	NOUN
ajcp-1612	6	16	and	and	CCONJ
ajcp-1612	6	17	diet	diet	NOUN
ajcp-1612	6	18	control	control	NOUN
ajcp-1612	6	19	contributes	contribute	VERB
ajcp-1612	6	20	to	to	ADP
ajcp-1612	6	21	better	well	ADJ
ajcp-1612	6	22	outcomes	outcome	NOUN
ajcp-1612	6	23	in	in	ADP
ajcp-1612	6	24	individuals	individual	NOUN
ajcp-1612	6	25	with	with	ADP
ajcp-1612	6	26	dm	dm	NOUN
ajcp-1612	6	27	,	,	PUNCT
ajcp-1612	6	28	particularly	particularly	ADV
ajcp-1612	6	29	for	for	ADP
ajcp-1612	6	30	microvascular	microvascular	ADJ
ajcp-1612	6	31	damage	damage	NOUN
ajcp-1612	6	32	.	.	PUNCT
ajcp-1612	7	1	while	while	SCONJ
ajcp-1612	7	2	,	,	PUNCT
ajcp-1612	7	3	hba1c	hba1c	PROPN
ajcp-1612	7	4	is	be	AUX
ajcp-1612	7	5	the	the	DET
ajcp-1612	7	6	most	most	ADV
ajcp-1612	7	7	well	well	ADV
ajcp-1612	7	8	-	-	PUNCT
ajcp-1612	7	9	known	know	VERB
ajcp-1612	7	10	glycemic	glycemic	ADJ
ajcp-1612	7	11	biomarker	biomarker	NOUN
ajcp-1612	7	12	of	of	ADP
ajcp-1612	7	13	long	long	ADJ
ajcp-1612	7	14	-	-	PUNCT
ajcp-1612	7	15	term	term	NOUN
ajcp-1612	7	16	glycemic	glycemic	ADJ
ajcp-1612	7	17	management	management	NOUN
ajcp-1612	7	18	.	.	PUNCT
ajcp-1612	8	1	this	this	PRON
ajcp-1612	8	2	suggests	suggest	VERB
ajcp-1612	8	3	that	that	SCONJ
ajcp-1612	8	4	effective	effective	ADJ
ajcp-1612	8	5	treatments	treatment	NOUN
ajcp-1612	8	6	are	be	AUX
ajcp-1612	8	7	progressing	progress	VERB
ajcp-1612	8	8	on	on	ADP
ajcp-1612	8	9	progression.this	progression.this	DET
ajcp-1612	8	10	review	review	NOUN
ajcp-1612	8	11	has	have	AUX
ajcp-1612	8	12	discussed	discuss	VERB
ajcp-1612	8	13	different	different	ADJ
ajcp-1612	8	14	ckd	ckd	PROPN
ajcp-1612	8	15	management	management	NOUN
ajcp-1612	8	16	parameters	parameter	NOUN
ajcp-1612	8	17	;	;	PUNCT
ajcp-1612	8	18	the	the	DET
ajcp-1612	8	19	authors	author	NOUN
ajcp-1612	8	20	have	have	AUX
ajcp-1612	8	21	discussed	discuss	VERB
ajcp-1612	8	22	the	the	DET
ajcp-1612	8	23	disease	disease	NOUN
ajcp-1612	8	24	’s	’s	PART
ajcp-1612	8	25	treatment	treatment	NOUN
ajcp-1612	8	26	criteria	criterion	NOUN
ajcp-1612	8	27	and	and	CCONJ
ajcp-1612	8	28	protocols	protocol	NOUN
ajcp-1612	8	29	,	,	PUNCT
ajcp-1612	8	30	such	such	ADJ
ajcp-1612	8	31	as	as	ADP
ajcp-1612	8	32	pharmacological	pharmacological	ADJ
ajcp-1612	8	33	therapies	therapy	NOUN
ajcp-1612	8	34	,	,	PUNCT
ajcp-1612	8	35	lifestyle	lifestyle	NOUN
ajcp-1612	8	36	modifications	modification	NOUN
ajcp-1612	8	37	,	,	PUNCT
ajcp-1612	8	38	physical	physical	ADJ
ajcp-1612	8	39	activities	activity	NOUN
ajcp-1612	8	40	and	and	CCONJ
ajcp-1612	8	41	insulin	insulin	NOUN
ajcp-1612	8	42	therapy	therapy	NOUN
ajcp-1612	8	43	and	and	CCONJ
ajcp-1612	8	44	concluded	conclude	VERB
ajcp-1612	8	45	that	that	SCONJ
ajcp-1612	8	46	to	to	PART
ajcp-1612	8	47	avoid	avoid	VERB
ajcp-1612	8	48	ckd	ckd	PROPN
ajcp-1612	8	49	,	,	PUNCT
ajcp-1612	8	50	it	it	PRON
ajcp-1612	8	51	’s	’	VERB
ajcp-1612	8	52	critical	critical	ADJ
ajcp-1612	8	53	to	to	PART
ajcp-1612	8	54	concentrate	concentrate	VERB
ajcp-1612	8	55	on	on	ADP
ajcp-1612	8	56	underlying	underlie	VERB
ajcp-1612	8	57	problems	problem	NOUN
ajcp-1612	8	58	including	include	VERB
ajcp-1612	8	59	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	8	60	,	,	PUNCT
ajcp-1612	8	61	hypertension	hypertension	NOUN
ajcp-1612	8	62	,	,	PUNCT
ajcp-1612	8	63	microalbuminuria	microalbuminuria	ADJ
ajcp-1612	8	64	,	,	PUNCT
ajcp-1612	8	65	sedentary	sedentary	ADJ
ajcp-1612	8	66	behaviour	behaviour	NOUN
ajcp-1612	8	67	,	,	PUNCT
ajcp-1612	8	68	and	and	CCONJ
ajcp-1612	8	69	smoking	smoking	NOUN
ajcp-1612	8	70	.	.	PUNCT
ajcp-1612	9	1	the	the	DET
ajcp-1612	9	2	occurrence	occurrence	NOUN
ajcp-1612	9	3	of	of	ADP
ajcp-1612	9	4	ckd	ckd	PROPN
ajcp-1612	9	5	can	can	AUX
ajcp-1612	9	6	be	be	AUX
ajcp-1612	9	7	reduced	reduce	VERB
ajcp-1612	9	8	with	with	ADP
ajcp-1612	9	9	changes	change	NOUN
ajcp-1612	9	10	in	in	ADP
ajcp-1612	9	11	lifestyle	lifestyle	NOUN
ajcp-1612	9	12	,	,	PUNCT
ajcp-1612	9	13	such	such	ADJ
ajcp-1612	9	14	as	as	ADP
ajcp-1612	9	15	increased	increase	VERB
ajcp-1612	9	16	physical	physical	ADJ
ajcp-1612	9	17	activity	activity	NOUN
ajcp-1612	9	18	,	,	PUNCT
ajcp-1612	9	19	nutritious	nutritious	ADJ
ajcp-1612	9	20	food	food	NOUN
ajcp-1612	9	21	,	,	PUNCT
ajcp-1612	9	22	and	and	CCONJ
ajcp-1612	9	23	water	water	NOUN
ajcp-1612	9	24	consumption	consumption	NOUN
ajcp-1612	9	25	.	.	PUNCT
ajcp-1612	10	1	keywords	keyword	NOUN
ajcp-1612	10	2	chronic	chronic	ADJ
ajcp-1612	10	3	kidney	kidney	NOUN
ajcp-1612	10	4	disease	disease	NOUN
ajcp-1612	10	5	,	,	PUNCT
ajcp-1612	10	6	end	end	NOUN
ajcp-1612	10	7	stage	stage	NOUN
ajcp-1612	10	8	renal	renal	ADJ
ajcp-1612	10	9	stage	stage	NOUN
ajcp-1612	10	10	,	,	PUNCT
ajcp-1612	10	11	albuminuria	albuminuria	NOUN
ajcp-1612	10	12	,	,	PUNCT
ajcp-1612	10	13	pharmacological	pharmacological	ADJ
ajcp-1612	10	14	therapies	therapy	NOUN
ajcp-1612	10	15	1	1	NUM
ajcp-1612	10	16	department	department	NOUN
ajcp-1612	10	17	of	of	ADP
ajcp-1612	10	18	internal	internal	ADJ
ajcp-1612	10	19	medicine	medicine	NOUN
ajcp-1612	10	20	,	,	PUNCT
ajcp-1612	10	21	mediclinic	mediclinic	PROPN
ajcp-1612	10	22	al	al	PROPN
ajcp-1612	10	23	ain	ain	PROPN
ajcp-1612	10	24	hospital	hospital	NOUN
ajcp-1612	10	25	,	,	PUNCT
ajcp-1612	10	26	heikh	heikh	NOUN
ajcp-1612	10	27	khalifa	khalifa	PROPN
ajcp-1612	10	28	bin	bin	PROPN
ajcp-1612	10	29	zayed	zayed	PROPN
ajcp-1612	10	30	st	st	PROPN
ajcp-1612	10	31	next	next	ADV
ajcp-1612	10	32	to	to	AUX
ajcp-1612	10	33	choithrams	choithram	VERB
ajcp-1612	10	34	supermarket	supermarket	NOUN
ajcp-1612	10	35	,	,	PUNCT
ajcp-1612	10	36	abu	abu	PROPN
ajcp-1612	10	37	dhabi	dhabi	PROPN
ajcp-1612	10	38	united	united	PROPN
ajcp-1612	10	39	arab	arab	PROPN
ajcp-1612	10	40	emirates	emirates	PROPN
ajcp-1612	11	1	*	*	PUNCT
ajcp-1612	11	2	corresponding	correspond	VERB
ajcp-1612	11	3	author	author	NOUN
ajcp-1612	11	4	’s	’s	PART
ajcp-1612	11	5	e	e	NOUN
ajcp-1612	11	6	-	-	NOUN
ajcp-1612	11	7	mail	mail	NOUN
ajcp-1612	11	8	:	:	PUNCT
ajcp-1612	11	9	safaamatarid12@outlook.com	safaamatarid12@outlook.com	X
ajcp-1612	11	10	introduction	introduction	NOUN
ajcp-1612	11	11	diabetes	diabetes	NOUN
ajcp-1612	11	12	mellitus	mellitus	NOUN
ajcp-1612	11	13	is	be	AUX
ajcp-1612	11	14	the	the	DET
ajcp-1612	11	15	most	most	ADV
ajcp-1612	11	16	common	common	ADJ
ajcp-1612	11	17	and	and	CCONJ
ajcp-1612	11	18	prevalent	prevalent	ADJ
ajcp-1612	11	19	disease	disease	NOUN
ajcp-1612	11	20	worldwide	worldwide	ADV
ajcp-1612	11	21	,	,	PUNCT
ajcp-1612	11	22	affecting	affect	VERB
ajcp-1612	11	23	approximately	approximately	ADV
ajcp-1612	11	24	29.2	29.2	NUM
ajcp-1612	11	25	%	%	NOUN
ajcp-1612	11	26	of	of	ADP
ajcp-1612	11	27	people	people	NOUN
ajcp-1612	11	28	per	per	ADP
ajcp-1612	11	29	year	year	NOUN
ajcp-1612	11	30	in	in	ADP
ajcp-1612	11	31	the	the	DET
ajcp-1612	11	32	united	united	PROPN
ajcp-1612	11	33	states	states	PROPN
ajcp-1612	11	34	;	;	PUNCT
ajcp-1612	11	35	while	while	SCONJ
ajcp-1612	11	36	537	537	NUM
ajcp-1612	11	37	million	million	NUM
ajcp-1612	11	38	people	people	NOUN
ajcp-1612	11	39	around	around	ADP
ajcp-1612	11	40	the	the	DET
ajcp-1612	11	41	world	world	NOUN
ajcp-1612	11	42	are	be	AUX
ajcp-1612	11	43	reported	report	VERB
ajcp-1612	11	44	to	to	PART
ajcp-1612	11	45	have	have	VERB
ajcp-1612	11	46	diabetes	diabetes	NOUN
ajcp-1612	11	47	,	,	PUNCT
ajcp-1612	11	48	this	this	DET
ajcp-1612	11	49	number	number	NOUN
ajcp-1612	11	50	is	be	AUX
ajcp-1612	11	51	expected	expect	VERB
ajcp-1612	11	52	to	to	PART
ajcp-1612	11	53	grow	grow	VERB
ajcp-1612	11	54	by	by	ADP
ajcp-1612	11	55	half	half	DET
ajcp-1612	11	56	a	a	DET
ajcp-1612	11	57	billion	billion	NUM
ajcp-1612	11	58	by	by	ADP
ajcp-1612	11	59	the	the	DET
ajcp-1612	11	60	year	year	NOUN
ajcp-1612	11	61	2040	2040	NUM
ajcp-1612	11	62	(	(	PUNCT
ajcp-1612	11	63	association	association	NOUN
ajcp-1612	11	64	,	,	PUNCT
ajcp-1612	11	65	2022	2022	NUM
ajcp-1612	11	66	;	;	PUNCT
ajcp-1612	11	67	idf	idf	PROPN
ajcp-1612	11	68	,	,	PUNCT
ajcp-1612	11	69	2021	2021	NUM
ajcp-1612	11	70	;	;	PUNCT
ajcp-1612	11	71	prevention	prevention	NOUN
ajcp-1612	11	72	,	,	PUNCT
ajcp-1612	11	73	2020	2020	NUM
ajcp-1612	11	74	)	)	PUNCT
ajcp-1612	11	75	.	.	PUNCT
ajcp-1612	12	1	diabetes	diabetes	NOUN
ajcp-1612	12	2	mellitus	mellitus	NOUN
ajcp-1612	12	3	is	be	AUX
ajcp-1612	12	4	a	a	DET
ajcp-1612	12	5	progressive	progressive	ADJ
ajcp-1612	12	6	metabolic	metabolic	NOUN
ajcp-1612	12	7	disease	disease	NOUN
ajcp-1612	12	8	that	that	PRON
ajcp-1612	12	9	is	be	AUX
ajcp-1612	12	10	implanted	implant	VERB
ajcp-1612	12	11	by	by	ADP
ajcp-1612	12	12	the	the	DET
ajcp-1612	12	13	constant	constant	ADJ
ajcp-1612	12	14	condition	condition	NOUN
ajcp-1612	12	15	of	of	ADP
ajcp-1612	12	16	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	12	17	.	.	PUNCT
ajcp-1612	13	1	diabetes	diabetes	NOUN
ajcp-1612	13	2	is	be	AUX
ajcp-1612	13	3	prompted	prompt	VERB
ajcp-1612	13	4	by	by	ADP
ajcp-1612	13	5	the	the	DET
ajcp-1612	13	6	action	action	NOUN
ajcp-1612	13	7	of	of	ADP
ajcp-1612	13	8	insulin	insulin	NOUN
ajcp-1612	13	9	that	that	PRON
ajcp-1612	13	10	decreases	decrease	VERB
ajcp-1612	13	11	insulin	insulin	NOUN
ajcp-1612	13	12	production	production	NOUN
ajcp-1612	13	13	,	,	PUNCT
ajcp-1612	13	14	insulin	insulin	NOUN
ajcp-1612	13	15	resistance	resistance	NOUN
ajcp-1612	13	16	,	,	PUNCT
ajcp-1612	13	17	or	or	CCONJ
ajcp-1612	13	18	both	both	DET
ajcp-1612	13	19	(	(	PUNCT
ajcp-1612	13	20	goyal	goyal	PROPN
ajcp-1612	13	21	&	&	CCONJ
ajcp-1612	13	22	jialal	jialal	PROPN
ajcp-1612	13	23	,	,	PUNCT
ajcp-1612	13	24	2018	2018	NUM
ajcp-1612	13	25	)	)	PUNCT
ajcp-1612	13	26	.	.	PUNCT
ajcp-1612	14	1	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	14	2	is	be	AUX
ajcp-1612	14	3	a	a	DET
ajcp-1612	14	4	recognised	recognise	VERB
ajcp-1612	14	5	marker	marker	NOUN
ajcp-1612	14	6	for	for	ADP
ajcp-1612	14	7	the	the	DET
ajcp-1612	14	8	onset	onset	NOUN
ajcp-1612	14	9	and	and	CCONJ
ajcp-1612	14	10	development	development	NOUN
ajcp-1612	14	11	of	of	ADP
ajcp-1612	14	12	both	both	CCONJ
ajcp-1612	14	13	dpn	dpn	PROPN
ajcp-1612	14	14	and	and	CCONJ
ajcp-1612	14	15	ckd	ckd	PROPN
ajcp-1612	14	16	.	.	PUNCT
ajcp-1612	15	1	this	this	DET
ajcp-1612	15	2	lethal	lethal	ADJ
ajcp-1612	15	3	disease	disease	NOUN
ajcp-1612	15	4	causes	cause	VERB
ajcp-1612	15	5	more	more	ADV
ajcp-1612	15	6	lethal	lethal	ADJ
ajcp-1612	15	7	macrovascular	macrovascular	ADJ
ajcp-1612	15	8	comorbidities	comorbiditie	NOUN
ajcp-1612	15	9	such	such	ADJ
ajcp-1612	15	10	as	as	ADP
ajcp-1612	15	11	cardiovascular	cardiovascular	ADJ
ajcp-1612	15	12	diseases	disease	NOUN
ajcp-1612	15	13	,	,	PUNCT
ajcp-1612	15	14	diabetic	diabetic	ADJ
ajcp-1612	15	15	peripheral	peripheral	ADJ
ajcp-1612	15	16	neuropathy	neuropathy	ADJ
ajcp-1612	15	17	,	,	PUNCT
ajcp-1612	15	18	diabetic	diabetic	ADJ
ajcp-1612	15	19	retinopathy	retinopathy	NOUN
ajcp-1612	15	20	and	and	CCONJ
ajcp-1612	15	21	ckd	ckd	PROPN
ajcp-1612	15	22	,	,	PUNCT
ajcp-1612	15	23	leading	lead	VERB
ajcp-1612	15	24	to	to	ADP
ajcp-1612	15	25	increased	increase	VERB
ajcp-1612	15	26	mortality	mortality	NOUN
ajcp-1612	15	27	rates	rate	NOUN
ajcp-1612	15	28	and	and	CCONJ
ajcp-1612	15	29	decreased	decrease	VERB
ajcp-1612	15	30	quality	quality	NOUN
ajcp-1612	15	31	of	of	ADP
ajcp-1612	15	32	life	life	NOUN
ajcp-1612	15	33	(	(	PUNCT
ajcp-1612	15	34	cole	cole	PROPN
ajcp-1612	15	35	&	&	CCONJ
ajcp-1612	15	36	florez	florez	PROPN
ajcp-1612	15	37	,	,	PUNCT
ajcp-1612	15	38	2020	2020	NUM
ajcp-1612	15	39	)	)	PUNCT
ajcp-1612	15	40	.	.	PUNCT
ajcp-1612	16	1	during	during	ADP
ajcp-1612	16	2	the	the	DET
ajcp-1612	16	3	1st	1st	ADJ
ajcp-1612	16	4	century	century	NOUN
ajcp-1612	16	5	ad	ad	NOUN
ajcp-1612	16	6	,	,	PUNCT
ajcp-1612	16	7	diabetes	diabetes	NOUN
ajcp-1612	16	8	was	be	AUX
ajcp-1612	16	9	considered	consider	VERB
ajcp-1612	16	10	a	a	DET
ajcp-1612	16	11	urinary	urinary	ADJ
ajcp-1612	16	12	tract	tract	NOUN
ajcp-1612	16	13	disease	disease	NOUN
ajcp-1612	16	14	or	or	CCONJ
ajcp-1612	16	15	a	a	DET
ajcp-1612	16	16	kidney	kidney	NOUN
ajcp-1612	16	17	disease	disease	NOUN
ajcp-1612	16	18	due	due	ADP
ajcp-1612	16	19	to	to	ADP
ajcp-1612	16	20	its	its	PRON
ajcp-1612	16	21	high	high	ADJ
ajcp-1612	16	22	urine	urine	NOUN
ajcp-1612	16	23	flow	flow	NOUN
ajcp-1612	16	24	.	.	PUNCT
ajcp-1612	17	1	diabetes	diabetes	NOUN
ajcp-1612	17	2	affects	affect	VERB
ajcp-1612	17	3	the	the	DET
ajcp-1612	17	4	kidneys	kidney	NOUN
ajcp-1612	17	5	primarily	primarily	ADV
ajcp-1612	17	6	due	due	ADJ
ajcp-1612	17	7	to	to	ADP
ajcp-1612	17	8	a	a	DET
ajcp-1612	17	9	deficiency	deficiency	NOUN
ajcp-1612	17	10	in	in	ADP
ajcp-1612	17	11	their	their	PRON
ajcp-1612	17	12	retentive	retentive	ADJ
ajcp-1612	17	13	properties	property	NOUN
ajcp-1612	17	14	.	.	PUNCT
ajcp-1612	18	1	diabetes	diabetes	NOUN
ajcp-1612	18	2	-	-	PUNCT
ajcp-1612	18	3	related	relate	VERB
ajcp-1612	18	4	urine	urine	NOUN
ajcp-1612	18	5	has	have	VERB
ajcp-1612	18	6	a	a	DET
ajcp-1612	18	7	sweet	sweet	ADJ
ajcp-1612	18	8	flavour	flavour	NOUN
ajcp-1612	18	9	because	because	SCONJ
ajcp-1612	18	10	it	it	PRON
ajcp-1612	18	11	contains	contain	VERB
ajcp-1612	18	12	nutrients	nutrient	NOUN
ajcp-1612	18	13	and	and	CCONJ
ajcp-1612	18	14	water	water	NOUN
ajcp-1612	18	15	that	that	PRON
ajcp-1612	18	16	have	have	AUX
ajcp-1612	18	17	been	be	AUX
ajcp-1612	18	18	ingested	ingest	VERB
ajcp-1612	18	19	but	but	CCONJ
ajcp-1612	18	20	not	not	PART
ajcp-1612	18	21	broken	break	VERB
ajcp-1612	18	22	down	down	ADP
ajcp-1612	18	23	(	(	PUNCT
ajcp-1612	18	24	eknoyan	eknoyan	PROPN
ajcp-1612	18	25	&	&	CCONJ
ajcp-1612	18	26	nagy	nagy	PROPN
ajcp-1612	18	27	,	,	PUNCT
ajcp-1612	18	28	2005	2005	NUM
ajcp-1612	18	29	)	)	PUNCT
ajcp-1612	18	30	.	.	PUNCT
ajcp-1612	19	1	the	the	DET
ajcp-1612	19	2	sweetness	sweetness	NOUN
ajcp-1612	19	3	of	of	ADP
ajcp-1612	19	4	diabetic	diabetic	ADJ
ajcp-1612	19	5	urine	urine	NOUN
ajcp-1612	19	6	was	be	AUX
ajcp-1612	19	7	the	the	DET
ajcp-1612	19	8	initial	initial	ADJ
ajcp-1612	19	9	indicator	indicator	NOUN
ajcp-1612	19	10	used	use	VERB
ajcp-1612	19	11	by	by	ADP
ajcp-1612	19	12	thomas	thomas	PROPN
ajcp-1612	19	13	willis	willis	PROPN
ajcp-1612	19	14	in	in	ADP
ajcp-1612	19	15	1674	1674	NUM
ajcp-1612	19	16	to	to	PART
ajcp-1612	19	17	distinguish	distinguish	VERB
ajcp-1612	19	18	diabetes	diabetes	NOUN
ajcp-1612	19	19	from	from	ADP
ajcp-1612	19	20	other	other	ADJ
ajcp-1612	19	21	types	type	NOUN
ajcp-1612	19	22	of	of	ADP
ajcp-1612	19	23	polyuria	polyuria	NOUN
ajcp-1612	19	24	,	,	PUNCT
ajcp-1612	19	25	and	and	CCONJ
ajcp-1612	19	26	he	he	PRON
ajcp-1612	19	27	proposed	propose	VERB
ajcp-1612	19	28	that	that	SCONJ
ajcp-1612	19	29	the	the	DET
ajcp-1612	19	30	sweet	sweet	ADJ
ajcp-1612	19	31	flavour	flavour	NOUN
ajcp-1612	19	32	initially	initially	ADV
ajcp-1612	19	33	manifests	manifest	VERB
ajcp-1612	19	34	in	in	ADP
ajcp-1612	19	35	the	the	DET
ajcp-1612	19	36	blood(sutherland	blood(sutherland	PROPN
ajcp-1612	19	37	&	&	CCONJ
ajcp-1612	19	38	gruessner	gruessner	NOUN
ajcp-1612	19	39	,	,	PUNCT
ajcp-1612	19	40	2020	2020	NUM
ajcp-1612	19	41	)	)	PUNCT
ajcp-1612	19	42	.	.	PUNCT
ajcp-1612	20	1	a	a	DET
ajcp-1612	20	2	century	century	NOUN
ajcp-1612	20	3	later	later	ADV
ajcp-1612	20	4	,	,	PUNCT
ajcp-1612	20	5	matthew	matthew	PROPN
ajcp-1612	20	6	dobson	dobson	PROPN
ajcp-1612	20	7	demonstrated	demonstrate	VERB
ajcp-1612	20	8	that	that	SCONJ
ajcp-1612	20	9	the	the	DET
ajcp-1612	20	10	sweet	sweet	ADJ
ajcp-1612	20	11	flavour	flavour	NOUN
ajcp-1612	20	12	of	of	ADP
ajcp-1612	20	13	urine	urine	NOUN
ajcp-1612	20	14	was	be	AUX
ajcp-1612	20	15	caused	cause	VERB
ajcp-1612	20	16	by	by	ADP
ajcp-1612	20	17	sugar	sugar	NOUN
ajcp-1612	20	18	and	and	CCONJ
ajcp-1612	20	19	that	that	SCONJ
ajcp-1612	20	20	blood	blood	NOUN
ajcp-1612	20	21	sugar	sugar	NOUN
ajcp-1612	20	22	had	have	AUX
ajcp-1612	20	23	both	both	CCONJ
ajcp-1612	20	24	paved	pave	VERB
ajcp-1612	20	25	and	and	CCONJ
ajcp-1612	20	26	followed	follow	VERB
ajcp-1612	20	27	it	it	PRON
ajcp-1612	20	28	.	.	PUNCT
ajcp-1612	21	1	although	although	SCONJ
ajcp-1612	21	2	diabetes	diabetes	NOUN
ajcp-1612	21	3	was	be	AUX
ajcp-1612	21	4	later	later	ADV
ajcp-1612	21	5	linked	link	VERB
ajcp-1612	21	6	to	to	ADP
ajcp-1612	21	7	higher	high	ADJ
ajcp-1612	21	8	blood	blood	NOUN
ajcp-1612	21	9	sugar	sugar	NOUN
ajcp-1612	21	10	levels	level	NOUN
ajcp-1612	21	11	,	,	PUNCT
ajcp-1612	21	12	sugar	sugar	NOUN
ajcp-1612	21	13	in	in	ADP
ajcp-1612	21	14	the	the	DET
ajcp-1612	21	15	urine	urine	NOUN
ajcp-1612	21	16	was	be	AUX
ajcp-1612	21	17	still	still	ADV
ajcp-1612	21	18	accredited	accredit	VERB
ajcp-1612	21	19	to	to	ADP
ajcp-1612	21	20	the	the	DET
ajcp-1612	21	21	kidneys	kidney	NOUN
ajcp-1612	21	22	’	'	PUNCT
ajcp-1612	21	23	reduced	reduce	VERB
ajcp-1612	21	24	ability	ability	NOUN
ajcp-1612	21	25	for	for	ADP
ajcp-1612	21	26	retentive	retentive	ADJ
ajcp-1612	21	27	functioning	functioning	NOUN
ajcp-1612	21	28	(	(	PUNCT
ajcp-1612	21	29	porta	porta	NOUN
ajcp-1612	21	30	,	,	PUNCT
ajcp-1612	21	31	2020	2020	NUM
ajcp-1612	21	32	)	)	PUNCT
ajcp-1612	21	33	.	.	PUNCT
ajcp-1612	22	1	diabetic	diabetic	ADJ
ajcp-1612	22	2	kidney	kidney	NOUN
ajcp-1612	22	3	disease	disease	NOUN
ajcp-1612	22	4	or	or	CCONJ
ajcp-1612	22	5	ckd	ckd	PROPN
ajcp-1612	22	6	happened	happen	VERB
ajcp-1612	22	7	by	by	ADP
ajcp-1612	22	8	diabetes	diabetes	NOUN
ajcp-1612	22	9	or	or	CCONJ
ajcp-1612	22	10	diabetic	diabetic	ADJ
ajcp-1612	22	11	nephropathy	nephropathy	NOUN
ajcp-1612	22	12	is	be	AUX
ajcp-1612	22	13	the	the	DET
ajcp-1612	22	14	most	most	ADV
ajcp-1612	22	15	typical	typical	ADJ
ajcp-1612	22	16	onset	onset	NOUN
ajcp-1612	22	17	of	of	ADP
ajcp-1612	22	18	diabetes	diabetes	NOUN
ajcp-1612	22	19	mellitus	mellitus	NOUN
ajcp-1612	22	20	and	and	CCONJ
ajcp-1612	22	21	also	also	ADV
ajcp-1612	22	22	the	the	DET
ajcp-1612	22	23	major	major	ADJ
ajcp-1612	22	24	reason	reason	NOUN
ajcp-1612	22	25	of	of	ADP
ajcp-1612	22	26	end	end	NOUN
ajcp-1612	22	27	-	-	PUNCT
ajcp-1612	22	28	stage	stage	NOUN
ajcp-1612	22	29	renal	renal	ADJ
ajcp-1612	22	30	disorder	disorder	NOUN
ajcp-1612	22	31	(	(	PUNCT
ajcp-1612	22	32	ersd	ersd	ADJ
ajcp-1612	22	33	)	)	PUNCT
ajcp-1612	22	34	.	.	PUNCT
ajcp-1612	23	1	diabetic	diabetic	ADJ
ajcp-1612	23	2	kidney	kidney	NOUN
ajcp-1612	23	3	disease	disease	NOUN
ajcp-1612	23	4	(	(	PUNCT
ajcp-1612	23	5	dn	dn	NOUN
ajcp-1612	23	6	)	)	PUNCT
ajcp-1612	23	7	is	be	AUX
ajcp-1612	23	8	characterised	characterise	VERB
ajcp-1612	23	9	by	by	ADP
ajcp-1612	23	10	hyperfiltration	hyperfiltration	NOUN
ajcp-1612	23	11	and	and	CCONJ
ajcp-1612	23	12	albuminuria	albuminuria	PROPN
ajcp-1612	23	13	,	,	PUNCT
ajcp-1612	23	14	followed	follow	VERB
ajcp-1612	23	15	by	by	ADP
ajcp-1612	23	16	a	a	DET
ajcp-1612	23	17	loss	loss	NOUN
ajcp-1612	23	18	of	of	ADP
ajcp-1612	23	19	renal	renal	ADJ
ajcp-1612	23	20	function	function	NOUN
ajcp-1612	23	21	.	.	PUNCT
ajcp-1612	24	1	it	it	PRON
ajcp-1612	24	2	can	can	AUX
ajcp-1612	24	3	show	show	VERB
ajcp-1612	24	4	in	in	ADP
ajcp-1612	24	5	various	various	ADJ
ajcp-1612	24	6	ways	way	NOUN
ajcp-1612	24	7	,	,	PUNCT
ajcp-1612	24	8	particularly	particularly	ADV
ajcp-1612	24	9	in	in	ADP
ajcp-1612	24	10	individuals	individual	NOUN
ajcp-1612	24	11	with	with	ADP
ajcp-1612	24	12	t2	t2	NOUN
ajcp-1612	24	13	dm	dm	NUM
ajcp-1612	24	14	who	who	PRON
ajcp-1612	24	15	may	may	AUX
ajcp-1612	24	16	also	also	ADV
ajcp-1612	24	17	have	have	VERB
ajcp-1612	24	18	peripheral	peripheral	ADJ
ajcp-1612	24	19	vascular	vascular	NOUN
ajcp-1612	24	20	and	and	CCONJ
ajcp-1612	24	21	other	other	ADJ
ajcp-1612	24	22	glomerular	glomerular	ADJ
ajcp-1612	24	23	/	/	SYM
ajcp-1612	24	24	tubular	tubular	ADJ
ajcp-1612	24	25	diseases	disease	NOUN
ajcp-1612	24	26	(	(	PUNCT
ajcp-1612	24	27	sagoo	sagoo	PROPN
ajcp-1612	24	28	&	&	CCONJ
ajcp-1612	24	29	gnudi	gnudi	PROPN
ajcp-1612	24	30	,	,	PUNCT
ajcp-1612	24	31	2020	2020	NUM
ajcp-1612	24	32	)	)	PUNCT
ajcp-1612	24	33	.	.	PUNCT
ajcp-1612	25	1	ckd	ckd	PROPN
ajcp-1612	25	2	is	be	AUX
ajcp-1612	25	3	reported	report	VERB
ajcp-1612	25	4	to	to	PART
ajcp-1612	25	5	affect	affect	VERB
ajcp-1612	25	6	approximately	approximately	ADV
ajcp-1612	25	7	8	8	NUM
ajcp-1612	25	8	to	to	PART
ajcp-1612	25	9	16	16	NUM
ajcp-1612	25	10	%	%	NOUN
ajcp-1612	25	11	population	population	NOUN
ajcp-1612	25	12	globally	globally	ADV
ajcp-1612	25	13	,	,	PUNCT
ajcp-1612	25	14	and	and	CCONJ
ajcp-1612	25	15	around	around	ADV
ajcp-1612	25	16	30	30	NUM
ajcp-1612	25	17	-	-	SYM
ajcp-1612	25	18	50	50	NUM
ajcp-1612	25	19	%	%	NOUN
ajcp-1612	25	20	of	of	ADP
ajcp-1612	25	21	cases	case	NOUN
ajcp-1612	25	22	of	of	ADP
ajcp-1612	25	23	end	end	NOUN
ajcp-1612	25	24	-	-	PUNCT
ajcp-1612	25	25	stage	stage	NOUN
ajcp-1612	25	26	renal	renal	ADJ
ajcp-1612	25	27	disorder	disorder	NOUN
ajcp-1612	25	28	are	be	AUX
ajcp-1612	25	29	considered	consider	VERB
ajcp-1612	25	30	to	to	PART
ajcp-1612	25	31	be	be	AUX
ajcp-1612	25	32	preceded	precede	VERB
ajcp-1612	25	33	by	by	ADP
ajcp-1612	25	34	diabetic	diabetic	ADJ
ajcp-1612	25	35	kidney	kidney	NOUN
ajcp-1612	25	36	disease	disease	NOUN
ajcp-1612	25	37	(	(	PUNCT
ajcp-1612	25	38	chen	chen	PROPN
ajcp-1612	25	39	et	et	PROPN
ajcp-1612	25	40	al	al	PROPN
ajcp-1612	25	41	.	.	PROPN
ajcp-1612	25	42	,	,	PUNCT
ajcp-1612	25	43	2019	2019	NUM
ajcp-1612	25	44	;	;	PUNCT
ajcp-1612	26	1	copur	copur	NOUN
ajcp-1612	26	2	et	et	PROPN
ajcp-1612	26	3	al	al	PROPN
ajcp-1612	26	4	.	.	PROPN
ajcp-1612	26	5	,	,	PUNCT
ajcp-1612	26	6	2020	2020	NUM
ajcp-1612	26	7	)	)	PUNCT
ajcp-1612	26	8	.	.	PUNCT
ajcp-1612	27	1	the	the	DET
ajcp-1612	27	2	incidence	incidence	NOUN
ajcp-1612	27	3	of	of	ADP
ajcp-1612	27	4	classic	classic	ADJ
ajcp-1612	27	5	diabetic	diabetic	ADJ
ajcp-1612	27	6	nephropathy	nephropathy	NOUN
ajcp-1612	27	7	in	in	ADP
ajcp-1612	27	8	type	type	NOUN
ajcp-1612	27	9	1	1	NUM
ajcp-1612	27	10	diabetes	diabetes	NOUN
ajcp-1612	27	11	has	have	AUX
ajcp-1612	27	12	decreased	decrease	VERB
ajcp-1612	27	13	from	from	ADP
ajcp-1612	27	14	25	25	NUM
ajcp-1612	27	15	%	%	NOUN
ajcp-1612	27	16	to	to	PART
ajcp-1612	27	17	10	10	NUM
ajcp-1612	27	18	-	-	SYM
ajcp-1612	27	19	15	15	NUM
ajcp-1612	27	20	%	%	NOUN
ajcp-1612	27	21	with	with	ADP
ajcp-1612	27	22	blood	blood	NOUN
ajcp-1612	27	23	pressure	pressure	NOUN
ajcp-1612	27	24	management	management	NOUN
ajcp-1612	27	25	and	and	CCONJ
ajcp-1612	27	26	more	more	ADJ
ajcp-1612	27	27	use	use	NOUN
ajcp-1612	27	28	of	of	ADP
ajcp-1612	27	29	an	an	DET
ajcp-1612	27	30	angiotensin	angiotensin	NOUN
ajcp-1612	27	31	converter	converter	NOUN
ajcp-1612	27	32	.	.	PUNCT
ajcp-1612	28	1	the	the	DET
ajcp-1612	28	2	overall	overall	ADJ
ajcp-1612	28	3	incidence	incidence	NOUN
ajcp-1612	28	4	of	of	ADP
ajcp-1612	28	5	diabetes	diabetes	NOUN
ajcp-1612	28	6	will	will	AUX
ajcp-1612	28	7	rise	rise	VERB
ajcp-1612	28	8	from	from	ADP
ajcp-1612	28	9	6	6	NUM
ajcp-1612	28	10	%	%	NOUN
ajcp-1612	28	11	to	to	PART
ajcp-1612	28	12	10	10	NUM
ajcp-1612	28	13	%	%	NOUN
ajcp-1612	28	14	of	of	ADP
ajcp-1612	28	15	adults	adult	NOUN
ajcp-1612	28	16	in	in	ADP
ajcp-1612	28	17	the	the	DET
ajcp-1612	28	18	coming	coming	ADJ
ajcp-1612	28	19	years	year	NOUN
ajcp-1612	28	20	,	,	PUNCT
ajcp-1612	28	21	leading	lead	VERB
ajcp-1612	28	22	to	to	ADP
ajcp-1612	28	23	more	more	ADJ
ajcp-1612	28	24	cases	case	NOUN
ajcp-1612	28	25	of	of	ADP
ajcp-1612	28	26	type	type	NOUN
ajcp-1612	28	27	2	2	NUM
ajcp-1612	28	28	diabetes	diabetes	NOUN
ajcp-1612	28	29	and	and	CCONJ
ajcp-1612	28	30	kidney	kidney	NOUN
ajcp-1612	28	31	disease	disease	NOUN
ajcp-1612	28	32	(	(	PUNCT
ajcp-1612	28	33	winocour	winocour	ADJ
ajcp-1612	28	34	,	,	PUNCT
ajcp-1612	28	35	2018	2018	NUM
ajcp-1612	28	36	)	)	PUNCT
ajcp-1612	28	37	.	.	PUNCT
ajcp-1612	29	1	ckd	ckd	PROPN
ajcp-1612	29	2	is	be	AUX
ajcp-1612	29	3	recognised	recognise	VERB
ajcp-1612	29	4	by	by	ADP
ajcp-1612	29	5	a	a	DET
ajcp-1612	29	6	biomarker	biomarker	NOUN
ajcp-1612	29	7	called	call	VERB
ajcp-1612	29	8	micro	micro	NOUN
ajcp-1612	29	9	-	-	NOUN
ajcp-1612	29	10	albumin	albumin	ADJ
ajcp-1612	29	11	,	,	PUNCT
ajcp-1612	29	12	which	which	PRON
ajcp-1612	29	13	is	be	AUX
ajcp-1612	29	14	present	present	ADJ
ajcp-1612	29	15	in	in	ADP
ajcp-1612	29	16	urine	urine	NOUN
ajcp-1612	29	17	.	.	PUNCT
ajcp-1612	30	1	the	the	DET
ajcp-1612	30	2	higher	high	ADJ
ajcp-1612	30	3	levels	level	NOUN
ajcp-1612	30	4	of	of	ADP
ajcp-1612	30	5	microhttps://doi.org/10.54536/ajcp.v2i2.1612	microhttps://doi.org/10.54536/ajcp.v2i2.1612	PROPN
ajcp-1612	30	6	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	30	7	pa	pa	PROPN
ajcp-1612	30	8	ge	ge	PROPN
ajcp-1612	30	9	9	9	NUM
ajcp-1612	30	10	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	30	11	am	be	AUX
ajcp-1612	30	12	.	.	PUNCT
ajcp-1612	31	1	j.	j.	PROPN
ajcp-1612	31	2	chem	chem	PROPN
ajcp-1612	31	3	.	.	PUNCT
ajcp-1612	32	1	pharm	pharm	PROPN
ajcp-1612	32	2	.	.	PUNCT
ajcp-1612	33	1	2(2	2(2	NUM
ajcp-1612	33	2	)	)	PUNCT
ajcp-1612	33	3	9	9	NUM
ajcp-1612	33	4	-	-	SYM
ajcp-1612	33	5	14	14	NUM
ajcp-1612	33	6	,	,	PUNCT
ajcp-1612	33	7	2023	2023	NUM
ajcp-1612	33	8	albumin	albumin	NOUN
ajcp-1612	33	9	in	in	ADP
ajcp-1612	33	10	urine	urine	NOUN
ajcp-1612	33	11	indicate	indicate	VERB
ajcp-1612	33	12	the	the	DET
ajcp-1612	33	13	presence	presence	NOUN
ajcp-1612	33	14	of	of	ADP
ajcp-1612	33	15	a	a	DET
ajcp-1612	33	16	disorder	disorder	NOUN
ajcp-1612	33	17	.	.	PUNCT
ajcp-1612	34	1	at	at	ADP
ajcp-1612	34	2	the	the	DET
ajcp-1612	34	3	same	same	ADJ
ajcp-1612	34	4	time	time	NOUN
ajcp-1612	34	5	,	,	PUNCT
ajcp-1612	34	6	albuminuria	albuminuria	PROPN
ajcp-1612	34	7	is	be	AUX
ajcp-1612	34	8	a	a	DET
ajcp-1612	34	9	condition	condition	NOUN
ajcp-1612	34	10	of	of	ADP
ajcp-1612	34	11	having	have	VERB
ajcp-1612	34	12	too	too	ADV
ajcp-1612	34	13	much	much	ADJ
ajcp-1612	34	14	protein	protein	NOUN
ajcp-1612	34	15	in	in	ADP
ajcp-1612	34	16	the	the	DET
ajcp-1612	34	17	urine	urine	NOUN
ajcp-1612	34	18	,	,	PUNCT
ajcp-1612	34	19	resulting	result	VERB
ajcp-1612	34	20	in	in	ADP
ajcp-1612	34	21	kidney	kidney	NOUN
ajcp-1612	34	22	damage	damage	NOUN
ajcp-1612	34	23	(	(	PUNCT
ajcp-1612	34	24	raja	raja	PROPN
ajcp-1612	34	25	et	et	PROPN
ajcp-1612	34	26	al	al	PROPN
ajcp-1612	34	27	.	.	PROPN
ajcp-1612	34	28	,	,	PUNCT
ajcp-1612	34	29	2021	2021	NUM
ajcp-1612	34	30	)	)	PUNCT
ajcp-1612	34	31	.	.	PUNCT
ajcp-1612	35	1	diabetes	diabetes	NOUN
ajcp-1612	35	2	and	and	CCONJ
ajcp-1612	35	3	ckd	ckd	PROPN
ajcp-1612	35	4	together	together	ADV
ajcp-1612	35	5	increase	increase	VERB
ajcp-1612	35	6	the	the	DET
ajcp-1612	35	7	probability	probability	NOUN
ajcp-1612	35	8	of	of	ADP
ajcp-1612	35	9	amputations	amputation	NOUN
ajcp-1612	35	10	of	of	ADP
ajcp-1612	35	11	the	the	DET
ajcp-1612	35	12	lower	low	ADJ
ajcp-1612	35	13	limbs	limb	NOUN
ajcp-1612	35	14	by	by	ADP
ajcp-1612	35	15	two	two	NUM
ajcp-1612	35	16	to	to	PART
ajcp-1612	35	17	six	six	NUM
ajcp-1612	35	18	times	time	NOUN
ajcp-1612	35	19	compared	compare	VERB
ajcp-1612	35	20	to	to	ADP
ajcp-1612	35	21	diabetes	diabetes	NOUN
ajcp-1612	35	22	alone	alone	ADV
ajcp-1612	35	23	in	in	ADP
ajcp-1612	35	24	patients	patient	NOUN
ajcp-1612	35	25	with	with	ADP
ajcp-1612	35	26	ckd	ckd	PROPN
ajcp-1612	35	27	(	(	PUNCT
ajcp-1612	35	28	rodrigues	rodrigues	PROPN
ajcp-1612	35	29	et	et	PROPN
ajcp-1612	35	30	al	al	PROPN
ajcp-1612	35	31	.	.	PROPN
ajcp-1612	35	32	,	,	PUNCT
ajcp-1612	35	33	2022	2022	NUM
ajcp-1612	35	34	)	)	PUNCT
ajcp-1612	35	35	.	.	PUNCT
ajcp-1612	36	1	literature	literature	NOUN
ajcp-1612	36	2	review	review	PROPN
ajcp-1612	36	3	progression	progression	NOUN
ajcp-1612	36	4	of	of	ADP
ajcp-1612	36	5	micro	micro	PROPN
ajcp-1612	36	6	and	and	CCONJ
ajcp-1612	36	7	macroalbuminuria	macroalbuminuria	PROPN
ajcp-1612	36	8	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	36	9	is	be	AUX
ajcp-1612	36	10	caused	cause	VERB
ajcp-1612	36	11	by	by	ADP
ajcp-1612	36	12	a	a	DET
ajcp-1612	36	13	malfunction	malfunction	NOUN
ajcp-1612	36	14	of	of	ADP
ajcp-1612	36	15	the	the	DET
ajcp-1612	36	16	glomerular	glomerular	ADJ
ajcp-1612	36	17	basement	basement	NOUN
ajcp-1612	36	18	membrane	membrane	NOUN
ajcp-1612	36	19	(	(	PUNCT
ajcp-1612	36	20	gbm	gbm	NOUN
ajcp-1612	36	21	)	)	PUNCT
ajcp-1612	36	22	.	.	PUNCT
ajcp-1612	37	1	this	this	DET
ajcp-1612	37	2	enzyme	enzyme	NOUN
ajcp-1612	37	3	is	be	AUX
ajcp-1612	37	4	inhibited	inhibit	VERB
ajcp-1612	37	5	by	by	ADP
ajcp-1612	37	6	insufficient	insufficient	ADJ
ajcp-1612	37	7	blood	blood	NOUN
ajcp-1612	37	8	sugar	sugar	NOUN
ajcp-1612	37	9	management	management	NOUN
ajcp-1612	37	10	,	,	PUNCT
ajcp-1612	37	11	which	which	PRON
ajcp-1612	37	12	lowers	lower	VERB
ajcp-1612	37	13	the	the	DET
ajcp-1612	37	14	negative	negative	ADJ
ajcp-1612	37	15	charge	charge	NOUN
ajcp-1612	37	16	on	on	ADP
ajcp-1612	37	17	gbm	gbm	PROPN
ajcp-1612	37	18	and	and	CCONJ
ajcp-1612	37	19	causes	cause	VERB
ajcp-1612	37	20	extra	extra	ADJ
ajcp-1612	37	21	albumin	albumin	NOUN
ajcp-1612	37	22	to	to	PART
ajcp-1612	37	23	leak	leak	VERB
ajcp-1612	37	24	out	out	ADP
ajcp-1612	37	25	.	.	PUNCT
ajcp-1612	38	1	it	it	PRON
ajcp-1612	38	2	is	be	AUX
ajcp-1612	38	3	linked	link	VERB
ajcp-1612	38	4	to	to	PART
ajcp-1612	38	5	type	type	VERB
ajcp-1612	38	6	1	1	NUM
ajcp-1612	38	7	and	and	CCONJ
ajcp-1612	38	8	type	type	NOUN
ajcp-1612	38	9	2	2	NUM
ajcp-1612	38	10	diabetic	diabetic	ADJ
ajcp-1612	38	11	individuals	individual	NOUN
ajcp-1612	38	12	(	(	PUNCT
ajcp-1612	38	13	prasad	prasad	PROPN
ajcp-1612	38	14	&	&	CCONJ
ajcp-1612	38	15	tikaria	tikaria	PROPN
ajcp-1612	38	16	,	,	PUNCT
ajcp-1612	38	17	2022	2022	NUM
ajcp-1612	38	18	)	)	PUNCT
ajcp-1612	38	19	.	.	PUNCT
ajcp-1612	39	1	in	in	ADP
ajcp-1612	39	2	those	those	PRON
ajcp-1612	39	3	with	with	ADP
ajcp-1612	39	4	type	type	NOUN
ajcp-1612	39	5	1	1	NUM
ajcp-1612	39	6	diabetes	diabete	NOUN
ajcp-1612	39	7	,	,	PUNCT
ajcp-1612	39	8	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	39	9	is	be	AUX
ajcp-1612	39	10	6	6	NUM
ajcp-1612	39	11	%	%	NOUN
ajcp-1612	39	12	prevalent	prevalent	NOUN
ajcp-1612	39	13	after	after	ADP
ajcp-1612	39	14	three	three	NUM
ajcp-1612	39	15	years	year	NOUN
ajcp-1612	39	16	but	but	CCONJ
ajcp-1612	39	17	41	41	NUM
ajcp-1612	39	18	%	%	NOUN
ajcp-1612	39	19	common	common	ADJ
ajcp-1612	39	20	after	after	ADP
ajcp-1612	39	21	five	five	NUM
ajcp-1612	39	22	.	.	PUNCT
ajcp-1612	40	1	type	type	NOUN
ajcp-1612	40	2	2	2	NUM
ajcp-1612	40	3	diabetes	diabetes	NOUN
ajcp-1612	40	4	affects	affect	VERB
ajcp-1612	40	5	20	20	NUM
ajcp-1612	40	6	%	%	NOUN
ajcp-1612	40	7	to	to	PART
ajcp-1612	40	8	25	25	NUM
ajcp-1612	40	9	%	%	NOUN
ajcp-1612	40	10	of	of	ADP
ajcp-1612	40	11	diabetic	diabetic	ADJ
ajcp-1612	40	12	paeople	paeople	NOUN
ajcp-1612	40	13	(	(	PUNCT
ajcp-1612	40	14	prasad	prasad	PROPN
ajcp-1612	40	15	&	&	CCONJ
ajcp-1612	40	16	tikaria	tikaria	PROPN
ajcp-1612	40	17	,	,	PUNCT
ajcp-1612	40	18	2022	2022	NUM
ajcp-1612	40	19	)	)	PUNCT
ajcp-1612	40	20	.	.	PUNCT
ajcp-1612	41	1	a	a	DET
ajcp-1612	41	2	decreased	decrease	VERB
ajcp-1612	41	3	glomerular	glomerular	ADJ
ajcp-1612	41	4	filtration	filtration	NOUN
ajcp-1612	41	5	rate	rate	NOUN
ajcp-1612	41	6	,	,	PUNCT
ajcp-1612	41	7	increased	increase	VERB
ajcp-1612	41	8	microalbuminuria	microalbuminuria	NOUN
ajcp-1612	41	9	,	,	PUNCT
ajcp-1612	41	10	or	or	CCONJ
ajcp-1612	41	11	both	both	PRON
ajcp-1612	41	12	characterise	characterise	VERB
ajcp-1612	41	13	diabetic	diabetic	ADJ
ajcp-1612	41	14	nephropathy	nephropathy	NOUN
ajcp-1612	41	15	or	or	CCONJ
ajcp-1612	41	16	dkd	dkd	ADJ
ajcp-1612	41	17	.	.	PUNCT
ajcp-1612	42	1	laboratory	laboratory	NOUN
ajcp-1612	42	2	tests	test	NOUN
ajcp-1612	42	3	are	be	AUX
ajcp-1612	42	4	used	use	VERB
ajcp-1612	42	5	to	to	PART
ajcp-1612	42	6	diagnose	diagnose	VERB
ajcp-1612	42	7	ckd	ckd	PROPN
ajcp-1612	42	8	,	,	PUNCT
ajcp-1612	42	9	most	most	ADV
ajcp-1612	42	10	frequently	frequently	ADV
ajcp-1612	42	11	by	by	ADP
ajcp-1612	42	12	estimating	estimate	VERB
ajcp-1612	42	13	glomerular	glomerular	ADJ
ajcp-1612	42	14	filtration	filtration	NOUN
ajcp-1612	42	15	rate	rate	NOUN
ajcp-1612	42	16	(	(	PUNCT
ajcp-1612	42	17	gfr	gfr	NOUN
ajcp-1612	42	18	)	)	PUNCT
ajcp-1612	42	19	using	use	VERB
ajcp-1612	42	20	a	a	DET
ajcp-1612	42	21	filtration	filtration	NOUN
ajcp-1612	42	22	marker	marker	NOUN
ajcp-1612	42	23	like	like	ADP
ajcp-1612	42	24	serum	serum	NOUN
ajcp-1612	42	25	creatinine	creatinine	NOUN
ajcp-1612	42	26	or	or	CCONJ
ajcp-1612	42	27	cystatin	cystatin	PROPN
ajcp-1612	42	28	c.	c.	PROPN
ajcp-1612	42	29	the	the	DET
ajcp-1612	42	30	albumin	albumin	NOUN
ajcp-1612	42	31	or	or	CCONJ
ajcp-1612	42	32	protein	protein	NOUN
ajcp-1612	42	33	in	in	ADP
ajcp-1612	42	34	the	the	DET
ajcp-1612	42	35	urine	urine	NOUN
ajcp-1612	42	36	can	can	AUX
ajcp-1612	42	37	be	be	AUX
ajcp-1612	42	38	determined	determine	VERB
ajcp-1612	42	39	using	use	VERB
ajcp-1612	42	40	several	several	ADJ
ajcp-1612	42	41	formulas	formula	NOUN
ajcp-1612	42	42	or	or	CCONJ
ajcp-1612	42	43	other	other	ADJ
ajcp-1612	42	44	methods	method	NOUN
ajcp-1612	42	45	(	(	PUNCT
ajcp-1612	42	46	kovesdy	kovesdy	NOUN
ajcp-1612	42	47	,	,	PUNCT
ajcp-1612	42	48	2022	2022	NUM
ajcp-1612	42	49	)	)	PUNCT
ajcp-1612	42	50	.	.	PUNCT
ajcp-1612	43	1	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	43	2	,	,	PUNCT
ajcp-1612	43	3	defined	define	VERB
ajcp-1612	43	4	by	by	ADP
ajcp-1612	43	5	urine	urine	NOUN
ajcp-1612	43	6	albumin	albumin	ADJ
ajcp-1612	43	7	excretion	excretion	NOUN
ajcp-1612	43	8	of	of	ADP
ajcp-1612	43	9	30	30	NUM
ajcp-1612	43	10	-	-	SYM
ajcp-1612	43	11	300	300	NUM
ajcp-1612	43	12	mg	mg	PROPN
ajcp-1612	43	13	/	/	SYM
ajcp-1612	43	14	day	day	NOUN
ajcp-1612	43	15	,	,	PUNCT
ajcp-1612	43	16	is	be	AUX
ajcp-1612	43	17	thought	think	VERB
ajcp-1612	43	18	to	to	PART
ajcp-1612	43	19	be	be	AUX
ajcp-1612	43	20	a	a	DET
ajcp-1612	43	21	predictor	predictor	NOUN
ajcp-1612	43	22	of	of	ADP
ajcp-1612	43	23	dkd	dkd	PROPN
ajcp-1612	43	24	.	.	PUNCT
ajcp-1612	44	1	it	it	PRON
ajcp-1612	44	2	is	be	AUX
ajcp-1612	44	3	regarded	regard	VERB
ajcp-1612	44	4	as	as	ADP
ajcp-1612	44	5	an	an	DET
ajcp-1612	44	6	adjustable	adjustable	ADJ
ajcp-1612	44	7	problem	problem	NOUN
ajcp-1612	44	8	for	for	ADP
ajcp-1612	44	9	the	the	DET
ajcp-1612	44	10	progression	progression	NOUN
ajcp-1612	44	11	of	of	ADP
ajcp-1612	44	12	renal	renal	ADJ
ajcp-1612	44	13	disease	disease	NOUN
ajcp-1612	44	14	to	to	ADP
ajcp-1612	44	15	its	its	PRON
ajcp-1612	44	16	terminal	terminal	ADJ
ajcp-1612	44	17	stages	stage	NOUN
ajcp-1612	44	18	(	(	PUNCT
ajcp-1612	44	19	hussain	hussain	PROPN
ajcp-1612	44	20	et	et	PROPN
ajcp-1612	44	21	al	al	PROPN
ajcp-1612	44	22	.	.	PROPN
ajcp-1612	44	23	,	,	PUNCT
ajcp-1612	44	24	2020	2020	NUM
ajcp-1612	44	25	)	)	PUNCT
ajcp-1612	44	26	.	.	PUNCT
ajcp-1612	45	1	the	the	DET
ajcp-1612	45	2	progression	progression	NOUN
ajcp-1612	45	3	of	of	ADP
ajcp-1612	45	4	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	45	5	can	can	AUX
ajcp-1612	45	6	vary	vary	VERB
ajcp-1612	45	7	depending	depend	VERB
ajcp-1612	45	8	on	on	ADP
ajcp-1612	45	9	the	the	DET
ajcp-1612	45	10	underlying	underlie	VERB
ajcp-1612	45	11	cause	cause	NOUN
ajcp-1612	45	12	and	and	CCONJ
ajcp-1612	45	13	individual	individual	ADJ
ajcp-1612	45	14	factors	factor	NOUN
ajcp-1612	45	15	such	such	ADJ
ajcp-1612	45	16	as	as	ADP
ajcp-1612	45	17	age	age	NOUN
ajcp-1612	45	18	,	,	PUNCT
ajcp-1612	45	19	blood	blood	NOUN
ajcp-1612	45	20	pressure	pressure	NOUN
ajcp-1612	45	21	,	,	PUNCT
ajcp-1612	45	22	and	and	CCONJ
ajcp-1612	45	23	blood	blood	NOUN
ajcp-1612	45	24	sugar	sugar	NOUN
ajcp-1612	45	25	control	control	NOUN
ajcp-1612	45	26	(	(	PUNCT
ajcp-1612	45	27	oshima	oshima	PROPN
ajcp-1612	45	28	et	et	PROPN
ajcp-1612	45	29	al	al	PROPN
ajcp-1612	45	30	.	.	PROPN
ajcp-1612	45	31	,	,	PUNCT
ajcp-1612	45	32	2021	2021	NUM
ajcp-1612	45	33	)	)	PUNCT
ajcp-1612	45	34	.	.	PUNCT
ajcp-1612	46	1	however	however	ADV
ajcp-1612	46	2	,	,	PUNCT
ajcp-1612	46	3	in	in	ADP
ajcp-1612	46	4	general	general	ADJ
ajcp-1612	46	5	,	,	PUNCT
ajcp-1612	46	6	the	the	DET
ajcp-1612	46	7	progression	progression	NOUN
ajcp-1612	46	8	of	of	ADP
ajcp-1612	46	9	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	46	10	can	can	AUX
ajcp-1612	46	11	be	be	AUX
ajcp-1612	46	12	divided	divide	VERB
ajcp-1612	46	13	into	into	ADP
ajcp-1612	46	14	three	three	NUM
ajcp-1612	46	15	stages	stage	NOUN
ajcp-1612	46	16	:	:	PUNCT
ajcp-1612	46	17	1	1	X
ajcp-1612	46	18	.	.	X
ajcp-1612	46	19	early	early	ADJ
ajcp-1612	46	20	stage	stage	NOUN
ajcp-1612	46	21	:	:	PUNCT
ajcp-1612	46	22	in	in	ADP
ajcp-1612	46	23	the	the	DET
ajcp-1612	46	24	early	early	ADJ
ajcp-1612	46	25	stages	stage	NOUN
ajcp-1612	46	26	of	of	ADP
ajcp-1612	46	27	microalbuminuria	microalbuminuria	NOUN
ajcp-1612	46	28	,	,	PUNCT
ajcp-1612	46	29	the	the	DET
ajcp-1612	46	30	albumin	albumin	NOUN
ajcp-1612	46	31	in	in	ADP
ajcp-1612	46	32	the	the	DET
ajcp-1612	46	33	urine	urine	NOUN
ajcp-1612	46	34	is	be	AUX
ajcp-1612	46	35	slightly	slightly	ADV
ajcp-1612	46	36	elevated	elevated	ADJ
ajcp-1612	46	37	but	but	CCONJ
ajcp-1612	46	38	still	still	ADV
ajcp-1612	46	39	within	within	ADP
ajcp-1612	46	40	a	a	DET
ajcp-1612	46	41	normal	normal	ADJ
ajcp-1612	46	42	range	range	NOUN
ajcp-1612	46	43	.	.	PUNCT
ajcp-1612	47	1	this	this	DET
ajcp-1612	47	2	stage	stage	NOUN
ajcp-1612	47	3	may	may	AUX
ajcp-1612	47	4	not	not	PART
ajcp-1612	47	5	cause	cause	VERB
ajcp-1612	47	6	symptoms	symptom	NOUN
ajcp-1612	47	7	,	,	PUNCT
ajcp-1612	47	8	and	and	CCONJ
ajcp-1612	47	9	kidney	kidney	NOUN
ajcp-1612	47	10	function	function	NOUN
ajcp-1612	47	11	may	may	AUX
ajcp-1612	47	12	still	still	ADV
ajcp-1612	47	13	be	be	AUX
ajcp-1612	47	14	normal	normal	ADJ
ajcp-1612	47	15	(	(	PUNCT
ajcp-1612	47	16	parving	parve	VERB
ajcp-1612	47	17	et	et	PROPN
ajcp-1612	47	18	al	al	PROPN
ajcp-1612	47	19	.	.	PROPN
ajcp-1612	47	20	,	,	PUNCT
ajcp-1612	47	21	2015	2015	NUM
ajcp-1612	47	22	)	)	PUNCT
ajcp-1612	47	23	.	.	PUNCT
ajcp-1612	48	1	2	2	X
ajcp-1612	48	2	.	.	NUM
ajcp-1612	48	3	moderate	moderate	ADJ
ajcp-1612	48	4	stage	stage	NOUN
ajcp-1612	48	5	:	:	PUNCT
ajcp-1612	48	6	as	as	SCONJ
ajcp-1612	48	7	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	48	8	progresses	progress	VERB
ajcp-1612	48	9	,	,	PUNCT
ajcp-1612	48	10	the	the	DET
ajcp-1612	48	11	albumin	albumin	NOUN
ajcp-1612	48	12	in	in	ADP
ajcp-1612	48	13	the	the	DET
ajcp-1612	48	14	urine	urine	NOUN
ajcp-1612	48	15	elevates	elevate	VERB
ajcp-1612	48	16	,	,	PUNCT
ajcp-1612	48	17	and	and	CCONJ
ajcp-1612	48	18	kidney	kidney	NOUN
ajcp-1612	48	19	function	function	NOUN
ajcp-1612	48	20	may	may	AUX
ajcp-1612	48	21	decline	decline	VERB
ajcp-1612	48	22	.	.	PUNCT
ajcp-1612	49	1	this	this	DET
ajcp-1612	49	2	stage	stage	NOUN
ajcp-1612	49	3	is	be	AUX
ajcp-1612	49	4	often	often	ADV
ajcp-1612	49	5	characterised	characterise	VERB
ajcp-1612	49	6	by	by	ADP
ajcp-1612	49	7	hypertension	hypertension	NOUN
ajcp-1612	49	8	,	,	PUNCT
ajcp-1612	49	9	an	an	DET
ajcp-1612	49	10	elevation	elevation	NOUN
ajcp-1612	49	11	in	in	ADP
ajcp-1612	49	12	albuminuria	albuminuria	PROPN
ajcp-1612	49	13	,	,	PUNCT
ajcp-1612	49	14	and	and	CCONJ
ajcp-1612	49	15	a	a	DET
ajcp-1612	49	16	decline	decline	NOUN
ajcp-1612	49	17	in	in	ADP
ajcp-1612	49	18	the	the	DET
ajcp-1612	49	19	glomerular	glomerular	ADJ
ajcp-1612	49	20	filtration	filtration	NOUN
ajcp-1612	49	21	rate	rate	NOUN
ajcp-1612	49	22	(	(	PUNCT
ajcp-1612	49	23	gfr	gfr	NOUN
ajcp-1612	49	24	)	)	PUNCT
ajcp-1612	49	25	(	(	PUNCT
ajcp-1612	49	26	webster	webster	PROPN
ajcp-1612	49	27	et	et	PROPN
ajcp-1612	49	28	al	al	PROPN
ajcp-1612	49	29	.	.	PROPN
ajcp-1612	49	30	,	,	PUNCT
ajcp-1612	49	31	2017	2017	NUM
ajcp-1612	49	32	)	)	PUNCT
ajcp-1612	49	33	.	.	PUNCT
ajcp-1612	50	1	3	3	X
ajcp-1612	50	2	.	.	X
ajcp-1612	50	3	severe	severe	ADJ
ajcp-1612	50	4	stage	stage	NOUN
ajcp-1612	50	5	:	:	PUNCT
ajcp-1612	50	6	in	in	ADP
ajcp-1612	50	7	the	the	DET
ajcp-1612	50	8	severe	severe	ADJ
ajcp-1612	50	9	stage	stage	NOUN
ajcp-1612	50	10	of	of	ADP
ajcp-1612	50	11	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	50	12	,	,	PUNCT
ajcp-1612	50	13	there	there	PRON
ajcp-1612	50	14	is	be	VERB
ajcp-1612	50	15	a	a	DET
ajcp-1612	50	16	significant	significant	ADJ
ajcp-1612	50	17	elevation	elevation	NOUN
ajcp-1612	50	18	in	in	ADP
ajcp-1612	50	19	the	the	DET
ajcp-1612	50	20	amount	amount	NOUN
ajcp-1612	50	21	of	of	ADP
ajcp-1612	50	22	albumin	albumin	NOUN
ajcp-1612	50	23	in	in	ADP
ajcp-1612	50	24	the	the	DET
ajcp-1612	50	25	urine	urine	NOUN
ajcp-1612	50	26	,	,	PUNCT
ajcp-1612	50	27	and	and	CCONJ
ajcp-1612	50	28	kidney	kidney	NOUN
ajcp-1612	50	29	function	function	NOUN
ajcp-1612	50	30	is	be	AUX
ajcp-1612	50	31	severely	severely	ADV
ajcp-1612	50	32	impaired	impaired	ADJ
ajcp-1612	50	33	.	.	PUNCT
ajcp-1612	51	1	at	at	ADP
ajcp-1612	51	2	this	this	DET
ajcp-1612	51	3	stage	stage	NOUN
ajcp-1612	51	4	,	,	PUNCT
ajcp-1612	51	5	patients	patient	NOUN
ajcp-1612	51	6	may	may	AUX
ajcp-1612	51	7	experience	experience	VERB
ajcp-1612	51	8	fatigue	fatigue	NOUN
ajcp-1612	51	9	,	,	PUNCT
ajcp-1612	51	10	weakness	weakness	NOUN
ajcp-1612	51	11	,	,	PUNCT
ajcp-1612	51	12	leg	leg	NOUN
ajcp-1612	51	13	swelling	swelling	NOUN
ajcp-1612	51	14	,	,	PUNCT
ajcp-1612	51	15	and	and	CCONJ
ajcp-1612	51	16	difficulty	difficulty	NOUN
ajcp-1612	51	17	concentrating	concentrate	VERB
ajcp-1612	51	18	(	(	PUNCT
ajcp-1612	51	19	romagnani	romagnani	PROPN
ajcp-1612	51	20	et	et	PROPN
ajcp-1612	51	21	al	al	PROPN
ajcp-1612	51	22	.	.	PROPN
ajcp-1612	51	23	,	,	PUNCT
ajcp-1612	51	24	2017	2017	NUM
ajcp-1612	51	25	)	)	PUNCT
ajcp-1612	51	26	.	.	PUNCT
ajcp-1612	52	1	it	it	PRON
ajcp-1612	52	2	is	be	AUX
ajcp-1612	52	3	essential	essential	ADJ
ajcp-1612	52	4	to	to	PART
ajcp-1612	52	5	diagnose	diagnose	VERB
ajcp-1612	52	6	and	and	CCONJ
ajcp-1612	52	7	treat	treat	VERB
ajcp-1612	52	8	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	52	9	in	in	ADP
ajcp-1612	52	10	the	the	DET
ajcp-1612	52	11	early	early	ADJ
ajcp-1612	52	12	stages	stage	NOUN
ajcp-1612	52	13	to	to	PART
ajcp-1612	52	14	prevent	prevent	VERB
ajcp-1612	52	15	the	the	DET
ajcp-1612	52	16	progression	progression	NOUN
ajcp-1612	52	17	of	of	ADP
ajcp-1612	52	18	kidney	kidney	NOUN
ajcp-1612	52	19	disease	disease	NOUN
ajcp-1612	52	20	.	.	PUNCT
ajcp-1612	53	1	treatment	treatment	NOUN
ajcp-1612	53	2	may	may	AUX
ajcp-1612	53	3	involve	involve	VERB
ajcp-1612	53	4	medication	medication	NOUN
ajcp-1612	53	5	to	to	PART
ajcp-1612	53	6	control	control	VERB
ajcp-1612	53	7	blood	blood	NOUN
ajcp-1612	53	8	pressure	pressure	NOUN
ajcp-1612	53	9	and	and	CCONJ
ajcp-1612	53	10	blood	blood	NOUN
ajcp-1612	53	11	sugar	sugar	NOUN
ajcp-1612	53	12	,	,	PUNCT
ajcp-1612	53	13	lifestyle	lifestyle	NOUN
ajcp-1612	53	14	changes	change	NOUN
ajcp-1612	53	15	such	such	ADJ
ajcp-1612	53	16	as	as	ADP
ajcp-1612	53	17	a	a	DET
ajcp-1612	53	18	healthy	healthy	ADJ
ajcp-1612	53	19	diet	diet	NOUN
ajcp-1612	53	20	and	and	CCONJ
ajcp-1612	53	21	exercise	exercise	NOUN
ajcp-1612	53	22	,	,	PUNCT
ajcp-1612	53	23	and	and	CCONJ
ajcp-1612	53	24	regular	regular	ADJ
ajcp-1612	53	25	monitoring	monitoring	NOUN
ajcp-1612	53	26	of	of	ADP
ajcp-1612	53	27	kidney	kidney	NOUN
ajcp-1612	53	28	function	function	NOUN
ajcp-1612	53	29	.	.	PUNCT
ajcp-1612	54	1	if	if	SCONJ
ajcp-1612	54	2	left	leave	VERB
ajcp-1612	54	3	untreated	untreated	ADJ
ajcp-1612	54	4	,	,	PUNCT
ajcp-1612	54	5	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	54	6	can	can	AUX
ajcp-1612	54	7	progress	progress	VERB
ajcp-1612	54	8	to	to	ADP
ajcp-1612	54	9	macroalbuminuria	macroalbuminuria	PROPN
ajcp-1612	54	10	,	,	PUNCT
ajcp-1612	54	11	which	which	PRON
ajcp-1612	54	12	is	be	AUX
ajcp-1612	54	13	the	the	DET
ajcp-1612	54	14	presence	presence	NOUN
ajcp-1612	54	15	of	of	ADP
ajcp-1612	54	16	large	large	ADJ
ajcp-1612	54	17	amounts	amount	NOUN
ajcp-1612	54	18	of	of	ADP
ajcp-1612	54	19	albumin	albumin	NOUN
ajcp-1612	54	20	in	in	ADP
ajcp-1612	54	21	the	the	DET
ajcp-1612	54	22	urine	urine	NOUN
ajcp-1612	54	23	(	(	PUNCT
ajcp-1612	54	24	persson	persson	PROPN
ajcp-1612	54	25	&	&	CCONJ
ajcp-1612	54	26	rossing	rossing	PROPN
ajcp-1612	54	27	,	,	PUNCT
ajcp-1612	54	28	2018	2018	NUM
ajcp-1612	54	29	)	)	PUNCT
ajcp-1612	54	30	.	.	PUNCT
ajcp-1612	55	1	macro	macro	ADJ
ajcp-1612	55	2	albuminuria	albuminuria	PROPN
ajcp-1612	55	3	is	be	AUX
ajcp-1612	55	4	a	a	DET
ajcp-1612	55	5	more	more	ADV
ajcp-1612	55	6	advanced	advanced	ADJ
ajcp-1612	55	7	stage	stage	NOUN
ajcp-1612	55	8	of	of	ADP
ajcp-1612	55	9	kidney	kidney	NOUN
ajcp-1612	55	10	disease	disease	NOUN
ajcp-1612	55	11	and	and	CCONJ
ajcp-1612	55	12	is	be	AUX
ajcp-1612	55	13	usually	usually	ADV
ajcp-1612	55	14	acknowledged	acknowledge	VERB
ajcp-1612	55	15	with	with	ADP
ajcp-1612	55	16	a	a	DET
ajcp-1612	55	17	degradation	degradation	NOUN
ajcp-1612	55	18	in	in	ADP
ajcp-1612	55	19	kidney	kidney	NOUN
ajcp-1612	55	20	function	function	NOUN
ajcp-1612	55	21	and	and	CCONJ
ajcp-1612	55	22	an	an	DET
ajcp-1612	55	23	increased	increase	VERB
ajcp-1612	55	24	risk	risk	NOUN
ajcp-1612	55	25	of	of	ADP
ajcp-1612	55	26	cardiovascular	cardiovascular	ADJ
ajcp-1612	55	27	disease	disease	NOUN
ajcp-1612	55	28	(	(	PUNCT
ajcp-1612	55	29	persson	persson	PROPN
ajcp-1612	55	30	&	&	CCONJ
ajcp-1612	55	31	rossing	rossing	PROPN
ajcp-1612	55	32	,	,	PUNCT
ajcp-1612	55	33	2018	2018	NUM
ajcp-1612	55	34	)	)	PUNCT
ajcp-1612	55	35	.	.	PUNCT
ajcp-1612	56	1	target	target	VERB
ajcp-1612	56	2	time	time	NOUN
ajcp-1612	56	3	in	in	ADP
ajcp-1612	56	4	range	range	NOUN
ajcp-1612	56	5	and	and	CCONJ
ajcp-1612	56	6	hba1c	hba1c	NOUN
ajcp-1612	56	7	the	the	DET
ajcp-1612	56	8	a1c	a1c	PROPN
ajcp-1612	56	9	test	test	NOUN
ajcp-1612	56	10	,	,	PUNCT
ajcp-1612	56	11	blood	blood	NOUN
ajcp-1612	56	12	glucose	glucose	NOUN
ajcp-1612	56	13	monitoring	monitoring	NOUN
ajcp-1612	56	14	(	(	PUNCT
ajcp-1612	56	15	bgm	bgm	PROPN
ajcp-1612	56	16	)	)	PUNCT
ajcp-1612	56	17	,	,	PUNCT
ajcp-1612	56	18	and	and	CCONJ
ajcp-1612	56	19	continuous	continuous	ADJ
ajcp-1612	56	20	glucose	glucose	NOUN
ajcp-1612	56	21	monitoring	monitoring	NOUN
ajcp-1612	56	22	(	(	PUNCT
ajcp-1612	56	23	cgm	cgm	PROPN
ajcp-1612	56	24	)	)	PUNCT
ajcp-1612	56	25	are	be	AUX
ajcp-1612	56	26	all	all	PRON
ajcp-1612	56	27	used	use	VERB
ajcp-1612	56	28	to	to	PART
ajcp-1612	56	29	examine	examine	VERB
ajcp-1612	56	30	glycemic	glycemic	ADJ
ajcp-1612	56	31	control	control	NOUN
ajcp-1612	56	32	.	.	PUNCT
ajcp-1612	57	1	the	the	DET
ajcp-1612	57	2	a1c	a1c	PROPN
ajcp-1612	57	3	is	be	AUX
ajcp-1612	57	4	the	the	DET
ajcp-1612	57	5	commonly	commonly	ADV
ajcp-1612	57	6	used	use	VERB
ajcp-1612	57	7	biomarker	biomarker	NOUN
ajcp-1612	57	8	for	for	ADP
ajcp-1612	57	9	assessing	assess	VERB
ajcp-1612	57	10	blood	blood	NOUN
ajcp-1612	57	11	glucose	glucose	NOUN
ajcp-1612	57	12	control	control	NOUN
ajcp-1612	57	13	in	in	ADP
ajcp-1612	57	14	diabetics	diabetic	NOUN
ajcp-1612	57	15	,	,	PUNCT
ajcp-1612	57	16	as	as	SCONJ
ajcp-1612	57	17	it	it	PRON
ajcp-1612	57	18	decreases	decrease	VERB
ajcp-1612	57	19	both	both	PRON
ajcp-1612	57	20	long	long	ADJ
ajcp-1612	57	21	-	-	PUNCT
ajcp-1612	57	22	term	term	NOUN
ajcp-1612	57	23	and	and	CCONJ
ajcp-1612	57	24	short	short	ADJ
ajcp-1612	57	25	-	-	PUNCT
ajcp-1612	57	26	term	term	NOUN
ajcp-1612	57	27	macrovascular	macrovascular	ADJ
ajcp-1612	57	28	disease	disease	NOUN
ajcp-1612	57	29	and	and	CCONJ
ajcp-1612	57	30	long	long	ADJ
ajcp-1612	57	31	-	-	PUNCT
ajcp-1612	57	32	term	term	NOUN
ajcp-1612	57	33	microvascular	microvascular	NOUN
ajcp-1612	57	34	consequences	consequence	NOUN
ajcp-1612	57	35	(	(	PUNCT
ajcp-1612	57	36	wright	wright	PROPN
ajcp-1612	57	37	et	et	PROPN
ajcp-1612	57	38	al	al	PROPN
ajcp-1612	57	39	.	.	PROPN
ajcp-1612	57	40	,	,	PUNCT
ajcp-1612	57	41	2020	2020	NUM
ajcp-1612	57	42	)	)	PUNCT
ajcp-1612	57	43	.	.	PUNCT
ajcp-1612	58	1	whereas	whereas	SCONJ
ajcp-1612	58	2	time	time	NOUN
ajcp-1612	58	3	in	in	ADP
ajcp-1612	58	4	range	range	NOUN
ajcp-1612	58	5	(	(	PUNCT
ajcp-1612	58	6	tir	tir	NOUN
ajcp-1612	58	7	)	)	PUNCT
ajcp-1612	58	8	refers	refer	VERB
ajcp-1612	58	9	to	to	ADP
ajcp-1612	58	10	the	the	DET
ajcp-1612	58	11	amount	amount	NOUN
ajcp-1612	58	12	of	of	ADP
ajcp-1612	58	13	time	time	NOUN
ajcp-1612	58	14	that	that	PRON
ajcp-1612	58	15	a	a	DET
ajcp-1612	58	16	person	person	NOUN
ajcp-1612	58	17	with	with	ADP
ajcp-1612	58	18	diabetes	diabetes	NOUN
ajcp-1612	58	19	spends	spend	VERB
ajcp-1612	58	20	within	within	ADP
ajcp-1612	58	21	a	a	DET
ajcp-1612	58	22	target	target	NOUN
ajcp-1612	58	23	range	range	NOUN
ajcp-1612	58	24	of	of	ADP
ajcp-1612	58	25	blood	blood	NOUN
ajcp-1612	58	26	glucose	glucose	NOUN
ajcp-1612	58	27	levels	level	NOUN
ajcp-1612	58	28	(	(	PUNCT
ajcp-1612	58	29	advani	advani	PROPN
ajcp-1612	58	30	,	,	PUNCT
ajcp-1612	58	31	2020	2020	NUM
ajcp-1612	58	32	)	)	PUNCT
ajcp-1612	58	33	.	.	PUNCT
ajcp-1612	59	1	for	for	ADP
ajcp-1612	59	2	diabetic	diabetic	ADJ
ajcp-1612	59	3	people	people	NOUN
ajcp-1612	59	4	,	,	PUNCT
ajcp-1612	59	5	maintaining	maintain	VERB
ajcp-1612	59	6	blood	blood	NOUN
ajcp-1612	59	7	glucose	glucose	NOUN
ajcp-1612	59	8	levels	level	NOUN
ajcp-1612	59	9	within	within	ADP
ajcp-1612	59	10	a	a	DET
ajcp-1612	59	11	target	target	NOUN
ajcp-1612	59	12	range	range	NOUN
ajcp-1612	59	13	is	be	AUX
ajcp-1612	59	14	important	important	ADJ
ajcp-1612	59	15	for	for	ADP
ajcp-1612	59	16	preventing	prevent	VERB
ajcp-1612	59	17	complications	complication	NOUN
ajcp-1612	59	18	such	such	ADJ
ajcp-1612	59	19	as	as	ADP
ajcp-1612	59	20	nerve	nerve	NOUN
ajcp-1612	59	21	damage	damage	NOUN
ajcp-1612	59	22	,	,	PUNCT
ajcp-1612	59	23	kidney	kidney	NOUN
ajcp-1612	59	24	disease	disease	NOUN
ajcp-1612	59	25	,	,	PUNCT
ajcp-1612	59	26	and	and	CCONJ
ajcp-1612	59	27	cardiovascular	cardiovascular	ADJ
ajcp-1612	59	28	disease	disease	NOUN
ajcp-1612	59	29	(	(	PUNCT
ajcp-1612	59	30	advani	advani	PROPN
ajcp-1612	59	31	,	,	PUNCT
ajcp-1612	59	32	2020	2020	NUM
ajcp-1612	59	33	)	)	PUNCT
ajcp-1612	59	34	.	.	PUNCT
ajcp-1612	60	1	tir	tir	PROPN
ajcp-1612	60	2	is	be	AUX
ajcp-1612	60	3	useful	useful	ADJ
ajcp-1612	60	4	for	for	ADP
ajcp-1612	60	5	monitoring	monitor	VERB
ajcp-1612	60	6	blood	blood	NOUN
ajcp-1612	60	7	glucose	glucose	NOUN
ajcp-1612	60	8	levels	level	NOUN
ajcp-1612	60	9	and	and	CCONJ
ajcp-1612	60	10	assessing	assess	VERB
ajcp-1612	60	11	how	how	SCONJ
ajcp-1612	60	12	well	well	ADV
ajcp-1612	60	13	diabetes	diabetes	NOUN
ajcp-1612	60	14	management	management	NOUN
ajcp-1612	60	15	strategies	strategy	NOUN
ajcp-1612	60	16	work	work	NOUN
ajcp-1612	60	17	(	(	PUNCT
ajcp-1612	60	18	mayeda	mayeda	PROPN
ajcp-1612	60	19	et	et	PROPN
ajcp-1612	60	20	al	al	PROPN
ajcp-1612	60	21	.	.	PROPN
ajcp-1612	60	22	,	,	PUNCT
ajcp-1612	60	23	2020	2020	NUM
ajcp-1612	60	24	)	)	PUNCT
ajcp-1612	60	25	.	.	PUNCT
ajcp-1612	61	1	the	the	DET
ajcp-1612	61	2	target	target	NOUN
ajcp-1612	61	3	range	range	VERB
ajcp-1612	61	4	for	for	ADP
ajcp-1612	61	5	tir	tir	NOUN
ajcp-1612	61	6	can	can	AUX
ajcp-1612	61	7	vary	vary	VERB
ajcp-1612	61	8	depending	depend	VERB
ajcp-1612	61	9	on	on	ADP
ajcp-1612	61	10	the	the	DET
ajcp-1612	61	11	individual	individual	NOUN
ajcp-1612	61	12	,	,	PUNCT
ajcp-1612	61	13	but	but	CCONJ
ajcp-1612	61	14	a	a	DET
ajcp-1612	61	15	common	common	ADJ
ajcp-1612	61	16	target	target	NOUN
ajcp-1612	61	17	range	range	NOUN
ajcp-1612	61	18	is	be	AUX
ajcp-1612	61	19	between	between	ADP
ajcp-1612	61	20	70	70	NUM
ajcp-1612	61	21	and	and	CCONJ
ajcp-1612	61	22	180	180	NUM
ajcp-1612	61	23	mg	mg	PROPN
ajcp-1612	61	24	/	/	SYM
ajcp-1612	61	25	dl	dl	PROPN
ajcp-1612	61	26	(	(	PUNCT
ajcp-1612	61	27	beck	beck	PROPN
ajcp-1612	61	28	et	et	PROPN
ajcp-1612	61	29	al	al	PROPN
ajcp-1612	61	30	.	.	PROPN
ajcp-1612	61	31	,	,	PUNCT
ajcp-1612	61	32	2019	2019	NUM
ajcp-1612	61	33	)	)	PUNCT
ajcp-1612	61	34	.	.	PUNCT
ajcp-1612	62	1	tir	tir	PROPN
ajcp-1612	62	2	can	can	AUX
ajcp-1612	62	3	be	be	AUX
ajcp-1612	62	4	measured	measure	VERB
ajcp-1612	62	5	using	use	VERB
ajcp-1612	62	6	continuous	continuous	ADJ
ajcp-1612	62	7	glucose	glucose	NOUN
ajcp-1612	62	8	monitoring	monitoring	NOUN
ajcp-1612	62	9	(	(	PUNCT
ajcp-1612	62	10	cgm	cgm	PROPN
ajcp-1612	62	11	)	)	PUNCT
ajcp-1612	62	12	devices	device	NOUN
ajcp-1612	62	13	,	,	PUNCT
ajcp-1612	62	14	which	which	PRON
ajcp-1612	62	15	provide	provide	VERB
ajcp-1612	62	16	real	real	ADJ
ajcp-1612	62	17	-	-	PUNCT
ajcp-1612	62	18	time	time	NOUN
ajcp-1612	62	19	glucose	glucose	NOUN
ajcp-1612	62	20	readings	reading	NOUN
ajcp-1612	62	21	throughout	throughout	ADP
ajcp-1612	62	22	the	the	DET
ajcp-1612	62	23	day	day	NOUN
ajcp-1612	62	24	and	and	CCONJ
ajcp-1612	62	25	night	night	NOUN
ajcp-1612	62	26	(	(	PUNCT
ajcp-1612	62	27	gabbay	gabbay	NOUN
ajcp-1612	62	28	et	et	PROPN
ajcp-1612	62	29	al	al	PROPN
ajcp-1612	62	30	.	.	PROPN
ajcp-1612	62	31	,	,	PUNCT
ajcp-1612	62	32	2020	2020	NUM
ajcp-1612	62	33	)	)	PUNCT
ajcp-1612	62	34	.	.	PUNCT
ajcp-1612	63	1	hba1c	hba1c	PROPN
ajcp-1612	63	2	and	and	CCONJ
ajcp-1612	63	3	tir	tir	PROPN
ajcp-1612	63	4	are	be	AUX
ajcp-1612	63	5	two	two	NUM
ajcp-1612	63	6	essential	essential	ADJ
ajcp-1612	63	7	diabetes	diabetes	NOUN
ajcp-1612	63	8	management	management	NOUN
ajcp-1612	63	9	metrics	metric	NOUN
ajcp-1612	63	10	.	.	PUNCT
ajcp-1612	64	1	however	however	ADV
ajcp-1612	64	2	,	,	PUNCT
ajcp-1612	64	3	they	they	PRON
ajcp-1612	64	4	serve	serve	VERB
ajcp-1612	64	5	different	different	ADJ
ajcp-1612	64	6	functions	function	NOUN
ajcp-1612	64	7	(	(	PUNCT
ajcp-1612	64	8	lu	lu	NOUN
ajcp-1612	64	9	et	et	PROPN
ajcp-1612	64	10	al	al	PROPN
ajcp-1612	64	11	.	.	PROPN
ajcp-1612	64	12	,	,	PUNCT
ajcp-1612	64	13	2020	2020	NUM
ajcp-1612	64	14	)	)	PUNCT
ajcp-1612	64	15	.	.	PUNCT
ajcp-1612	65	1	tir	tir	PROPN
ajcp-1612	65	2	is	be	AUX
ajcp-1612	65	3	used	use	VERB
ajcp-1612	65	4	to	to	PART
ajcp-1612	65	5	monitor	monitor	VERB
ajcp-1612	65	6	short	short	ADJ
ajcp-1612	65	7	-	-	PUNCT
ajcp-1612	65	8	term	term	NOUN
ajcp-1612	65	9	changes	change	NOUN
ajcp-1612	65	10	in	in	ADP
ajcp-1612	65	11	blood	blood	NOUN
ajcp-1612	65	12	glucose	glucose	NOUN
ajcp-1612	65	13	levels	level	NOUN
ajcp-1612	65	14	and	and	CCONJ
ajcp-1612	65	15	evaluate	evaluate	VERB
ajcp-1612	65	16	the	the	DET
ajcp-1612	65	17	efficacy	efficacy	NOUN
ajcp-1612	65	18	of	of	ADP
ajcp-1612	65	19	diabetes	diabetes	NOUN
ajcp-1612	65	20	management	management	NOUN
ajcp-1612	65	21	techniques	technique	NOUN
ajcp-1612	65	22	,	,	PUNCT
ajcp-1612	65	23	while	while	SCONJ
ajcp-1612	65	24	hba1c	hba1c	PROPN
ajcp-1612	65	25	is	be	AUX
ajcp-1612	65	26	used	use	VERB
ajcp-1612	65	27	to	to	PART
ajcp-1612	65	28	examine	examine	VERB
ajcp-1612	65	29	long	long	ADJ
ajcp-1612	65	30	-	-	PUNCT
ajcp-1612	65	31	term	term	NOUN
ajcp-1612	65	32	glycemic	glycemic	ADJ
ajcp-1612	65	33	control	control	NOUN
ajcp-1612	65	34	and	and	CCONJ
ajcp-1612	65	35	assist	assist	VERB
ajcp-1612	65	36	with	with	ADP
ajcp-1612	65	37	treatment	treatment	NOUN
ajcp-1612	65	38	options	option	NOUN
ajcp-1612	65	39	(	(	PUNCT
ajcp-1612	65	40	yoo	yoo	PROPN
ajcp-1612	65	41	&	&	CCONJ
ajcp-1612	65	42	kim	kim	PROPN
ajcp-1612	65	43	,	,	PUNCT
ajcp-1612	65	44	2020	2020	NUM
ajcp-1612	65	45	)	)	PUNCT
ajcp-1612	65	46	.	.	PUNCT
ajcp-1612	66	1	however	however	ADV
ajcp-1612	66	2	,	,	PUNCT
ajcp-1612	66	3	a	a	DET
ajcp-1612	66	4	correlation	correlation	NOUN
ajcp-1612	66	5	exists	exist	VERB
ajcp-1612	66	6	between	between	ADP
ajcp-1612	66	7	hba1c	hba1c	PROPN
ajcp-1612	66	8	and	and	CCONJ
ajcp-1612	66	9	tir	tir	PROPN
ajcp-1612	66	10	due	due	ADP
ajcp-1612	66	11	to	to	ADP
ajcp-1612	66	12	the	the	DET
ajcp-1612	66	13	same	same	ADJ
ajcp-1612	66	14	variables	variable	NOUN
ajcp-1612	66	15	impacting	impact	VERB
ajcp-1612	66	16	blood	blood	NOUN
ajcp-1612	66	17	sugar	sugar	NOUN
ajcp-1612	66	18	levels	level	NOUN
ajcp-1612	66	19	,	,	PUNCT
ajcp-1612	66	20	such	such	ADJ
ajcp-1612	66	21	as	as	ADP
ajcp-1612	66	22	food	food	NOUN
ajcp-1612	66	23	,	,	PUNCT
ajcp-1612	66	24	exercise	exercise	NOUN
ajcp-1612	66	25	,	,	PUNCT
ajcp-1612	66	26	and	and	CCONJ
ajcp-1612	66	27	medication	medication	NOUN
ajcp-1612	66	28	use	use	NOUN
ajcp-1612	66	29	(	(	PUNCT
ajcp-1612	66	30	vigersky	vigersky	PROPN
ajcp-1612	66	31	&	&	CCONJ
ajcp-1612	66	32	mcmahon	mcmahon	PROPN
ajcp-1612	66	33	,	,	PUNCT
ajcp-1612	66	34	2019	2019	NUM
ajcp-1612	66	35	)	)	PUNCT
ajcp-1612	66	36	.	.	PUNCT
ajcp-1612	67	1	a	a	DET
ajcp-1612	67	2	lower	low	ADJ
ajcp-1612	67	3	hba1c	hba1c	NOUN
ajcp-1612	67	4	indicates	indicate	VERB
ajcp-1612	67	5	better	well	ADJ
ajcp-1612	67	6	long	long	ADJ
ajcp-1612	67	7	-	-	PUNCT
ajcp-1612	67	8	term	term	NOUN
ajcp-1612	67	9	glycemic	glycemic	ADJ
ajcp-1612	67	10	management	management	NOUN
ajcp-1612	67	11	and	and	CCONJ
ajcp-1612	67	12	is	be	AUX
ajcp-1612	67	13	more	more	ADV
ajcp-1612	67	14	common	common	ADJ
ajcp-1612	67	15	in	in	ADP
ajcp-1612	67	16	patients	patient	NOUN
ajcp-1612	67	17	with	with	ADP
ajcp-1612	67	18	higher	high	ADJ
ajcp-1612	67	19	tir	tir	PROPN
ajcp-1612	67	20	levels	level	NOUN
ajcp-1612	67	21	.	.	PUNCT
ajcp-1612	68	1	generally	generally	ADV
ajcp-1612	68	2	,	,	PUNCT
ajcp-1612	68	3	a	a	DET
ajcp-1612	68	4	higher	high	ADJ
ajcp-1612	68	5	tir	tir	NOUN
ajcp-1612	68	6	is	be	AUX
ajcp-1612	68	7	associated	associate	VERB
ajcp-1612	68	8	with	with	ADP
ajcp-1612	68	9	better	well	ADJ
ajcp-1612	68	10	diabetes	diabetes	NOUN
ajcp-1612	68	11	management	management	NOUN
ajcp-1612	68	12	and	and	CCONJ
ajcp-1612	68	13	lower	low	ADJ
ajcp-1612	68	14	risk	risk	NOUN
ajcp-1612	68	15	of	of	ADP
ajcp-1612	68	16	complications	complication	NOUN
ajcp-1612	68	17	(	(	PUNCT
ajcp-1612	68	18	shah	shah	PROPN
ajcp-1612	68	19	et	et	PROPN
ajcp-1612	68	20	al	al	PROPN
ajcp-1612	68	21	.	.	PROPN
ajcp-1612	68	22	,	,	PUNCT
ajcp-1612	68	23	2021	2021	NUM
ajcp-1612	68	24	)	)	PUNCT
ajcp-1612	68	25	.	.	PUNCT
ajcp-1612	69	1	through	through	ADP
ajcp-1612	69	2	tir	tir	PROPN
ajcp-1612	69	3	and	and	CCONJ
ajcp-1612	69	4	hba1c	hba1c	PROPN
ajcp-1612	69	5	metrics	metric	NOUN
ajcp-1612	69	6	,	,	PUNCT
ajcp-1612	69	7	diabetes	diabetes	NOUN
ajcp-1612	69	8	can	can	AUX
ajcp-1612	69	9	be	be	AUX
ajcp-1612	69	10	managed	manage	VERB
ajcp-1612	69	11	,	,	PUNCT
ajcp-1612	69	12	preventing	prevent	VERB
ajcp-1612	69	13	the	the	DET
ajcp-1612	69	14	chances	chance	NOUN
ajcp-1612	69	15	of	of	ADP
ajcp-1612	69	16	ckd	ckd	PROPN
ajcp-1612	69	17	and	and	CCONJ
ajcp-1612	69	18	other	other	ADJ
ajcp-1612	69	19	diabetes	diabetes	NOUN
ajcp-1612	69	20	-	-	PUNCT
ajcp-1612	69	21	related	relate	VERB
ajcp-1612	69	22	complications	complication	NOUN
ajcp-1612	69	23	.	.	PUNCT
ajcp-1612	70	1	prevention	prevention	NOUN
ajcp-1612	70	2	at	at	ADP
ajcp-1612	70	3	the	the	DET
ajcp-1612	70	4	level	level	NOUN
ajcp-1612	70	5	of	of	ADP
ajcp-1612	70	6	impaired	impaired	ADJ
ajcp-1612	70	7	fasting	fasting	NOUN
ajcp-1612	70	8	glucose	glucose	NOUN
ajcp-1612	70	9	and	and	CCONJ
ajcp-1612	70	10	prediabetes	prediabete	NOUN
ajcp-1612	70	11	prevention	prevention	NOUN
ajcp-1612	70	12	of	of	ADP
ajcp-1612	70	13	ckd	ckd	PROPN
ajcp-1612	70	14	and	and	CCONJ
ajcp-1612	70	15	diabetes	diabetes	NOUN
ajcp-1612	70	16	can	can	AUX
ajcp-1612	70	17	only	only	ADV
ajcp-1612	70	18	be	be	AUX
ajcp-1612	70	19	done	do	VERB
ajcp-1612	70	20	by	by	ADP
ajcp-1612	70	21	managing	manage	VERB
ajcp-1612	70	22	the	the	DET
ajcp-1612	70	23	disease	disease	NOUN
ajcp-1612	70	24	at	at	ADP
ajcp-1612	70	25	impaired	impaired	ADJ
ajcp-1612	70	26	fasting	fasting	NOUN
ajcp-1612	70	27	glucose	glucose	NOUN
ajcp-1612	70	28	(	(	PUNCT
ajcp-1612	70	29	ifg	ifg	PROPN
ajcp-1612	70	30	)	)	PUNCT
ajcp-1612	70	31	and	and	CCONJ
ajcp-1612	70	32	prediabetes	prediabete	NOUN
ajcp-1612	70	33	levels	level	NOUN
ajcp-1612	70	34	.	.	PUNCT
ajcp-1612	71	1	impaired	impair	VERB
ajcp-1612	71	2	fasting	fast	VERB
ajcp-1612	71	3	blood	blood	NOUN
ajcp-1612	71	4	sugar	sugar	NOUN
ajcp-1612	71	5	(	(	PUNCT
ajcp-1612	71	6	ifg	ifg	PROPN
ajcp-1612	71	7	)	)	PUNCT
ajcp-1612	71	8	is	be	AUX
ajcp-1612	71	9	a	a	DET
ajcp-1612	71	10	pre	pre	ADJ
ajcp-1612	71	11	-	-	ADJ
ajcp-1612	71	12	diabetic	diabetic	ADJ
ajcp-1612	71	13	condition	condition	NOUN
ajcp-1612	71	14	linked	link	VERB
ajcp-1612	71	15	to	to	ADP
ajcp-1612	71	16	a	a	DET
ajcp-1612	71	17	relatively	relatively	ADV
ajcp-1612	71	18	elevated	elevated	ADJ
ajcp-1612	71	19	probability	probability	NOUN
ajcp-1612	71	20	of	of	ADP
ajcp-1612	71	21	developing	develop	VERB
ajcp-1612	71	22	diabetes2	diabetes2	NOUN
ajcp-1612	71	23	(	(	PUNCT
ajcp-1612	71	24	yu	yu	PROPN
ajcp-1612	71	25	et	et	PROPN
ajcp-1612	71	26	al	al	PROPN
ajcp-1612	71	27	.	.	PROPN
ajcp-1612	71	28	,	,	PUNCT
ajcp-1612	71	29	2020	2020	NUM
ajcp-1612	71	30	)	)	PUNCT
ajcp-1612	71	31	.	.	PUNCT
ajcp-1612	72	1	early	early	ADJ
ajcp-1612	72	2	identification	identification	NOUN
ajcp-1612	72	3	of	of	ADP
ajcp-1612	72	4	prediabetes	prediabete	NOUN
ajcp-1612	72	5	and	and	CCONJ
ajcp-1612	72	6	individualised	individualised	ADJ
ajcp-1612	72	7	therapy	therapy	NOUN
ajcp-1612	72	8	are	be	AUX
ajcp-1612	72	9	required	require	VERB
ajcp-1612	72	10	to	to	PART
ajcp-1612	72	11	effectively	effectively	ADV
ajcp-1612	72	12	manage	manage	VERB
ajcp-1612	72	13	this	this	DET
ajcp-1612	72	14	steadily	steadily	ADV
ajcp-1612	72	15	increasing	increase	VERB
ajcp-1612	72	16	diabetic	diabetic	ADJ
ajcp-1612	72	17	population	population	NOUN
ajcp-1612	72	18	.	.	PUNCT
ajcp-1612	73	1	ifg	ifg	PROPN
ajcp-1612	73	2	is	be	AUX
ajcp-1612	73	3	a	a	DET
ajcp-1612	73	4	significant	significant	ADJ
ajcp-1612	73	5	indicator	indicator	NOUN
ajcp-1612	73	6	of	of	ADP
ajcp-1612	73	7	diabetes	diabetes	NOUN
ajcp-1612	73	8	and	and	CCONJ
ajcp-1612	73	9	its	its	PRON
ajcp-1612	73	10	comorbidities	comorbiditie	NOUN
ajcp-1612	73	11	(	(	PUNCT
ajcp-1612	73	12	yu	yu	X
ajcp-1612	73	13	et	et	PROPN
ajcp-1612	73	14	al	al	PROPN
ajcp-1612	73	15	.	.	PROPN
ajcp-1612	73	16	,	,	PUNCT
ajcp-1612	73	17	2020	2020	NUM
ajcp-1612	73	18	)	)	PUNCT
ajcp-1612	73	19	.	.	PUNCT
ajcp-1612	74	1	consistently	consistently	ADV
ajcp-1612	74	2	high	high	ADJ
ajcp-1612	74	3	blood	blood	NOUN
ajcp-1612	74	4	sugar	sugar	NOUN
ajcp-1612	74	5	levels	level	NOUN
ajcp-1612	74	6	can	can	AUX
ajcp-1612	74	7	cause	cause	VERB
ajcp-1612	74	8	heart	heart	NOUN
ajcp-1612	74	9	problems	problem	NOUN
ajcp-1612	74	10	,	,	PUNCT
ajcp-1612	74	11	diabetic	diabetic	ADJ
ajcp-1612	74	12	nephropathy	nephropathy	ADJ
ajcp-1612	74	13	,	,	PUNCT
ajcp-1612	74	14	retinopathy	retinopathy	ADJ
ajcp-1612	74	15	,	,	PUNCT
ajcp-1612	74	16	neuropathy	neuropathy	ADJ
ajcp-1612	74	17	,	,	PUNCT
ajcp-1612	74	18	and	and	CCONJ
ajcp-1612	74	19	increased	increase	VERB
ajcp-1612	74	20	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	74	21	pa	pa	PROPN
ajcp-1612	74	22	ge	ge	PROPN
ajcp-1612	74	23	10	10	NUM
ajcp-1612	74	24	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	74	25	am	be	AUX
ajcp-1612	74	26	.	.	PUNCT
ajcp-1612	75	1	j.	j.	PROPN
ajcp-1612	75	2	chem	chem	PROPN
ajcp-1612	75	3	.	.	PUNCT
ajcp-1612	76	1	pharm	pharm	PROPN
ajcp-1612	76	2	.	.	PUNCT
ajcp-1612	77	1	2(2	2(2	NUM
ajcp-1612	77	2	)	)	PUNCT
ajcp-1612	77	3	9	9	NUM
ajcp-1612	77	4	-	-	SYM
ajcp-1612	77	5	14	14	NUM
ajcp-1612	77	6	,	,	PUNCT
ajcp-1612	77	7	2023	2023	NUM
ajcp-1612	77	8	mortality	mortality	NOUN
ajcp-1612	77	9	(	(	PUNCT
ajcp-1612	77	10	tong	tong	PROPN
ajcp-1612	77	11	&	&	CCONJ
ajcp-1612	77	12	adler	adler	PROPN
ajcp-1612	77	13	,	,	PUNCT
ajcp-1612	77	14	2018	2018	NUM
ajcp-1612	77	15	)	)	PUNCT
ajcp-1612	77	16	.	.	PUNCT
ajcp-1612	78	1	impaired	impair	VERB
ajcp-1612	78	2	fasting	fasting	NOUN
ajcp-1612	78	3	glucose	glucose	NOUN
ajcp-1612	78	4	(	(	PUNCT
ajcp-1612	78	5	ifg	ifg	PROPN
ajcp-1612	78	6	)	)	PUNCT
ajcp-1612	78	7	and	and	CCONJ
ajcp-1612	78	8	prediabetes	prediabete	NOUN
ajcp-1612	78	9	are	be	AUX
ajcp-1612	78	10	conditions	condition	NOUN
ajcp-1612	78	11	that	that	PRON
ajcp-1612	78	12	can	can	AUX
ajcp-1612	78	13	highten	highten	VERB
ajcp-1612	78	14	the	the	DET
ajcp-1612	78	15	probability	probability	NOUN
ajcp-1612	78	16	of	of	ADP
ajcp-1612	78	17	developing	develop	VERB
ajcp-1612	78	18	ckd	ckd	PROPN
ajcp-1612	78	19	and	and	CCONJ
ajcp-1612	78	20	other	other	ADJ
ajcp-1612	78	21	issues	issue	NOUN
ajcp-1612	78	22	,	,	PUNCT
ajcp-1612	78	23	such	such	ADJ
ajcp-1612	78	24	as	as	ADP
ajcp-1612	78	25	cardiovascular	cardiovascular	ADJ
ajcp-1612	78	26	disease	disease	NOUN
ajcp-1612	78	27	(	(	PUNCT
ajcp-1612	78	28	kim	kim	PROPN
ajcp-1612	78	29	et	et	PROPN
ajcp-1612	78	30	al	al	PROPN
ajcp-1612	78	31	.	.	PROPN
ajcp-1612	78	32	,	,	PUNCT
ajcp-1612	78	33	2020	2020	NUM
ajcp-1612	78	34	)	)	PUNCT
ajcp-1612	78	35	.	.	PUNCT
ajcp-1612	79	1	management	management	NOUN
ajcp-1612	79	2	of	of	ADP
ajcp-1612	79	3	these	these	DET
ajcp-1612	79	4	conditions	condition	NOUN
ajcp-1612	79	5	typically	typically	ADV
ajcp-1612	79	6	involves	involve	VERB
ajcp-1612	79	7	lifestyle	lifestyle	NOUN
ajcp-1612	79	8	modifications	modification	NOUN
ajcp-1612	79	9	and	and	CCONJ
ajcp-1612	79	10	medication	medication	NOUN
ajcp-1612	79	11	,	,	PUNCT
ajcp-1612	79	12	as	as	ADP
ajcp-1612	79	13	appropriate	appropriate	ADJ
ajcp-1612	79	14	,	,	PUNCT
ajcp-1612	79	15	to	to	PART
ajcp-1612	79	16	improve	improve	VERB
ajcp-1612	79	17	glucose	glucose	NOUN
ajcp-1612	79	18	control	control	NOUN
ajcp-1612	79	19	and	and	CCONJ
ajcp-1612	79	20	reduce	reduce	VERB
ajcp-1612	79	21	the	the	DET
ajcp-1612	79	22	risk	risk	NOUN
ajcp-1612	79	23	of	of	ADP
ajcp-1612	79	24	complications	complication	NOUN
ajcp-1612	79	25	.	.	PUNCT
ajcp-1612	80	1	1	1	X
ajcp-1612	80	2	.	.	X
ajcp-1612	80	3	lifestyle	lifestyle	NOUN
ajcp-1612	80	4	modifications	modification	NOUN
ajcp-1612	80	5	:	:	PUNCT
ajcp-1612	80	6	a	a	DET
ajcp-1612	80	7	nutritious	nutritious	ADJ
ajcp-1612	80	8	diet	diet	NOUN
ajcp-1612	80	9	,	,	PUNCT
ajcp-1612	80	10	frequent	frequent	ADJ
ajcp-1612	80	11	exercise	exercise	NOUN
ajcp-1612	80	12	,	,	PUNCT
ajcp-1612	80	13	and	and	CCONJ
ajcp-1612	80	14	weight	weight	NOUN
ajcp-1612	80	15	management	management	NOUN
ajcp-1612	80	16	are	be	AUX
ajcp-1612	80	17	examples	example	NOUN
ajcp-1612	80	18	of	of	ADP
ajcp-1612	80	19	lifestyle	lifestyle	NOUN
ajcp-1612	80	20	changes	change	NOUN
ajcp-1612	80	21	.	.	PUNCT
ajcp-1612	81	1	frequent	frequent	ADJ
ajcp-1612	81	2	exercises	exercise	NOUN
ajcp-1612	81	3	,	,	PUNCT
ajcp-1612	81	4	like	like	ADP
ajcp-1612	81	5	brisk	brisk	ADJ
ajcp-1612	81	6	walking	walking	NOUN
ajcp-1612	81	7	or	or	CCONJ
ajcp-1612	81	8	cycling	cycling	NOUN
ajcp-1612	81	9	,	,	PUNCT
ajcp-1612	81	10	can	can	AUX
ajcp-1612	81	11	also	also	ADV
ajcp-1612	81	12	improve	improve	VERB
ajcp-1612	81	13	glucose	glucose	NOUN
ajcp-1612	81	14	control	control	NOUN
ajcp-1612	81	15	and	and	CCONJ
ajcp-1612	81	16	lower	low	ADJ
ajcp-1612	81	17	the	the	DET
ajcp-1612	81	18	risk	risk	NOUN
ajcp-1612	81	19	of	of	ADP
ajcp-1612	81	20	comorbidities	comorbiditie	NOUN
ajcp-1612	81	21	(	(	PUNCT
ajcp-1612	81	22	beulens	beulen	NOUN
ajcp-1612	81	23	et	et	PROPN
ajcp-1612	81	24	al	al	PROPN
ajcp-1612	81	25	.	.	PROPN
ajcp-1612	81	26	,	,	PUNCT
ajcp-1612	81	27	2020	2020	NUM
ajcp-1612	81	28	)	)	PUNCT
ajcp-1612	81	29	.	.	PUNCT
ajcp-1612	82	1	2	2	X
ajcp-1612	82	2	.	.	X
ajcp-1612	82	3	medication	medication	NOUN
ajcp-1612	82	4	:	:	PUNCT
ajcp-1612	82	5	sometimes	sometimes	ADV
ajcp-1612	82	6	,	,	PUNCT
ajcp-1612	82	7	medication	medication	NOUN
ajcp-1612	82	8	may	may	AUX
ajcp-1612	82	9	be	be	AUX
ajcp-1612	82	10	prescribed	prescribe	VERB
ajcp-1612	82	11	to	to	PART
ajcp-1612	82	12	improve	improve	VERB
ajcp-1612	82	13	glucose	glucose	NOUN
ajcp-1612	82	14	control	control	NOUN
ajcp-1612	82	15	.	.	PUNCT
ajcp-1612	83	1	metformin	metformin	NOUN
ajcp-1612	83	2	is	be	AUX
ajcp-1612	83	3	commonly	commonly	ADV
ajcp-1612	83	4	used	use	VERB
ajcp-1612	83	5	to	to	PART
ajcp-1612	83	6	treat	treat	VERB
ajcp-1612	83	7	prediabetes	prediabete	NOUN
ajcp-1612	83	8	and	and	CCONJ
ajcp-1612	83	9	ifg	ifg	NOUN
ajcp-1612	83	10	(	(	PUNCT
ajcp-1612	83	11	beulens	beulen	NOUN
ajcp-1612	83	12	et	et	PROPN
ajcp-1612	83	13	al	al	PROPN
ajcp-1612	83	14	.	.	PROPN
ajcp-1612	83	15	,	,	PUNCT
ajcp-1612	83	16	2020	2020	NUM
ajcp-1612	83	17	)	)	PUNCT
ajcp-1612	83	18	.	.	PUNCT
ajcp-1612	84	1	3	3	X
ajcp-1612	84	2	.	.	X
ajcp-1612	84	3	blood	blood	NOUN
ajcp-1612	84	4	pressure	pressure	NOUN
ajcp-1612	84	5	management	management	NOUN
ajcp-1612	84	6	:	:	PUNCT
ajcp-1612	84	7	high	high	ADJ
ajcp-1612	84	8	blood	blood	NOUN
ajcp-1612	84	9	pressure	pressure	NOUN
ajcp-1612	84	10	increases	increase	VERB
ajcp-1612	84	11	ckd	ckd	NOUN
ajcp-1612	84	12	risk	risk	NOUN
ajcp-1612	84	13	and	and	CCONJ
ajcp-1612	84	14	can	can	AUX
ajcp-1612	84	15	accelerate	accelerate	VERB
ajcp-1612	84	16	the	the	DET
ajcp-1612	84	17	development	development	NOUN
ajcp-1612	84	18	of	of	ADP
ajcp-1612	84	19	ifg	ifg	NOUN
ajcp-1612	84	20	and	and	CCONJ
ajcp-1612	84	21	prediabetes	prediabete	NOUN
ajcp-1612	84	22	.	.	PUNCT
ajcp-1612	85	1	periodic	periodic	ADJ
ajcp-1612	85	2	blood	blood	NOUN
ajcp-1612	85	3	pressure	pressure	NOUN
ajcp-1612	85	4	assessments	assessment	NOUN
ajcp-1612	85	5	are	be	AUX
ajcp-1612	85	6	recommended	recommend	VERB
ajcp-1612	85	7	,	,	PUNCT
ajcp-1612	85	8	and	and	CCONJ
ajcp-1612	85	9	medication	medication	NOUN
ajcp-1612	85	10	for	for	ADP
ajcp-1612	85	11	hypertension	hypertension	NOUN
ajcp-1612	85	12	can	can	AUX
ajcp-1612	85	13	also	also	ADV
ajcp-1612	85	14	be	be	AUX
ajcp-1612	85	15	provided	provide	VERB
ajcp-1612	85	16	when	when	SCONJ
ajcp-1612	85	17	necessary	necessary	ADJ
ajcp-1612	85	18	.	.	PUNCT
ajcp-1612	86	1	(	(	PUNCT
ajcp-1612	86	2	ohishi	ohishi	ADJ
ajcp-1612	86	3	,	,	PUNCT
ajcp-1612	86	4	2018	2018	NUM
ajcp-1612	86	5	)	)	PUNCT
ajcp-1612	86	6	4	4	NUM
ajcp-1612	86	7	.	.	X
ajcp-1612	87	1	regular	regular	ADJ
ajcp-1612	87	2	monitoring	monitoring	NOUN
ajcp-1612	87	3	:	:	PUNCT
ajcp-1612	87	4	regular	regular	ADJ
ajcp-1612	87	5	blood	blood	NOUN
ajcp-1612	87	6	tests	test	NOUN
ajcp-1612	87	7	can	can	AUX
ajcp-1612	87	8	help	help	VERB
ajcp-1612	87	9	to	to	PART
ajcp-1612	87	10	monitor	monitor	VERB
ajcp-1612	87	11	glycemic	glycemic	ADJ
ajcp-1612	87	12	control	control	NOUN
ajcp-1612	87	13	and	and	CCONJ
ajcp-1612	87	14	kidney	kidney	NOUN
ajcp-1612	87	15	function	function	NOUN
ajcp-1612	87	16	.	.	PUNCT
ajcp-1612	88	1	this	this	PRON
ajcp-1612	88	2	may	may	AUX
ajcp-1612	88	3	include	include	VERB
ajcp-1612	88	4	a	a	DET
ajcp-1612	88	5	blood	blood	NOUN
ajcp-1612	88	6	test	test	NOUN
ajcp-1612	88	7	called	call	VERB
ajcp-1612	88	8	the	the	DET
ajcp-1612	88	9	estimated	estimate	VERB
ajcp-1612	88	10	glomerular	glomerular	ADJ
ajcp-1612	88	11	filtration	filtration	NOUN
ajcp-1612	88	12	rate	rate	NOUN
ajcp-1612	88	13	(	(	PUNCT
ajcp-1612	88	14	egfr	egfr	X
ajcp-1612	88	15	)	)	PUNCT
ajcp-1612	88	16	to	to	PART
ajcp-1612	88	17	assess	assess	VERB
ajcp-1612	88	18	kidney	kidney	NOUN
ajcp-1612	88	19	function	function	NOUN
ajcp-1612	88	20	(	(	PUNCT
ajcp-1612	88	21	miller	miller	PROPN
ajcp-1612	88	22	&	&	CCONJ
ajcp-1612	88	23	jones	jones	PROPN
ajcp-1612	88	24	,	,	PUNCT
ajcp-1612	88	25	2018	2018	NUM
ajcp-1612	88	26	)	)	PUNCT
ajcp-1612	88	27	.	.	PUNCT
ajcp-1612	89	1	overall	overall	ADJ
ajcp-1612	89	2	,	,	PUNCT
ajcp-1612	89	3	early	early	ADJ
ajcp-1612	89	4	identification	identification	NOUN
ajcp-1612	89	5	and	and	CCONJ
ajcp-1612	89	6	management	management	NOUN
ajcp-1612	89	7	of	of	ADP
ajcp-1612	89	8	prediabetes	prediabete	NOUN
ajcp-1612	89	9	and	and	CCONJ
ajcp-1612	89	10	ifg	ifg	NOUN
ajcp-1612	89	11	are	be	AUX
ajcp-1612	89	12	important	important	ADJ
ajcp-1612	89	13	to	to	PART
ajcp-1612	89	14	prevent	prevent	VERB
ajcp-1612	89	15	the	the	DET
ajcp-1612	89	16	development	development	NOUN
ajcp-1612	89	17	or	or	CCONJ
ajcp-1612	89	18	progression	progression	NOUN
ajcp-1612	89	19	of	of	ADP
ajcp-1612	89	20	ckd	ckd	PROPN
ajcp-1612	89	21	and	and	CCONJ
ajcp-1612	89	22	other	other	ADJ
ajcp-1612	89	23	complications	complication	NOUN
ajcp-1612	89	24	.	.	PUNCT
ajcp-1612	90	1	methodology	methodology	NOUN
ajcp-1612	90	2	to	to	PART
ajcp-1612	90	3	indicate	indicate	VERB
ajcp-1612	90	4	the	the	DET
ajcp-1612	90	5	development	development	NOUN
ajcp-1612	90	6	of	of	ADP
ajcp-1612	90	7	ckd	ckd	PROPN
ajcp-1612	90	8	into	into	ADP
ajcp-1612	90	9	end	end	NOUN
ajcp-1612	90	10	-	-	PUNCT
ajcp-1612	90	11	stage	stage	NOUN
ajcp-1612	90	12	renal	renal	ADJ
ajcp-1612	90	13	failure	failure	NOUN
ajcp-1612	90	14	by	by	ADP
ajcp-1612	90	15	managing	manage	VERB
ajcp-1612	90	16	diabetes	diabetes	NOUN
ajcp-1612	90	17	mellitus	mellitus	NOUN
ajcp-1612	90	18	,	,	PUNCT
ajcp-1612	90	19	several	several	ADJ
ajcp-1612	90	20	recent	recent	ADJ
ajcp-1612	90	21	studies	study	NOUN
ajcp-1612	90	22	,	,	PUNCT
ajcp-1612	90	23	review	review	NOUN
ajcp-1612	90	24	articles	article	NOUN
ajcp-1612	90	25	,	,	PUNCT
ajcp-1612	90	26	prospective	prospective	ADJ
ajcp-1612	90	27	studies	study	NOUN
ajcp-1612	90	28	,	,	PUNCT
ajcp-1612	90	29	cross	cross	ADJ
ajcp-1612	90	30	-	-	ADJ
ajcp-1612	90	31	sectional	sectional	ADJ
ajcp-1612	90	32	studies	study	NOUN
ajcp-1612	90	33	,	,	PUNCT
ajcp-1612	90	34	and	and	CCONJ
ajcp-1612	90	35	literature	literature	NOUN
ajcp-1612	90	36	reviews	review	NOUN
ajcp-1612	90	37	,	,	PUNCT
ajcp-1612	90	38	all	all	PRON
ajcp-1612	90	39	published	publish	VERB
ajcp-1612	90	40	and	and	CCONJ
ajcp-1612	90	41	peerreviewed	peerreviewe	VERB
ajcp-1612	90	42	articles	article	NOUN
ajcp-1612	90	43	,	,	PUNCT
ajcp-1612	90	44	were	be	AUX
ajcp-1612	90	45	searched	search	VERB
ajcp-1612	90	46	and	and	CCONJ
ajcp-1612	90	47	considered	consider	VERB
ajcp-1612	90	48	.	.	PUNCT
ajcp-1612	91	1	the	the	DET
ajcp-1612	91	2	area	area	NOUN
ajcp-1612	91	3	of	of	ADP
ajcp-1612	91	4	search	search	NOUN
ajcp-1612	91	5	was	be	AUX
ajcp-1612	91	6	based	base	VERB
ajcp-1612	91	7	on	on	ADP
ajcp-1612	91	8	how	how	SCONJ
ajcp-1612	91	9	effective	effective	ADJ
ajcp-1612	91	10	the	the	DET
ajcp-1612	91	11	management	management	NOUN
ajcp-1612	91	12	of	of	ADP
ajcp-1612	91	13	debates	debate	NOUN
ajcp-1612	91	14	mellitus	mellitus	NOUN
ajcp-1612	91	15	is	be	AUX
ajcp-1612	91	16	in	in	ADP
ajcp-1612	91	17	preventing	prevent	VERB
ajcp-1612	91	18	chronic	chronic	ADJ
ajcp-1612	91	19	kidney	kidney	NOUN
ajcp-1612	91	20	disease	disease	NOUN
ajcp-1612	91	21	,	,	PUNCT
ajcp-1612	91	22	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	91	23	and	and	CCONJ
ajcp-1612	91	24	other	other	ADJ
ajcp-1612	91	25	comorbidities	comorbiditie	NOUN
ajcp-1612	91	26	.	.	PUNCT
ajcp-1612	92	1	data	datum	NOUN
ajcp-1612	92	2	was	be	AUX
ajcp-1612	92	3	gathered	gather	VERB
ajcp-1612	92	4	from	from	ADP
ajcp-1612	92	5	different	different	ADJ
ajcp-1612	92	6	search	search	NOUN
ajcp-1612	92	7	engines	engine	NOUN
ajcp-1612	92	8	and	and	CCONJ
ajcp-1612	92	9	databases	database	NOUN
ajcp-1612	92	10	such	such	ADJ
ajcp-1612	92	11	as	as	ADP
ajcp-1612	92	12	;	;	PUNCT
ajcp-1612	92	13	google	google	PROPN
ajcp-1612	92	14	scholar	scholar	NOUN
ajcp-1612	92	15	,	,	PUNCT
ajcp-1612	92	16	scopus	scopus	PROPN
ajcp-1612	92	17	,	,	PUNCT
ajcp-1612	92	18	pubmed	pubmed	PROPN
ajcp-1612	92	19	,	,	PUNCT
ajcp-1612	92	20	elsevier	elsevier	PROPN
ajcp-1612	92	21	,	,	PUNCT
ajcp-1612	92	22	cochrane	cochrane	PROPN
ajcp-1612	92	23	,	,	PUNCT
ajcp-1612	92	24	sage	sage	NOUN
ajcp-1612	92	25	,	,	PUNCT
ajcp-1612	92	26	medline	medline	NOUN
ajcp-1612	92	27	,	,	PUNCT
ajcp-1612	92	28	and	and	CCONJ
ajcp-1612	92	29	web	web	NOUN
ajcp-1612	92	30	of	of	ADP
ajcp-1612	92	31	science	science	NOUN
ajcp-1612	92	32	,	,	PUNCT
ajcp-1612	92	33	elsevier	elsevier	NOUN
ajcp-1612	92	34	.	.	PUNCT
ajcp-1612	93	1	numerous	numerous	ADJ
ajcp-1612	93	2	studies	study	NOUN
ajcp-1612	93	3	were	be	AUX
ajcp-1612	93	4	selected	select	VERB
ajcp-1612	93	5	from	from	ADP
ajcp-1612	93	6	2018	2018	NUM
ajcp-1612	93	7	-	-	SYM
ajcp-1612	93	8	2023	2023	NUM
ajcp-1612	93	9	,	,	PUNCT
ajcp-1612	93	10	using	use	VERB
ajcp-1612	93	11	the	the	DET
ajcp-1612	93	12	keywords	keyword	NOUN
ajcp-1612	93	13	diabetes	diabete	VERB
ajcp-1612	93	14	mellitus	mellitus	NOUN
ajcp-1612	93	15	management	management	PROPN
ajcp-1612	93	16	,	,	PUNCT
ajcp-1612	93	17	chronic	chronic	ADJ
ajcp-1612	93	18	kidney	kidney	NOUN
ajcp-1612	93	19	disease	disease	NOUN
ajcp-1612	93	20	,	,	PUNCT
ajcp-1612	93	21	microalbuminuria	microalbuminuria	NOUN
ajcp-1612	93	22	,	,	PUNCT
ajcp-1612	93	23	target	target	VERB
ajcp-1612	93	24	time	time	NOUN
ajcp-1612	93	25	in	in	ADP
ajcp-1612	93	26	range	range	NOUN
ajcp-1612	93	27	,	,	PUNCT
ajcp-1612	93	28	impaired	impaired	ADJ
ajcp-1612	93	29	fasting	fasting	NOUN
ajcp-1612	93	30	glucose	glucose	NOUN
ajcp-1612	93	31	,	,	PUNCT
ajcp-1612	93	32	management	management	NOUN
ajcp-1612	93	33	ways	way	NOUN
ajcp-1612	93	34	lifestyle	lifestyle	NOUN
ajcp-1612	93	35	modification	modification	NOUN
ajcp-1612	93	36	,	,	PUNCT
ajcp-1612	93	37	and	and	CCONJ
ajcp-1612	93	38	medication	medication	NOUN
ajcp-1612	93	39	treatment	treatment	NOUN
ajcp-1612	93	40	,	,	PUNCT
ajcp-1612	93	41	diet	diet	NOUN
ajcp-1612	93	42	control	control	PROPN
ajcp-1612	93	43	.	.	PUNCT
ajcp-1612	94	1	the	the	DET
ajcp-1612	94	2	full	full	ADJ
ajcp-1612	94	3	texts	text	NOUN
ajcp-1612	94	4	of	of	ADP
ajcp-1612	94	5	the	the	DET
ajcp-1612	94	6	retrieved	retrieve	VERB
ajcp-1612	94	7	articles	article	NOUN
ajcp-1612	94	8	were	be	AUX
ajcp-1612	94	9	made	make	VERB
ajcp-1612	94	10	accessible	accessible	ADJ
ajcp-1612	94	11	.	.	PUNCT
ajcp-1612	95	1	this	this	DET
ajcp-1612	95	2	article	article	NOUN
ajcp-1612	95	3	is	be	AUX
ajcp-1612	95	4	a	a	DET
ajcp-1612	95	5	review	review	NOUN
ajcp-1612	95	6	.	.	PUNCT
ajcp-1612	96	1	thus	thus	ADV
ajcp-1612	96	2	not	not	PART
ajcp-1612	96	3	all	all	PRON
ajcp-1612	96	4	information	information	NOUN
ajcp-1612	96	5	on	on	ADP
ajcp-1612	96	6	the	the	DET
ajcp-1612	96	7	prevention	prevention	NOUN
ajcp-1612	96	8	of	of	ADP
ajcp-1612	96	9	ckd	ckd	PROPN
ajcp-1612	96	10	by	by	ADP
ajcp-1612	96	11	management	management	NOUN
ajcp-1612	96	12	of	of	ADP
ajcp-1612	96	13	diabetes	diabetes	NOUN
ajcp-1612	96	14	mellitus	mellitus	NOUN
ajcp-1612	96	15	has	have	AUX
ajcp-1612	96	16	been	be	AUX
ajcp-1612	96	17	provided	provide	VERB
ajcp-1612	96	18	are	be	AUX
ajcp-1612	96	19	contained	contain	VERB
ajcp-1612	96	20	in	in	ADP
ajcp-1612	96	21	this	this	PRON
ajcp-1612	96	22	.	.	PUNCT
ajcp-1612	97	1	we	we	PRON
ajcp-1612	97	2	have	have	AUX
ajcp-1612	97	3	included	include	VERB
ajcp-1612	97	4	observational	observational	ADJ
ajcp-1612	97	5	studies	study	NOUN
ajcp-1612	97	6	and	and	CCONJ
ajcp-1612	97	7	all	all	DET
ajcp-1612	97	8	significant	significant	ADJ
ajcp-1612	97	9	,	,	PUNCT
ajcp-1612	97	10	pertinent	pertinent	ADJ
ajcp-1612	97	11	big	big	ADJ
ajcp-1612	97	12	trials	trial	NOUN
ajcp-1612	97	13	to	to	PART
ajcp-1612	97	14	highlight	highlight	VERB
ajcp-1612	97	15	the	the	DET
ajcp-1612	97	16	overall	overall	ADJ
ajcp-1612	97	17	conclusions	conclusion	NOUN
ajcp-1612	97	18	.	.	PUNCT
ajcp-1612	98	1	although	although	SCONJ
ajcp-1612	98	2	we	we	PRON
ajcp-1612	98	3	tried	try	VERB
ajcp-1612	98	4	to	to	PART
ajcp-1612	98	5	incorporate	incorporate	VERB
ajcp-1612	98	6	the	the	DET
ajcp-1612	98	7	largest	large	ADJ
ajcp-1612	98	8	and	and	CCONJ
ajcp-1612	98	9	most	most	ADV
ajcp-1612	98	10	pertinent	pertinent	ADJ
ajcp-1612	98	11	research	research	NOUN
ajcp-1612	98	12	,	,	PUNCT
ajcp-1612	98	13	it	it	PRON
ajcp-1612	98	14	is	be	AUX
ajcp-1612	98	15	important	important	ADJ
ajcp-1612	98	16	to	to	PART
ajcp-1612	98	17	remember	remember	VERB
ajcp-1612	98	18	that	that	SCONJ
ajcp-1612	98	19	the	the	DET
ajcp-1612	98	20	tiny	tiny	ADJ
ajcp-1612	98	21	,	,	PUNCT
ajcp-1612	98	22	hopeful	hopeful	ADJ
ajcp-1612	98	23	observational	observational	ADJ
ajcp-1612	98	24	studies	study	NOUN
ajcp-1612	98	25	were	be	AUX
ajcp-1612	98	26	likely	likely	ADV
ajcp-1612	98	27	chosen	choose	VERB
ajcp-1612	98	28	due	due	ADP
ajcp-1612	98	29	to	to	ADP
ajcp-1612	98	30	publication	publication	NOUN
ajcp-1612	98	31	bias	bias	NOUN
ajcp-1612	98	32	.	.	PUNCT
ajcp-1612	99	1	discussion	discussion	NOUN
ajcp-1612	99	2	occurrence	occurrence	NOUN
ajcp-1612	99	3	of	of	ADP
ajcp-1612	99	4	ckd	ckd	PROPN
ajcp-1612	99	5	in	in	ADP
ajcp-1612	99	6	t2	t2	PROPN
ajcp-1612	99	7	dm	dm	X
ajcp-1612	99	8	for	for	ADP
ajcp-1612	99	9	populations	population	NOUN
ajcp-1612	99	10	with	with	ADP
ajcp-1612	99	11	type	type	NOUN
ajcp-1612	99	12	2	2	NUM
ajcp-1612	99	13	diabetes	diabetes	NOUN
ajcp-1612	99	14	or	or	CCONJ
ajcp-1612	99	15	a	a	DET
ajcp-1612	99	16	mix	mix	NOUN
ajcp-1612	99	17	of	of	ADP
ajcp-1612	99	18	diabetes	diabetes	NOUN
ajcp-1612	99	19	types	type	NOUN
ajcp-1612	99	20	,	,	PUNCT
ajcp-1612	99	21	the	the	DET
ajcp-1612	99	22	yearly	yearly	ADJ
ajcp-1612	99	23	rate	rate	NOUN
ajcp-1612	99	24	of	of	ADP
ajcp-1612	99	25	albuminuria	albuminuria	PROPN
ajcp-1612	99	26	is	be	AUX
ajcp-1612	99	27	typically	typically	ADV
ajcp-1612	99	28	around	around	ADV
ajcp-1612	99	29	8	8	NUM
ajcp-1612	99	30	%	%	NOUN
ajcp-1612	99	31	,	,	PUNCT
ajcp-1612	99	32	while	while	SCONJ
ajcp-1612	99	33	for	for	ADP
ajcp-1612	99	34	groups	group	NOUN
ajcp-1612	99	35	with	with	ADP
ajcp-1612	99	36	type	type	NOUN
ajcp-1612	99	37	1	1	NUM
ajcp-1612	99	38	diabetes	diabete	NOUN
ajcp-1612	99	39	,	,	PUNCT
ajcp-1612	99	40	it	it	PRON
ajcp-1612	99	41	ranges	range	VERB
ajcp-1612	99	42	from	from	ADP
ajcp-1612	99	43	2	2	NUM
ajcp-1612	99	44	%	%	NOUN
ajcp-1612	99	45	to	to	PART
ajcp-1612	99	46	3	3	NUM
ajcp-1612	99	47	%	%	NOUN
ajcp-1612	99	48	.	.	PUNCT
ajcp-1612	100	1	regardless	regardless	ADV
ajcp-1612	100	2	of	of	ADP
ajcp-1612	100	3	the	the	DET
ajcp-1612	100	4	type	type	NOUN
ajcp-1612	100	5	of	of	ADP
ajcp-1612	100	6	diabetes	diabetes	NOUN
ajcp-1612	100	7	,	,	PUNCT
ajcp-1612	100	8	low	low	ADJ
ajcp-1612	100	9	egfr	egfr	NOUN
ajcp-1612	100	10	occurs	occur	VERB
ajcp-1612	100	11	between	between	ADP
ajcp-1612	100	12	2	2	NUM
ajcp-1612	100	13	%	%	NOUN
ajcp-1612	100	14	and	and	CCONJ
ajcp-1612	100	15	4	4	NUM
ajcp-1612	100	16	%	%	NOUN
ajcp-1612	100	17	of	of	ADP
ajcp-1612	100	18	the	the	DET
ajcp-1612	100	19	time	time	NOUN
ajcp-1612	100	20	.	.	PUNCT
ajcp-1612	101	1	however	however	ADV
ajcp-1612	101	2	,	,	PUNCT
ajcp-1612	101	3	due	due	ADP
ajcp-1612	101	4	to	to	ADP
ajcp-1612	101	5	significant	significant	ADJ
ajcp-1612	101	6	demographic	demographic	ADJ
ajcp-1612	101	7	estimate	estimate	NOUN
ajcp-1612	101	8	variability	variability	NOUN
ajcp-1612	101	9	,	,	PUNCT
ajcp-1612	101	10	combined	combined	ADJ
ajcp-1612	101	11	ckd	ckd	PROPN
ajcp-1612	101	12	incidence	incidence	NOUN
ajcp-1612	101	13	rates	rate	NOUN
ajcp-1612	101	14	are	be	AUX
ajcp-1612	101	15	impractical	impractical	ADJ
ajcp-1612	101	16	(	(	PUNCT
ajcp-1612	101	17	koye	koye	NOUN
ajcp-1612	101	18	et	et	NOUN
ajcp-1612	101	19	al	al	PROPN
ajcp-1612	101	20	.	.	PROPN
ajcp-1612	101	21	,	,	PUNCT
ajcp-1612	101	22	2018	2018	NUM
ajcp-1612	101	23	)	)	PUNCT
ajcp-1612	101	24	.	.	PUNCT
ajcp-1612	102	1	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	102	2	and	and	CCONJ
ajcp-1612	102	3	albuminuria	albuminuria	NOUN
ajcp-1612	102	4	occur	occur	VERB
ajcp-1612	102	5	about	about	ADV
ajcp-1612	102	6	2	2	NUM
ajcp-1612	102	7	-	-	SYM
ajcp-1612	102	8	3	3	NUM
ajcp-1612	102	9	%	%	NOUN
ajcp-1612	102	10	of	of	ADP
ajcp-1612	102	11	the	the	DET
ajcp-1612	102	12	time	time	NOUN
ajcp-1612	102	13	in	in	ADP
ajcp-1612	102	14	type	type	NOUN
ajcp-1612	102	15	1	1	NUM
ajcp-1612	102	16	diabetes	diabetes	NOUN
ajcp-1612	102	17	and	and	CCONJ
ajcp-1612	102	18	about	about	ADV
ajcp-1612	102	19	8	8	NUM
ajcp-1612	102	20	%	%	NOUN
ajcp-1612	102	21	in	in	ADP
ajcp-1612	102	22	type	type	NOUN
ajcp-1612	102	23	2	2	NUM
ajcp-1612	102	24	diabetes	diabetes	NOUN
ajcp-1612	102	25	or	or	CCONJ
ajcp-1612	102	26	mixed	mixed	ADJ
ajcp-1612	102	27	diabetes	diabetes	NOUN
ajcp-1612	102	28	types	type	NOUN
ajcp-1612	102	29	.	.	PUNCT
ajcp-1612	103	1	the	the	DET
ajcp-1612	103	2	yearly	yearly	ADJ
ajcp-1612	103	3	occurrence	occurrence	NOUN
ajcp-1612	103	4	of	of	ADP
ajcp-1612	103	5	egfr	egfr	NOUN
ajcp-1612	103	6	60	60	NUM
ajcp-1612	103	7	ml	ml	NOUN
ajcp-1612	103	8	/	/	SYM
ajcp-1612	103	9	min/1.73	min/1.73	NOUN
ajcp-1612	103	10	m2	m2	PROPN
ajcp-1612	103	11	is	be	AUX
ajcp-1612	103	12	between	between	ADP
ajcp-1612	103	13	2	2	NUM
ajcp-1612	103	14	and	and	CCONJ
ajcp-1612	103	15	4	4	NUM
ajcp-1612	103	16	per	per	ADP
ajcp-1612	103	17	cent	cent	NOUN
ajcp-1612	103	18	.	.	PUNCT
ajcp-1612	104	1	there	there	PRON
ajcp-1612	104	2	was	be	VERB
ajcp-1612	104	3	a	a	DET
ajcp-1612	104	4	relatively	relatively	ADV
ajcp-1612	104	5	slight	slight	ADJ
ajcp-1612	104	6	difference	difference	NOUN
ajcp-1612	104	7	in	in	ADP
ajcp-1612	104	8	prevalence	prevalence	NOUN
ajcp-1612	104	9	rates	rate	NOUN
ajcp-1612	104	10	within	within	ADP
ajcp-1612	104	11	a	a	DET
ajcp-1612	104	12	single	single	ADJ
ajcp-1612	104	13	category	category	NOUN
ajcp-1612	104	14	of	of	ADP
ajcp-1612	104	15	kidney	kidney	NOUN
ajcp-1612	104	16	illness	illness	NOUN
ajcp-1612	104	17	,	,	PUNCT
ajcp-1612	104	18	despite	despite	SCONJ
ajcp-1612	104	19	the	the	DET
ajcp-1612	104	20	considerable	considerable	ADJ
ajcp-1612	104	21	variation	variation	NOUN
ajcp-1612	104	22	in	in	ADP
ajcp-1612	104	23	methodologies	methodology	NOUN
ajcp-1612	104	24	and	and	CCONJ
ajcp-1612	104	25	research	research	NOUN
ajcp-1612	104	26	design	design	NOUN
ajcp-1612	104	27	(	(	PUNCT
ajcp-1612	104	28	koye	koye	NOUN
ajcp-1612	104	29	et	et	NOUN
ajcp-1612	104	30	al	al	PROPN
ajcp-1612	104	31	.	.	PROPN
ajcp-1612	104	32	,	,	PUNCT
ajcp-1612	104	33	2017	2017	NUM
ajcp-1612	104	34	)	)	PUNCT
ajcp-1612	104	35	.	.	PUNCT
ajcp-1612	105	1	various	various	ADJ
ajcp-1612	105	2	studies	study	NOUN
ajcp-1612	105	3	have	have	AUX
ajcp-1612	105	4	determined	determine	VERB
ajcp-1612	105	5	that	that	SCONJ
ajcp-1612	105	6	an	an	DET
ajcp-1612	105	7	elevation	elevation	NOUN
ajcp-1612	105	8	in	in	ADP
ajcp-1612	105	9	the	the	DET
ajcp-1612	105	10	occurrence	occurrence	NOUN
ajcp-1612	105	11	rates	rate	NOUN
ajcp-1612	105	12	of	of	ADP
ajcp-1612	105	13	diabetes	diabetes	NOUN
ajcp-1612	105	14	and	and	CCONJ
ajcp-1612	105	15	hypertension	hypertension	NOUN
ajcp-1612	105	16	increases	increase	VERB
ajcp-1612	105	17	the	the	DET
ajcp-1612	105	18	probability	probability	NOUN
ajcp-1612	105	19	of	of	ADP
ajcp-1612	105	20	ckd	ckd	PROPN
ajcp-1612	105	21	.	.	PUNCT
ajcp-1612	106	1	however	however	ADV
ajcp-1612	106	2	,	,	PUNCT
ajcp-1612	106	3	according	accord	VERB
ajcp-1612	106	4	to	to	ADP
ajcp-1612	106	5	a	a	DET
ajcp-1612	106	6	population	population	NOUN
ajcp-1612	106	7	-	-	PUNCT
ajcp-1612	106	8	based	base	VERB
ajcp-1612	106	9	cohort	cohort	NOUN
ajcp-1612	106	10	study	study	NOUN
ajcp-1612	106	11	,	,	PUNCT
ajcp-1612	106	12	it	it	PRON
ajcp-1612	106	13	was	be	AUX
ajcp-1612	106	14	reported	report	VERB
ajcp-1612	106	15	that	that	SCONJ
ajcp-1612	106	16	diabetes	diabetes	NOUN
ajcp-1612	106	17	and	and	CCONJ
ajcp-1612	106	18	high	high	ADJ
ajcp-1612	106	19	blood	blood	NOUN
ajcp-1612	106	20	pressure	pressure	NOUN
ajcp-1612	106	21	do	do	AUX
ajcp-1612	106	22	not	not	PART
ajcp-1612	106	23	have	have	VERB
ajcp-1612	106	24	an	an	DET
ajcp-1612	106	25	alliance	alliance	NOUN
ajcp-1612	106	26	when	when	SCONJ
ajcp-1612	106	27	it	it	PRON
ajcp-1612	106	28	comes	come	VERB
ajcp-1612	106	29	to	to	ADP
ajcp-1612	106	30	the	the	DET
ajcp-1612	106	31	incidence	incidence	NOUN
ajcp-1612	106	32	of	of	ADP
ajcp-1612	106	33	chronic	chronic	ADJ
ajcp-1612	106	34	kidney	kidney	NOUN
ajcp-1612	106	35	disease	disease	NOUN
ajcp-1612	106	36	(	(	PUNCT
ajcp-1612	106	37	erfanpoor	erfanpoor	PROPN
ajcp-1612	106	38	et	et	PROPN
ajcp-1612	106	39	al	al	PROPN
ajcp-1612	106	40	.	.	PROPN
ajcp-1612	106	41	,	,	PUNCT
ajcp-1612	106	42	2021	2021	NUM
ajcp-1612	106	43	)	)	PUNCT
ajcp-1612	106	44	.	.	PUNCT
ajcp-1612	107	1	prevalence	prevalence	NOUN
ajcp-1612	107	2	of	of	ADP
ajcp-1612	107	3	ckd	ckd	PROPN
ajcp-1612	107	4	in	in	ADP
ajcp-1612	107	5	all	all	DET
ajcp-1612	107	6	phases	phase	NOUN
ajcp-1612	107	7	varies	vary	VERB
ajcp-1612	107	8	globally	globally	ADV
ajcp-1612	107	9	,	,	PUNCT
ajcp-1612	107	10	with	with	ADP
ajcp-1612	107	11	1.7	1.7	NUM
ajcp-1612	107	12	%	%	NOUN
ajcp-1612	107	13	in	in	ADP
ajcp-1612	107	14	china	china	PROPN
ajcp-1612	107	15	,	,	PUNCT
ajcp-1612	107	16	3.1	3.1	NUM
ajcp-1612	107	17	%	%	NOUN
ajcp-1612	107	18	in	in	ADP
ajcp-1612	107	19	canada	canada	PROPN
ajcp-1612	107	20	,	,	PUNCT
ajcp-1612	107	21	6.7	6.7	NUM
ajcp-1612	107	22	%	%	NOUN
ajcp-1612	107	23	in	in	ADP
ajcp-1612	107	24	the	the	DET
ajcp-1612	107	25	us	us	PROPN
ajcp-1612	107	26	and	and	CCONJ
ajcp-1612	107	27	5.8	5.8	NUM
ajcp-1612	107	28	%	%	NOUN
ajcp-1612	107	29	in	in	ADP
ajcp-1612	107	30	australia	australia	PROPN
ajcp-1612	107	31	.	.	PUNCT
ajcp-1612	108	1	in	in	ADP
ajcp-1612	108	2	europe	europe	PROPN
ajcp-1612	108	3	,	,	PUNCT
ajcp-1612	108	4	2.3	2.3	NUM
ajcp-1612	108	5	%	%	NOUN
ajcp-1612	108	6	in	in	ADP
ajcp-1612	108	7	germany	germany	PROPN
ajcp-1612	108	8	,	,	PUNCT
ajcp-1612	108	9	8.2	8.2	NUM
ajcp-1612	108	10	%	%	NOUN
ajcp-1612	108	11	in	in	ADP
ajcp-1612	108	12	finland	finland	PROPN
ajcp-1612	108	13	,	,	PUNCT
ajcp-1612	108	14	9.2	9.2	NUM
ajcp-1612	108	15	%	%	NOUN
ajcp-1612	108	16	in	in	ADP
ajcp-1612	108	17	spain	spain	PROPN
ajcp-1612	108	18	and	and	CCONJ
ajcp-1612	108	19	5.2	5.2	NUM
ajcp-1612	108	20	%	%	NOUN
ajcp-1612	108	21	in	in	ADP
ajcp-1612	108	22	england	england	PROPN
ajcp-1612	108	23	(	(	PUNCT
ajcp-1612	108	24	romagnani	romagnani	PROPN
ajcp-1612	108	25	et	et	PROPN
ajcp-1612	108	26	al	al	PROPN
ajcp-1612	108	27	.	.	PROPN
ajcp-1612	108	28	,	,	PUNCT
ajcp-1612	108	29	2017	2017	NUM
ajcp-1612	108	30	)	)	PUNCT
ajcp-1612	108	31	.	.	PUNCT
ajcp-1612	109	1	risk	risk	NOUN
ajcp-1612	109	2	factors	factor	NOUN
ajcp-1612	109	3	ckd	ckd	PROPN
ajcp-1612	109	4	is	be	AUX
ajcp-1612	109	5	a	a	DET
ajcp-1612	109	6	progressive	progressive	ADJ
ajcp-1612	109	7	problem	problem	NOUN
ajcp-1612	109	8	of	of	ADP
ajcp-1612	109	9	diabetes	diabetes	NOUN
ajcp-1612	109	10	,	,	PUNCT
ajcp-1612	109	11	particularly	particularly	ADV
ajcp-1612	109	12	in	in	ADP
ajcp-1612	109	13	people	people	NOUN
ajcp-1612	109	14	with	with	ADP
ajcp-1612	109	15	poorly	poorly	ADV
ajcp-1612	109	16	controlled	control	VERB
ajcp-1612	109	17	blood	blood	NOUN
ajcp-1612	109	18	glucose	glucose	NOUN
ajcp-1612	109	19	levels	level	NOUN
ajcp-1612	109	20	.	.	PUNCT
ajcp-1612	110	1	several	several	ADJ
ajcp-1612	110	2	indisputable	indisputable	ADJ
ajcp-1612	110	3	risk	risk	NOUN
ajcp-1612	110	4	factors	factor	NOUN
ajcp-1612	110	5	are	be	AUX
ajcp-1612	110	6	crucial	crucial	ADJ
ajcp-1612	110	7	for	for	ADP
ajcp-1612	110	8	diagnosing	diagnosing	NOUN
ajcp-1612	110	9	,	,	PUNCT
ajcp-1612	110	10	treating	treat	VERB
ajcp-1612	110	11	and	and	CCONJ
ajcp-1612	110	12	managing	manage	VERB
ajcp-1612	110	13	ckd	ckd	NOUN
ajcp-1612	110	14	in	in	ADP
ajcp-1612	110	15	diabetes	diabetes	NOUN
ajcp-1612	110	16	(	(	PUNCT
ajcp-1612	110	17	kazancioğlu	kazancioğlu	NOUN
ajcp-1612	110	18	,	,	PUNCT
ajcp-1612	110	19	2013	2013	NUM
ajcp-1612	110	20	)	)	PUNCT
ajcp-1612	110	21	.	.	PUNCT
ajcp-1612	111	1	the	the	DET
ajcp-1612	111	2	risk	risk	NOUN
ajcp-1612	111	3	factors	factor	NOUN
ajcp-1612	111	4	for	for	ADP
ajcp-1612	111	5	ckd	ckd	PROPN
ajcp-1612	111	6	in	in	ADP
ajcp-1612	111	7	diabetes	diabetes	NOUN
ajcp-1612	111	8	can	can	AUX
ajcp-1612	111	9	be	be	AUX
ajcp-1612	111	10	categorised	categorise	VERB
ajcp-1612	111	11	as	as	ADP
ajcp-1612	111	12	modifiable	modifiable	ADJ
ajcp-1612	111	13	and	and	CCONJ
ajcp-1612	111	14	non	non	ADJ
ajcp-1612	111	15	-	-	ADJ
ajcp-1612	111	16	modifiable	modifiable	ADJ
ajcp-1612	111	17	.	.	PUNCT
ajcp-1612	112	1	to	to	PART
ajcp-1612	112	2	stop	stop	VERB
ajcp-1612	112	3	or	or	CCONJ
ajcp-1612	112	4	slow	slow	VERB
ajcp-1612	112	5	the	the	DET
ajcp-1612	112	6	start	start	NOUN
ajcp-1612	112	7	and	and	CCONJ
ajcp-1612	112	8	advancement	advancement	NOUN
ajcp-1612	112	9	of	of	ADP
ajcp-1612	112	10	ckd	ckd	PROPN
ajcp-1612	112	11	in	in	ADP
ajcp-1612	112	12	patients	patient	NOUN
ajcp-1612	112	13	with	with	ADP
ajcp-1612	112	14	diabetes	diabetes	NOUN
ajcp-1612	112	15	,	,	PUNCT
ajcp-1612	112	16	early	early	ADJ
ajcp-1612	112	17	detection	detection	NOUN
ajcp-1612	112	18	and	and	CCONJ
ajcp-1612	112	19	management	management	NOUN
ajcp-1612	112	20	of	of	ADP
ajcp-1612	112	21	these	these	DET
ajcp-1612	112	22	risk	risk	NOUN
ajcp-1612	112	23	factors	factor	NOUN
ajcp-1612	112	24	are	be	AUX
ajcp-1612	112	25	crucial	crucial	ADJ
ajcp-1612	112	26	(	(	PUNCT
ajcp-1612	112	27	hannan	hannan	PROPN
ajcp-1612	112	28	et	et	PROPN
ajcp-1612	112	29	al	al	PROPN
ajcp-1612	112	30	.	.	PROPN
ajcp-1612	112	31	,	,	PUNCT
ajcp-1612	112	32	2021	2021	NUM
ajcp-1612	112	33	)	)	PUNCT
ajcp-1612	113	1	.	.	PUNCT
ajcp-1612	114	1	this	this	PRON
ajcp-1612	114	2	may	may	AUX
ajcp-1612	114	3	include	include	VERB
ajcp-1612	114	4	regular	regular	ADJ
ajcp-1612	114	5	monitoring	monitoring	NOUN
ajcp-1612	114	6	of	of	ADP
ajcp-1612	114	7	blood	blood	NOUN
ajcp-1612	114	8	glucose	glucose	NOUN
ajcp-1612	114	9	and	and	CCONJ
ajcp-1612	114	10	blood	blood	NOUN
ajcp-1612	114	11	pressure	pressure	NOUN
ajcp-1612	114	12	levels	level	NOUN
ajcp-1612	114	13	,	,	PUNCT
ajcp-1612	114	14	lifestyle	lifestyle	NOUN
ajcp-1612	114	15	modifications	modification	NOUN
ajcp-1612	114	16	such	such	ADJ
ajcp-1612	114	17	as	as	ADP
ajcp-1612	114	18	healthy	healthy	ADJ
ajcp-1612	114	19	eating	eating	NOUN
ajcp-1612	114	20	and	and	CCONJ
ajcp-1612	114	21	regular	regular	ADJ
ajcp-1612	114	22	physical	physical	ADJ
ajcp-1612	114	23	activity	activity	NOUN
ajcp-1612	114	24	,	,	PUNCT
ajcp-1612	114	25	and	and	CCONJ
ajcp-1612	114	26	medication	medication	NOUN
ajcp-1612	114	27	as	as	ADP
ajcp-1612	114	28	appropriate	appropriate	ADJ
ajcp-1612	114	29	.	.	PUNCT
ajcp-1612	115	1	non	non	ADJ
ajcp-1612	115	2	-	-	ADJ
ajcp-1612	115	3	modifiable	modifiable	ADJ
ajcp-1612	115	4	factors	factor	NOUN
ajcp-1612	115	5	may	may	AUX
ajcp-1612	115	6	include	include	VERB
ajcp-1612	115	7	genetics	genetic	NOUN
ajcp-1612	115	8	,	,	PUNCT
ajcp-1612	115	9	male	male	NOUN
ajcp-1612	115	10	,	,	PUNCT
ajcp-1612	115	11	age	age	NOUN
ajcp-1612	115	12	,	,	PUNCT
ajcp-1612	115	13	table	table	NOUN
ajcp-1612	115	14	1	1	NUM
ajcp-1612	115	15	:	:	PUNCT
ajcp-1612	115	16	modifiable	modifiable	ADJ
ajcp-1612	115	17	and	and	CCONJ
ajcp-1612	115	18	un	un	ADJ
ajcp-1612	115	19	-	-	ADJ
ajcp-1612	115	20	modifiable	modifiable	ADJ
ajcp-1612	115	21	risk	risk	NOUN
ajcp-1612	115	22	factors	factor	NOUN
ajcp-1612	115	23	of	of	ADP
ajcp-1612	115	24	ckd	ckd	PROPN
ajcp-1612	115	25	nonmodifiable	nonmodifiable	ADJ
ajcp-1612	115	26	risk	risk	NOUN
ajcp-1612	115	27	factors	factor	NOUN
ajcp-1612	115	28	modifiable	modifiable	ADJ
ajcp-1612	115	29	risk	risk	NOUN
ajcp-1612	115	30	factors	factor	NOUN
ajcp-1612	115	31	genetics	genetic	NOUN
ajcp-1612	115	32	factor	factor	NOUN
ajcp-1612	115	33	hypertension	hypertension	NOUN
ajcp-1612	115	34	male	male	NOUN
ajcp-1612	115	35	sex	sex	NOUN
ajcp-1612	115	36	poor	poor	ADJ
ajcp-1612	115	37	glycemic	glycemic	ADJ
ajcp-1612	115	38	control	control	NOUN
ajcp-1612	115	39	age	age	NOUN
ajcp-1612	115	40	at	at	ADP
ajcp-1612	115	41	onset	onset	NOUN
ajcp-1612	115	42	of	of	ADP
ajcp-1612	115	43	diabetes	diabetes	NOUN
ajcp-1612	115	44	lipid	lipid	NOUN
ajcp-1612	115	45	abnormalities	abnormality	NOUN
ajcp-1612	115	46	duration	duration	NOUN
ajcp-1612	115	47	of	of	ADP
ajcp-1612	115	48	diabetes	diabetes	NOUN
ajcp-1612	115	49	smoking	smoke	VERB
ajcp-1612	115	50	family	family	NOUN
ajcp-1612	115	51	history	history	NOUN
ajcp-1612	115	52	obesity	obesity	NOUN
ajcp-1612	115	53	metabolic	metabolic	NOUN
ajcp-1612	115	54	syndrome	syndrome	NOUN
ajcp-1612	115	55	vitamin	vitamin	NOUN
ajcp-1612	115	56	d	d	NOUN
ajcp-1612	115	57	deficiency	deficiency	NOUN
ajcp-1612	115	58	and	and	CCONJ
ajcp-1612	115	59	salt	salt	NOUN
ajcp-1612	115	60	intake	intake	ADJ
ajcp-1612	115	61	gestational	gestational	ADJ
ajcp-1612	115	62	diabetes	diabetes	NOUN
ajcp-1612	115	63	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	115	64	pa	pa	PROPN
ajcp-1612	115	65	ge	ge	PROPN
ajcp-1612	115	66	11	11	NUM
ajcp-1612	115	67	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	115	68	am	be	AUX
ajcp-1612	115	69	.	.	PUNCT
ajcp-1612	116	1	j.	j.	PROPN
ajcp-1612	116	2	chem	chem	PROPN
ajcp-1612	116	3	.	.	PUNCT
ajcp-1612	117	1	pharm	pharm	PROPN
ajcp-1612	117	2	.	.	PUNCT
ajcp-1612	118	1	2(2	2(2	NUM
ajcp-1612	118	2	)	)	PUNCT
ajcp-1612	118	3	9	9	NUM
ajcp-1612	118	4	-	-	SYM
ajcp-1612	118	5	14	14	NUM
ajcp-1612	118	6	,	,	PUNCT
ajcp-1612	118	7	2023	2023	NUM
ajcp-1612	118	8	family	family	NOUN
ajcp-1612	118	9	history	history	NOUN
ajcp-1612	118	10	,	,	PUNCT
ajcp-1612	118	11	the	the	DET
ajcp-1612	118	12	onset	onset	NOUN
ajcp-1612	118	13	of	of	ADP
ajcp-1612	118	14	diabetes	diabetes	NOUN
ajcp-1612	118	15	etc	etc	X
ajcp-1612	118	16	.	.	X
ajcp-1612	118	17	,	,	PUNCT
ajcp-1612	118	18	while	while	SCONJ
ajcp-1612	118	19	modifiable	modifiable	ADJ
ajcp-1612	118	20	factors	factor	NOUN
ajcp-1612	118	21	contain	contain	VERB
ajcp-1612	118	22	hypertension	hypertension	NOUN
ajcp-1612	118	23	,	,	PUNCT
ajcp-1612	118	24	poor	poor	ADJ
ajcp-1612	118	25	glycemic	glycemic	ADJ
ajcp-1612	118	26	control	control	NOUN
ajcp-1612	118	27	,	,	PUNCT
ajcp-1612	118	28	insulin	insulin	NOUN
ajcp-1612	118	29	resistance	resistance	NOUN
ajcp-1612	118	30	,	,	PUNCT
ajcp-1612	118	31	smoking	smoking	NOUN
ajcp-1612	118	32	,	,	PUNCT
ajcp-1612	118	33	metabolic	metabolic	NOUN
ajcp-1612	118	34	syndrome	syndrome	NOUN
ajcp-1612	118	35	,	,	PUNCT
ajcp-1612	118	36	vitamin	vitamin	NOUN
ajcp-1612	118	37	d	d	NOUN
ajcp-1612	118	38	deficiency	deficiency	NOUN
ajcp-1612	118	39	etc	etc	X
ajcp-1612	118	40	.	.	X
ajcp-1612	119	1	(	(	PUNCT
ajcp-1612	119	2	hannan	hannan	PROPN
ajcp-1612	119	3	et	et	PROPN
ajcp-1612	119	4	al	al	PROPN
ajcp-1612	119	5	.	.	PROPN
ajcp-1612	119	6	,	,	PUNCT
ajcp-1612	119	7	2021	2021	NUM
ajcp-1612	119	8	;	;	PUNCT
ajcp-1612	119	9	koye	koye	VERB
ajcp-1612	119	10	et	et	NOUN
ajcp-1612	119	11	al	al	PROPN
ajcp-1612	119	12	.	.	PROPN
ajcp-1612	119	13	,	,	PUNCT
ajcp-1612	119	14	2018	2018	NUM
ajcp-1612	119	15	;	;	PUNCT
ajcp-1612	119	16	kurzhagen	kurzhagen	PROPN
ajcp-1612	119	17	et	et	PROPN
ajcp-1612	119	18	al	al	PROPN
ajcp-1612	119	19	.	.	PROPN
ajcp-1612	119	20	,	,	PUNCT
ajcp-1612	119	21	2020	2020	NUM
ajcp-1612	119	22	)	)	PUNCT
ajcp-1612	119	23	.	.	PUNCT
ajcp-1612	120	1	elevated	elevated	ADJ
ajcp-1612	120	2	blood	blood	NOUN
ajcp-1612	120	3	glucose	glucose	NOUN
ajcp-1612	120	4	levels	level	NOUN
ajcp-1612	120	5	can	can	AUX
ajcp-1612	120	6	damage	damage	VERB
ajcp-1612	120	7	the	the	DET
ajcp-1612	120	8	kidney	kidney	NOUN
ajcp-1612	120	9	’s	’s	PART
ajcp-1612	120	10	small	small	ADJ
ajcp-1612	120	11	blood	blood	NOUN
ajcp-1612	120	12	vessels	vessel	NOUN
ajcp-1612	120	13	,	,	PUNCT
ajcp-1612	120	14	leading	lead	VERB
ajcp-1612	120	15	to	to	ADP
ajcp-1612	120	16	ckd	ckd	PROPN
ajcp-1612	120	17	.	.	PUNCT
ajcp-1612	121	1	hypertension	hypertension	NOUN
ajcp-1612	121	2	or	or	CCONJ
ajcp-1612	121	3	high	high	ADJ
ajcp-1612	121	4	blood	blood	NOUN
ajcp-1612	121	5	pressure	pressure	NOUN
ajcp-1612	121	6	also	also	ADV
ajcp-1612	121	7	damages	damage	VERB
ajcp-1612	121	8	the	the	DET
ajcp-1612	121	9	blood	blood	NOUN
ajcp-1612	121	10	vessels	vessel	NOUN
ajcp-1612	121	11	and	and	CCONJ
ajcp-1612	121	12	contributes	contribute	VERB
ajcp-1612	121	13	to	to	ADP
ajcp-1612	121	14	the	the	DET
ajcp-1612	121	15	risk	risk	NOUN
ajcp-1612	121	16	of	of	ADP
ajcp-1612	121	17	causing	cause	VERB
ajcp-1612	121	18	ckd	ckd	PROPN
ajcp-1612	121	19	(	(	PUNCT
ajcp-1612	121	20	kurzhagen	kurzhagen	PROPN
ajcp-1612	121	21	et	et	PROPN
ajcp-1612	121	22	al	al	PROPN
ajcp-1612	121	23	.	.	PROPN
ajcp-1612	121	24	,	,	PUNCT
ajcp-1612	121	25	2020	2020	NUM
ajcp-1612	121	26	)	)	PUNCT
ajcp-1612	121	27	.	.	PUNCT
ajcp-1612	122	1	ckd	ckd	PROPN
ajcp-1612	122	2	also	also	ADV
ajcp-1612	122	3	depends	depend	VERB
ajcp-1612	122	4	upon	upon	SCONJ
ajcp-1612	122	5	the	the	DET
ajcp-1612	122	6	duration	duration	NOUN
ajcp-1612	122	7	of	of	ADP
ajcp-1612	122	8	diabetes	diabetes	NOUN
ajcp-1612	122	9	onset	onset	VERB
ajcp-1612	122	10	;	;	PUNCT
ajcp-1612	122	11	according	accord	VERB
ajcp-1612	122	12	to	to	ADP
ajcp-1612	122	13	the	the	DET
ajcp-1612	122	14	reported	report	VERB
ajcp-1612	122	15	studies	study	NOUN
ajcp-1612	122	16	that	that	SCONJ
ajcp-1612	122	17	a	a	DET
ajcp-1612	122	18	longer	long	ADJ
ajcp-1612	122	19	duration	duration	NOUN
ajcp-1612	122	20	of	of	ADP
ajcp-1612	122	21	diabetes	diabetes	NOUN
ajcp-1612	122	22	can	can	AUX
ajcp-1612	122	23	increase	increase	VERB
ajcp-1612	122	24	the	the	DET
ajcp-1612	122	25	risk	risk	NOUN
ajcp-1612	122	26	of	of	ADP
ajcp-1612	122	27	developing	develop	VERB
ajcp-1612	122	28	ckd	ckd	PROPN
ajcp-1612	122	29	in	in	ADP
ajcp-1612	122	30	patients	patient	NOUN
ajcp-1612	122	31	(	(	PUNCT
ajcp-1612	122	32	hannan	hannan	PROPN
ajcp-1612	122	33	et	et	PROPN
ajcp-1612	122	34	al	al	PROPN
ajcp-1612	122	35	.	.	PROPN
ajcp-1612	122	36	,	,	PUNCT
ajcp-1612	122	37	2021	2021	NUM
ajcp-1612	122	38	)	)	PUNCT
ajcp-1612	122	39	.	.	PUNCT
ajcp-1612	123	1	smoking	smoking	NOUN
ajcp-1612	123	2	is	be	AUX
ajcp-1612	123	3	injurious	injurious	ADJ
ajcp-1612	123	4	on	on	ADP
ajcp-1612	123	5	many	many	ADJ
ajcp-1612	123	6	levels	level	NOUN
ajcp-1612	123	7	;	;	PUNCT
ajcp-1612	123	8	it	it	PRON
ajcp-1612	123	9	damages	damage	VERB
ajcp-1612	123	10	the	the	DET
ajcp-1612	123	11	lungs	lung	NOUN
ajcp-1612	123	12	and	and	CCONJ
ajcp-1612	123	13	kidneys	kidney	NOUN
ajcp-1612	123	14	and	and	CCONJ
ajcp-1612	123	15	worsens	worsen	VERB
ajcp-1612	123	16	glucose	glucose	NOUN
ajcp-1612	123	17	control	control	NOUN
ajcp-1612	123	18	in	in	ADP
ajcp-1612	123	19	diabetic	diabetic	ADJ
ajcp-1612	123	20	people	people	NOUN
ajcp-1612	123	21	(	(	PUNCT
ajcp-1612	123	22	kazancioğlu	kazancioğlu	NOUN
ajcp-1612	123	23	,	,	PUNCT
ajcp-1612	123	24	2013	2013	NUM
ajcp-1612	123	25	)	)	PUNCT
ajcp-1612	123	26	.	.	PUNCT
ajcp-1612	124	1	prevention	prevention	NOUN
ajcp-1612	124	2	of	of	ADP
ajcp-1612	124	3	ckd	ckd	PROPN
ajcp-1612	124	4	ckd	ckd	PROPN
ajcp-1612	124	5	can	can	AUX
ajcp-1612	124	6	be	be	AUX
ajcp-1612	124	7	prevented	prevent	VERB
ajcp-1612	124	8	or	or	CCONJ
ajcp-1612	124	9	delayed	delay	VERB
ajcp-1612	124	10	by	by	ADP
ajcp-1612	124	11	taking	take	VERB
ajcp-1612	124	12	measures	measure	NOUN
ajcp-1612	124	13	to	to	PART
ajcp-1612	124	14	maintain	maintain	VERB
ajcp-1612	124	15	healthy	healthy	ADJ
ajcp-1612	124	16	kidneys	kidney	NOUN
ajcp-1612	124	17	.	.	PUNCT
ajcp-1612	125	1	maintaining	maintain	VERB
ajcp-1612	125	2	underlying	underlie	VERB
ajcp-1612	125	3	conditions	condition	NOUN
ajcp-1612	125	4	,	,	PUNCT
ajcp-1612	125	5	quitting	quit	VERB
ajcp-1612	125	6	smoking	smoking	NOUN
ajcp-1612	125	7	,	,	PUNCT
ajcp-1612	125	8	eating	eat	VERB
ajcp-1612	125	9	healthy	healthy	ADJ
ajcp-1612	125	10	foods	food	NOUN
ajcp-1612	125	11	,	,	PUNCT
ajcp-1612	125	12	exercising	exercise	VERB
ajcp-1612	125	13	regularly	regularly	ADV
ajcp-1612	125	14	and	and	CCONJ
ajcp-1612	125	15	drinking	drink	VERB
ajcp-1612	125	16	enough	enough	ADJ
ajcp-1612	125	17	water	water	NOUN
ajcp-1612	125	18	can	can	AUX
ajcp-1612	125	19	help	help	VERB
ajcp-1612	125	20	stabilise	stabilise	VERB
ajcp-1612	125	21	ckd	ckd	PROPN
ajcp-1612	125	22	and	and	CCONJ
ajcp-1612	125	23	diabetes	diabetes	NOUN
ajcp-1612	125	24	.	.	PUNCT
ajcp-1612	126	1	other	other	ADJ
ajcp-1612	126	2	than	than	ADP
ajcp-1612	126	3	these	these	DET
ajcp-1612	126	4	preventions	prevention	NOUN
ajcp-1612	126	5	,	,	PUNCT
ajcp-1612	126	6	insulin	insulin	NOUN
ajcp-1612	126	7	therapies	therapy	NOUN
ajcp-1612	126	8	play	play	VERB
ajcp-1612	126	9	a	a	DET
ajcp-1612	126	10	vital	vital	ADJ
ajcp-1612	126	11	role	role	NOUN
ajcp-1612	126	12	in	in	ADP
ajcp-1612	126	13	managing	manage	VERB
ajcp-1612	126	14	ckd	ckd	PROPN
ajcp-1612	126	15	,	,	PUNCT
ajcp-1612	126	16	while	while	SCONJ
ajcp-1612	126	17	some	some	DET
ajcp-1612	126	18	medications	medication	NOUN
ajcp-1612	126	19	are	be	AUX
ajcp-1612	126	20	widely	widely	ADV
ajcp-1612	126	21	used	use	VERB
ajcp-1612	126	22	to	to	PART
ajcp-1612	126	23	prevent	prevent	VERB
ajcp-1612	126	24	mortality	mortality	NOUN
ajcp-1612	126	25	.	.	PUNCT
ajcp-1612	127	1	some	some	DET
ajcp-1612	127	2	interventions	intervention	NOUN
ajcp-1612	127	3	to	to	PART
ajcp-1612	127	4	manage	manage	VERB
ajcp-1612	127	5	and	and	CCONJ
ajcp-1612	127	6	prevent	prevent	VERB
ajcp-1612	127	7	ckd	ckd	PROPN
ajcp-1612	127	8	are	be	AUX
ajcp-1612	127	9	explained	explain	VERB
ajcp-1612	127	10	in	in	ADP
ajcp-1612	127	11	this	this	DET
ajcp-1612	127	12	review	review	NOUN
ajcp-1612	127	13	.	.	PUNCT
ajcp-1612	128	1	lifestyle	lifestyle	PROPN
ajcp-1612	128	2	modification	modification	NOUN
ajcp-1612	128	3	healthy	healthy	ADJ
ajcp-1612	128	4	dietary	dietary	ADJ
ajcp-1612	128	5	intake	intake	NOUN
ajcp-1612	128	6	and	and	CCONJ
ajcp-1612	128	7	weight	weight	NOUN
ajcp-1612	128	8	are	be	AUX
ajcp-1612	128	9	vital	vital	ADJ
ajcp-1612	128	10	in	in	ADP
ajcp-1612	128	11	reducing	reduce	VERB
ajcp-1612	128	12	most	most	ADJ
ajcp-1612	128	13	chronic	chronic	ADJ
ajcp-1612	128	14	diseases	disease	NOUN
ajcp-1612	128	15	,	,	PUNCT
ajcp-1612	128	16	including	include	VERB
ajcp-1612	128	17	renal	renal	ADJ
ajcp-1612	128	18	end	end	NOUN
ajcp-1612	128	19	-	-	PUNCT
ajcp-1612	128	20	stage	stage	NOUN
ajcp-1612	128	21	diseases	disease	NOUN
ajcp-1612	128	22	.	.	PUNCT
ajcp-1612	129	1	dietary	dietary	ADJ
ajcp-1612	129	2	and	and	CCONJ
ajcp-1612	129	3	lifestyle	lifestyle	NOUN
ajcp-1612	129	4	modifications	modification	NOUN
ajcp-1612	129	5	have	have	AUX
ajcp-1612	129	6	been	be	AUX
ajcp-1612	129	7	shown	show	VERB
ajcp-1612	129	8	to	to	PART
ajcp-1612	129	9	help	help	VERB
ajcp-1612	129	10	treat	treat	VERB
ajcp-1612	129	11	diabetes	diabetes	NOUN
ajcp-1612	129	12	and	and	CCONJ
ajcp-1612	129	13	improve	improve	VERB
ajcp-1612	129	14	glycemic	glycemic	ADJ
ajcp-1612	129	15	control	control	NOUN
ajcp-1612	129	16	.	.	PUNCT
ajcp-1612	130	1	when	when	SCONJ
ajcp-1612	130	2	a	a	DET
ajcp-1612	130	3	patient	patient	NOUN
ajcp-1612	130	4	’s	’s	PART
ajcp-1612	130	5	egfr	egfr	NOUN
ajcp-1612	130	6	drops	drop	NOUN
ajcp-1612	130	7	below	below	ADP
ajcp-1612	130	8	60	60	NUM
ajcp-1612	130	9	ml	ml	NOUN
ajcp-1612	130	10	/	/	SYM
ajcp-1612	130	11	min/1.73	min/1.73	NOUN
ajcp-1612	130	12	m2	m2	PROPN
ajcp-1612	130	13	,	,	PUNCT
ajcp-1612	130	14	it	it	PRON
ajcp-1612	130	15	is	be	AUX
ajcp-1612	130	16	recommended	recommend	VERB
ajcp-1612	130	17	that	that	SCONJ
ajcp-1612	130	18	they	they	PRON
ajcp-1612	130	19	seek	seek	VERB
ajcp-1612	130	20	the	the	DET
ajcp-1612	130	21	advice	advice	NOUN
ajcp-1612	130	22	of	of	ADP
ajcp-1612	130	23	a	a	DET
ajcp-1612	130	24	nutritionist	nutritionist	NOUN
ajcp-1612	130	25	to	to	PART
ajcp-1612	130	26	optimise	optimise	VERB
ajcp-1612	130	27	their	their	PRON
ajcp-1612	130	28	diet	diet	NOUN
ajcp-1612	130	29	to	to	PART
ajcp-1612	130	30	improve	improve	VERB
ajcp-1612	130	31	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	130	32	and	and	CCONJ
ajcp-1612	130	33	ensure	ensure	VERB
ajcp-1612	130	34	they	they	PRON
ajcp-1612	130	35	are	be	AUX
ajcp-1612	130	36	getting	get	VERB
ajcp-1612	130	37	enough	enough	ADJ
ajcp-1612	130	38	protein	protein	NOUN
ajcp-1612	130	39	,	,	PUNCT
ajcp-1612	130	40	potassium	potassium	NOUN
ajcp-1612	130	41	,	,	PUNCT
ajcp-1612	130	42	and	and	CCONJ
ajcp-1612	130	43	phosphorus	phosphorus	NOUN
ajcp-1612	130	44	to	to	PART
ajcp-1612	130	45	prevent	prevent	VERB
ajcp-1612	130	46	the	the	DET
ajcp-1612	130	47	condition	condition	NOUN
ajcp-1612	130	48	from	from	ADP
ajcp-1612	130	49	worsening	worsen	VERB
ajcp-1612	130	50	(	(	PUNCT
ajcp-1612	130	51	williams	williams	PROPN
ajcp-1612	130	52	,	,	PUNCT
ajcp-1612	130	53	2017	2017	NUM
ajcp-1612	130	54	)	)	PUNCT
ajcp-1612	130	55	.	.	PUNCT
ajcp-1612	131	1	nutrition	nutrition	NOUN
ajcp-1612	131	2	is	be	AUX
ajcp-1612	131	3	essential	essential	ADJ
ajcp-1612	131	4	for	for	SCONJ
ajcp-1612	131	5	people	people	NOUN
ajcp-1612	131	6	with	with	ADP
ajcp-1612	131	7	diabetic	diabetic	ADJ
ajcp-1612	131	8	kidney	kidney	NOUN
ajcp-1612	131	9	disease	disease	NOUN
ajcp-1612	131	10	to	to	PART
ajcp-1612	131	11	maintain	maintain	VERB
ajcp-1612	131	12	an	an	DET
ajcp-1612	131	13	equilibrium	equilibrium	NOUN
ajcp-1612	131	14	of	of	ADP
ajcp-1612	131	15	salt	salt	NOUN
ajcp-1612	131	16	,	,	PUNCT
ajcp-1612	131	17	potassium	potassium	NOUN
ajcp-1612	131	18	,	,	PUNCT
ajcp-1612	131	19	phosphorus	phosphorus	NOUN
ajcp-1612	131	20	,	,	PUNCT
ajcp-1612	131	21	protein	protein	NOUN
ajcp-1612	131	22	,	,	PUNCT
ajcp-1612	131	23	carbohydrate	carbohydrate	NOUN
ajcp-1612	131	24	,	,	PUNCT
ajcp-1612	131	25	and	and	CCONJ
ajcp-1612	131	26	unhealthy	unhealthy	ADJ
ajcp-1612	131	27	fat	fat	ADJ
ajcp-1612	131	28	intake	intake	NOUN
ajcp-1612	131	29	.	.	PUNCT
ajcp-1612	132	1	patients	patient	NOUN
ajcp-1612	132	2	who	who	PRON
ajcp-1612	132	3	are	be	AUX
ajcp-1612	132	4	overweight	overweight	ADJ
ajcp-1612	132	5	or	or	CCONJ
ajcp-1612	132	6	obese	obese	NOUN
ajcp-1612	132	7	should	should	AUX
ajcp-1612	132	8	reduce	reduce	VERB
ajcp-1612	132	9	their	their	PRON
ajcp-1612	132	10	weight	weight	NOUN
ajcp-1612	132	11	and	and	CCONJ
ajcp-1612	132	12	improve	improve	VERB
ajcp-1612	132	13	their	their	PRON
ajcp-1612	132	14	exercise	exercise	NOUN
ajcp-1612	132	15	,	,	PUNCT
ajcp-1612	132	16	as	as	SCONJ
ajcp-1612	132	17	cardiac	cardiac	ADJ
ajcp-1612	132	18	stress	stress	NOUN
ajcp-1612	132	19	testing	testing	NOUN
ajcp-1612	132	20	is	be	AUX
ajcp-1612	132	21	necessary	necessary	ADJ
ajcp-1612	132	22	(	(	PUNCT
ajcp-1612	132	23	hahr	hahr	PROPN
ajcp-1612	132	24	&	&	CCONJ
ajcp-1612	132	25	molitch	molitch	PROPN
ajcp-1612	132	26	,	,	PUNCT
ajcp-1612	132	27	2015	2015	NUM
ajcp-1612	132	28	)	)	PUNCT
ajcp-1612	132	29	.	.	PUNCT
ajcp-1612	133	1	according	accord	VERB
ajcp-1612	133	2	to	to	ADP
ajcp-1612	133	3	the	the	DET
ajcp-1612	133	4	kidney	kidney	NOUN
ajcp-1612	133	5	disease	disease	NOUN
ajcp-1612	133	6	outcomes	outcome	VERB
ajcp-1612	133	7	quality	quality	NOUN
ajcp-1612	133	8	initiative	initiative	NOUN
ajcp-1612	133	9	(	(	PUNCT
ajcp-1612	133	10	kdoqi	kdoqi	NOUN
ajcp-1612	133	11	)	)	PUNCT
ajcp-1612	133	12	of	of	ADP
ajcp-1612	133	13	the	the	DET
ajcp-1612	133	14	national	national	PROPN
ajcp-1612	133	15	kidney	kidney	PROPN
ajcp-1612	133	16	foundation	foundation	PROPN
ajcp-1612	133	17	,	,	PUNCT
ajcp-1612	133	18	following	follow	VERB
ajcp-1612	133	19	a	a	DET
ajcp-1612	133	20	low	low	ADJ
ajcp-1612	133	21	-	-	PUNCT
ajcp-1612	133	22	protein	protein	NOUN
ajcp-1612	133	23	diet	diet	NOUN
ajcp-1612	133	24	(	(	PUNCT
ajcp-1612	133	25	lpd	lpd	PROPN
ajcp-1612	133	26	)	)	PUNCT
ajcp-1612	133	27	can	can	AUX
ajcp-1612	133	28	help	help	VERB
ajcp-1612	133	29	ckd	ckd	NOUN
ajcp-1612	133	30	patients	patient	NOUN
ajcp-1612	133	31	live	live	VERB
ajcp-1612	133	32	better	well	ADJ
ajcp-1612	133	33	lives	life	NOUN
ajcp-1612	133	34	and	and	CCONJ
ajcp-1612	133	35	decrease	decrease	VERB
ajcp-1612	133	36	the	the	DET
ajcp-1612	133	37	progression	progression	NOUN
ajcp-1612	133	38	of	of	ADP
ajcp-1612	133	39	esrd	esrd	PROPN
ajcp-1612	133	40	(	(	PUNCT
ajcp-1612	133	41	alkhatib	alkhatib	PROPN
ajcp-1612	133	42	et	et	PROPN
ajcp-1612	133	43	al	al	PROPN
ajcp-1612	133	44	.	.	PROPN
ajcp-1612	133	45	,	,	PUNCT
ajcp-1612	133	46	2023	2023	NUM
ajcp-1612	133	47	)	)	PUNCT
ajcp-1612	133	48	.	.	PUNCT
ajcp-1612	134	1	it	it	PRON
ajcp-1612	134	2	has	have	AUX
ajcp-1612	134	3	been	be	AUX
ajcp-1612	134	4	proven	prove	VERB
ajcp-1612	134	5	that	that	SCONJ
ajcp-1612	134	6	diets	diet	VERB
ajcp-1612	134	7	high	high	ADJ
ajcp-1612	134	8	in	in	ADP
ajcp-1612	134	9	fruits	fruit	NOUN
ajcp-1612	134	10	and	and	CCONJ
ajcp-1612	134	11	vegetables	vegetable	NOUN
ajcp-1612	134	12	and	and	CCONJ
ajcp-1612	134	13	low	low	ADJ
ajcp-1612	134	14	in	in	ADP
ajcp-1612	134	15	saturated	saturate	VERB
ajcp-1612	134	16	fat	fat	NOUN
ajcp-1612	134	17	can	can	AUX
ajcp-1612	134	18	effectively	effectively	ADV
ajcp-1612	134	19	lower	lower	VERB
ajcp-1612	134	20	blood	blood	NOUN
ajcp-1612	134	21	pressure	pressure	NOUN
ajcp-1612	134	22	.	.	PUNCT
ajcp-1612	135	1	these	these	DET
ajcp-1612	135	2	diets	diet	NOUN
ajcp-1612	135	3	also	also	ADV
ajcp-1612	135	4	limit	limit	VERB
ajcp-1612	135	5	salt	salt	NOUN
ajcp-1612	135	6	intake	intake	NOUN
ajcp-1612	135	7	(	(	PUNCT
ajcp-1612	135	8	bello	bello	PROPN
ajcp-1612	135	9	et	et	PROPN
ajcp-1612	135	10	al	al	PROPN
ajcp-1612	135	11	.	.	PROPN
ajcp-1612	135	12	,	,	PUNCT
ajcp-1612	135	13	2005	2005	NUM
ajcp-1612	135	14	)	)	PUNCT
ajcp-1612	135	15	.	.	PUNCT
ajcp-1612	136	1	moreover	moreover	ADV
ajcp-1612	136	2	,	,	PUNCT
ajcp-1612	136	3	cessation	cessation	NOUN
ajcp-1612	136	4	of	of	ADP
ajcp-1612	136	5	smoking	smoking	NOUN
ajcp-1612	136	6	also	also	ADV
ajcp-1612	136	7	helps	help	VERB
ajcp-1612	136	8	in	in	ADP
ajcp-1612	136	9	maintaining	maintain	VERB
ajcp-1612	136	10	healthy	healthy	ADJ
ajcp-1612	136	11	kidney	kidney	NOUN
ajcp-1612	136	12	pharmacological	pharmacological	ADJ
ajcp-1612	136	13	management	management	NOUN
ajcp-1612	136	14	intense	intense	ADJ
ajcp-1612	136	15	care	care	NOUN
ajcp-1612	136	16	of	of	ADP
ajcp-1612	136	17	glycemic	glycemic	ADJ
ajcp-1612	136	18	control	control	NOUN
ajcp-1612	136	19	decreases	decrease	VERB
ajcp-1612	136	20	the	the	DET
ajcp-1612	136	21	risk	risk	NOUN
ajcp-1612	136	22	of	of	ADP
ajcp-1612	136	23	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	136	24	and	and	CCONJ
ajcp-1612	136	25	macroalbuminuria	macroalbuminuria	PROPN
ajcp-1612	136	26	.	.	PUNCT
ajcp-1612	137	1	according	accord	VERB
ajcp-1612	137	2	to	to	ADP
ajcp-1612	137	3	a	a	DET
ajcp-1612	137	4	report	report	NOUN
ajcp-1612	137	5	,	,	PUNCT
ajcp-1612	137	6	every	every	DET
ajcp-1612	137	7	increase	increase	NOUN
ajcp-1612	137	8	in	in	ADP
ajcp-1612	137	9	systolic	systolic	ADJ
ajcp-1612	137	10	blood	blood	NOUN
ajcp-1612	137	11	pressure	pressure	NOUN
ajcp-1612	137	12	in	in	ADP
ajcp-1612	137	13	the	the	DET
ajcp-1612	137	14	general	general	ADJ
ajcp-1612	137	15	population	population	NOUN
ajcp-1612	137	16	above	above	ADP
ajcp-1612	137	17	115	115	NUM
ajcp-1612	137	18	mm	mm	NOUN
ajcp-1612	137	19	hg	hg	NOUN
ajcp-1612	137	20	has	have	AUX
ajcp-1612	137	21	been	be	AUX
ajcp-1612	137	22	said	say	VERB
ajcp-1612	137	23	to	to	PART
ajcp-1612	137	24	double	double	VERB
ajcp-1612	137	25	the	the	DET
ajcp-1612	137	26	risk	risk	NOUN
ajcp-1612	137	27	of	of	ADP
ajcp-1612	137	28	cardiovascular	cardiovascular	ADJ
ajcp-1612	137	29	disease	disease	NOUN
ajcp-1612	137	30	(	(	PUNCT
ajcp-1612	137	31	cvd	cvd	PROPN
ajcp-1612	137	32	)	)	PUNCT
ajcp-1612	137	33	.	.	PUNCT
ajcp-1612	138	1	management	management	NOUN
ajcp-1612	138	2	of	of	ADP
ajcp-1612	138	3	hypertension	hypertension	NOUN
ajcp-1612	138	4	is	be	AUX
ajcp-1612	138	5	essential	essential	ADJ
ajcp-1612	138	6	to	to	PART
ajcp-1612	138	7	prevent	prevent	VERB
ajcp-1612	138	8	albuminuria	albuminuria	PROPN
ajcp-1612	138	9	/	/	SYM
ajcp-1612	138	10	proteinuria	proteinuria	PROPN
ajcp-1612	138	11	and	and	CCONJ
ajcp-1612	138	12	the	the	DET
ajcp-1612	138	13	ensuing	ensue	VERB
ajcp-1612	138	14	development	development	NOUN
ajcp-1612	138	15	of	of	ADP
ajcp-1612	138	16	ckd	ckd	PROPN
ajcp-1612	138	17	in	in	ADP
ajcp-1612	138	18	both	both	CCONJ
ajcp-1612	138	19	diabetic	diabetic	ADJ
ajcp-1612	138	20	and	and	CCONJ
ajcp-1612	138	21	non	non	ADJ
ajcp-1612	138	22	-	-	ADJ
ajcp-1612	138	23	diabetic	diabetic	ADJ
ajcp-1612	138	24	individuals	individual	NOUN
ajcp-1612	138	25	.	.	PUNCT
ajcp-1612	139	1	pre	pre	ADJ
ajcp-1612	139	2	-	-	ADJ
ajcp-1612	139	3	hypertensive	hypertensive	ADJ
ajcp-1612	139	4	conditions	condition	NOUN
ajcp-1612	139	5	,	,	PUNCT
ajcp-1612	139	6	lower	low	ADJ
ajcp-1612	139	7	blood	blood	NOUN
ajcp-1612	139	8	pressure	pressure	NOUN
ajcp-1612	139	9	levels	level	NOUN
ajcp-1612	139	10	in	in	ADP
ajcp-1612	139	11	the	the	DET
ajcp-1612	139	12	general	general	ADJ
ajcp-1612	139	13	population	population	NOUN
ajcp-1612	139	14	,	,	PUNCT
ajcp-1612	139	15	and	and	CCONJ
ajcp-1612	139	16	more	more	ADV
ajcp-1612	139	17	active	active	ADJ
ajcp-1612	139	18	blood	blood	NOUN
ajcp-1612	139	19	pressure	pressure	NOUN
ajcp-1612	139	20	lowering	lower	VERB
ajcp-1612	139	21	in	in	ADP
ajcp-1612	139	22	patients	patient	NOUN
ajcp-1612	139	23	with	with	ADP
ajcp-1612	139	24	hypertension	hypertension	NOUN
ajcp-1612	139	25	and	and	CCONJ
ajcp-1612	139	26	underlying	underlying	ADJ
ajcp-1612	139	27	ckd	ckd	NOUN
ajcp-1612	139	28	are	be	AUX
ajcp-1612	139	29	essential	essential	ADJ
ajcp-1612	139	30	(	(	PUNCT
ajcp-1612	139	31	bello	bello	PROPN
ajcp-1612	139	32	et	et	PROPN
ajcp-1612	139	33	al	al	PROPN
ajcp-1612	139	34	.	.	PROPN
ajcp-1612	139	35	,	,	PUNCT
ajcp-1612	139	36	2005	2005	NUM
ajcp-1612	139	37	)	)	PUNCT
ajcp-1612	139	38	.	.	PUNCT
ajcp-1612	140	1	standardising	standardise	VERB
ajcp-1612	140	2	a	a	DET
ajcp-1612	140	3	distinct	distinct	ADJ
ajcp-1612	140	4	ratio	ratio	NOUN
ajcp-1612	140	5	for	for	ADP
ajcp-1612	140	6	every	every	DET
ajcp-1612	140	7	patient	patient	NOUN
ajcp-1612	140	8	is	be	AUX
ajcp-1612	140	9	crucial	crucial	ADJ
ajcp-1612	140	10	for	for	ADP
ajcp-1612	140	11	blood	blood	NOUN
ajcp-1612	140	12	glucose	glucose	NOUN
ajcp-1612	140	13	management	management	NOUN
ajcp-1612	140	14	and	and	CCONJ
ajcp-1612	140	15	ckd	ckd	PROPN
ajcp-1612	140	16	prevention	prevention	NOUN
ajcp-1612	140	17	.	.	PUNCT
ajcp-1612	141	1	maintaining	maintain	VERB
ajcp-1612	141	2	a	a	DET
ajcp-1612	141	3	blood	blood	NOUN
ajcp-1612	141	4	pressure	pressure	NOUN
ajcp-1612	141	5	(	(	PUNCT
ajcp-1612	141	6	bp	bp	PROPN
ajcp-1612	141	7	)	)	PUNCT
ajcp-1612	141	8	less	less	ADJ
ajcp-1612	141	9	than	than	ADP
ajcp-1612	141	10	130/80	130/80	NUM
ajcp-1612	141	11	in	in	ADP
ajcp-1612	141	12	dkd	dkd	ADJ
ajcp-1612	141	13	patients	patient	NOUN
ajcp-1612	141	14	is	be	AUX
ajcp-1612	141	15	the	the	DET
ajcp-1612	141	16	typical	typical	ADJ
ajcp-1612	141	17	aim	aim	NOUN
ajcp-1612	141	18	advised	advise	VERB
ajcp-1612	141	19	by	by	ADP
ajcp-1612	141	20	the	the	DET
ajcp-1612	141	21	national	national	PROPN
ajcp-1612	141	22	kidney	kidney	PROPN
ajcp-1612	141	23	foundation	foundation	PROPN
ajcp-1612	141	24	;	;	PUNCT
ajcp-1612	141	25	nevertheless	nevertheless	ADV
ajcp-1612	141	26	,	,	PUNCT
ajcp-1612	141	27	there	there	PRON
ajcp-1612	141	28	is	be	VERB
ajcp-1612	141	29	considerable	considerable	ADJ
ajcp-1612	141	30	debate	debate	NOUN
ajcp-1612	141	31	around	around	ADP
ajcp-1612	141	32	this	this	DET
ajcp-1612	141	33	recommendation	recommendation	NOUN
ajcp-1612	141	34	(	(	PUNCT
ajcp-1612	141	35	williams	williams	PROPN
ajcp-1612	141	36	,	,	PUNCT
ajcp-1612	141	37	2017	2017	NUM
ajcp-1612	141	38	)	)	PUNCT
ajcp-1612	141	39	.	.	PUNCT
ajcp-1612	142	1	due	due	ADP
ajcp-1612	142	2	to	to	ADP
ajcp-1612	142	3	their	their	PRON
ajcp-1612	142	4	ability	ability	NOUN
ajcp-1612	142	5	to	to	PART
ajcp-1612	142	6	preserve	preserve	VERB
ajcp-1612	142	7	the	the	DET
ajcp-1612	142	8	kidneys	kidney	NOUN
ajcp-1612	142	9	,	,	PUNCT
ajcp-1612	142	10	ace	ace	AUX
ajcp-1612	142	11	inhibitors	inhibitor	NOUN
ajcp-1612	142	12	and	and	CCONJ
ajcp-1612	142	13	arbs	arb	NOUN
ajcp-1612	142	14	are	be	AUX
ajcp-1612	142	15	typically	typically	ADV
ajcp-1612	142	16	regarded	regard	VERB
ajcp-1612	142	17	as	as	ADP
ajcp-1612	142	18	first	first	ADJ
ajcp-1612	142	19	-	-	PUNCT
ajcp-1612	142	20	line	line	NOUN
ajcp-1612	142	21	treatments	treatment	NOUN
ajcp-1612	142	22	for	for	ADP
ajcp-1612	142	23	hypertension	hypertension	NOUN
ajcp-1612	142	24	in	in	ADP
ajcp-1612	142	25	diabetic	diabetic	ADJ
ajcp-1612	142	26	people	people	NOUN
ajcp-1612	142	27	.	.	PUNCT
ajcp-1612	143	1	patients	patient	NOUN
ajcp-1612	143	2	with	with	ADP
ajcp-1612	143	3	diabetes	diabetes	NOUN
ajcp-1612	143	4	mellitus	mellitus	NOUN
ajcp-1612	143	5	have	have	AUX
ajcp-1612	143	6	been	be	AUX
ajcp-1612	143	7	shown	show	VERB
ajcp-1612	143	8	to	to	PART
ajcp-1612	143	9	benefit	benefit	VERB
ajcp-1612	143	10	from	from	ADP
ajcp-1612	143	11	ace	ace	ADJ
ajcp-1612	143	12	inhibitors	inhibitor	NOUN
ajcp-1612	143	13	in	in	ADP
ajcp-1612	143	14	terms	term	NOUN
ajcp-1612	143	15	of	of	ADP
ajcp-1612	143	16	kidney	kidney	NOUN
ajcp-1612	143	17	,	,	PUNCT
ajcp-1612	143	18	heart	heart	NOUN
ajcp-1612	143	19	,	,	PUNCT
ajcp-1612	143	20	and	and	CCONJ
ajcp-1612	143	21	,	,	PUNCT
ajcp-1612	143	22	to	to	ADP
ajcp-1612	143	23	a	a	DET
ajcp-1612	143	24	lesser	less	ADJ
ajcp-1612	143	25	extent	extent	NOUN
ajcp-1612	143	26	,	,	PUNCT
ajcp-1612	143	27	eye	eye	NOUN
ajcp-1612	143	28	and	and	CCONJ
ajcp-1612	143	29	peripheral	peripheral	ADJ
ajcp-1612	143	30	nerve	nerve	NOUN
ajcp-1612	143	31	function	function	NOUN
ajcp-1612	143	32	.	.	PUNCT
ajcp-1612	144	1	these	these	DET
ajcp-1612	144	2	positive	positive	ADJ
ajcp-1612	144	3	outcomes	outcome	NOUN
ajcp-1612	144	4	result	result	VERB
ajcp-1612	144	5	from	from	ADP
ajcp-1612	144	6	angiotensin	angiotensin	PROPN
ajcp-1612	144	7	ii	ii	PROPN
ajcp-1612	144	8	’s	’s	PART
ajcp-1612	144	9	hemodynamic	hemodynamic	ADJ
ajcp-1612	144	10	and	and	CCONJ
ajcp-1612	144	11	tissular	tissular	ADJ
ajcp-1612	144	12	actions	action	NOUN
ajcp-1612	144	13	being	be	AUX
ajcp-1612	144	14	inhibited	inhibit	VERB
ajcp-1612	144	15	(	(	PUNCT
ajcp-1612	144	16	williams	williams	PROPN
ajcp-1612	144	17	,	,	PUNCT
ajcp-1612	144	18	2017	2017	NUM
ajcp-1612	144	19	)	)	PUNCT
ajcp-1612	144	20	.	.	PUNCT
ajcp-1612	145	1	medications	medication	NOUN
ajcp-1612	145	2	some	some	DET
ajcp-1612	145	3	treatments	treatment	NOUN
ajcp-1612	145	4	suggested	suggest	VERB
ajcp-1612	145	5	by	by	ADP
ajcp-1612	145	6	healthcare	healthcare	NOUN
ajcp-1612	145	7	professionals	professional	NOUN
ajcp-1612	145	8	are	be	AUX
ajcp-1612	145	9	first	first	ADJ
ajcp-1612	145	10	-	-	PUNCT
ajcp-1612	145	11	line	line	NOUN
ajcp-1612	145	12	care	care	NOUN
ajcp-1612	145	13	for	for	ADP
ajcp-1612	145	14	the	the	DET
ajcp-1612	145	15	prevention	prevention	NOUN
ajcp-1612	145	16	of	of	ADP
ajcp-1612	145	17	ckd	ckd	PROPN
ajcp-1612	145	18	,	,	PUNCT
ajcp-1612	145	19	such	such	ADJ
ajcp-1612	145	20	as	as	ADP
ajcp-1612	145	21	metformin	metformin	NOUN
ajcp-1612	145	22	(	(	PUNCT
ajcp-1612	145	23	betônico	betônico	NOUN
ajcp-1612	145	24	et	et	PROPN
ajcp-1612	145	25	al	al	PROPN
ajcp-1612	145	26	.	.	PROPN
ajcp-1612	145	27	,	,	PUNCT
ajcp-1612	145	28	2016	2016	NUM
ajcp-1612	145	29	;	;	PUNCT
ajcp-1612	145	30	beulens	beulen	VERB
ajcp-1612	145	31	et	et	PROPN
ajcp-1612	145	32	al	al	PROPN
ajcp-1612	145	33	.	.	PROPN
ajcp-1612	145	34	,	,	PUNCT
ajcp-1612	145	35	2020	2020	NUM
ajcp-1612	145	36	)	)	PUNCT
ajcp-1612	145	37	.	.	PUNCT
ajcp-1612	146	1	this	this	DET
ajcp-1612	146	2	medication	medication	NOUN
ajcp-1612	146	3	has	have	AUX
ajcp-1612	146	4	been	be	AUX
ajcp-1612	146	5	advised	advise	VERB
ajcp-1612	146	6	to	to	ADP
ajcp-1612	146	7	patients	patient	NOUN
ajcp-1612	146	8	for	for	ADP
ajcp-1612	146	9	years	year	NOUN
ajcp-1612	146	10	.	.	PUNCT
ajcp-1612	147	1	the	the	DET
ajcp-1612	147	2	mechanism	mechanism	NOUN
ajcp-1612	147	3	of	of	ADP
ajcp-1612	147	4	this	this	DET
ajcp-1612	147	5	drug	drug	NOUN
ajcp-1612	147	6	is	be	AUX
ajcp-1612	147	7	to	to	PART
ajcp-1612	147	8	decrease	decrease	VERB
ajcp-1612	147	9	the	the	DET
ajcp-1612	147	10	production	production	NOUN
ajcp-1612	147	11	of	of	ADP
ajcp-1612	147	12	hepatic	hepatic	ADJ
ajcp-1612	147	13	glucose	glucose	NOUN
ajcp-1612	147	14	,	,	PUNCT
ajcp-1612	147	15	improve	improve	VERB
ajcp-1612	147	16	insulin	insulin	NOUN
ajcp-1612	147	17	tolerance	tolerance	NOUN
ajcp-1612	147	18	,	,	PUNCT
ajcp-1612	147	19	lowering	lower	VERB
ajcp-1612	147	20	impaired	impaired	ADJ
ajcp-1612	147	21	fasting	fasting	NOUN
ajcp-1612	147	22	glucose	glucose	NOUN
ajcp-1612	147	23	and	and	CCONJ
ajcp-1612	147	24	plasma	plasma	NOUN
ajcp-1612	147	25	glucose	glucose	NOUN
ajcp-1612	147	26	.	.	PUNCT
ajcp-1612	148	1	although	although	SCONJ
ajcp-1612	148	2	metformin	metformin	NOUN
ajcp-1612	148	3	is	be	AUX
ajcp-1612	148	4	the	the	DET
ajcp-1612	148	5	most	most	ADV
ajcp-1612	148	6	common	common	ADJ
ajcp-1612	148	7	drug	drug	NOUN
ajcp-1612	148	8	to	to	PART
ajcp-1612	148	9	prevent	prevent	VERB
ajcp-1612	148	10	and	and	CCONJ
ajcp-1612	148	11	manage	manage	VERB
ajcp-1612	148	12	ckd	ckd	PROPN
ajcp-1612	148	13	,	,	PUNCT
ajcp-1612	148	14	it	it	PRON
ajcp-1612	148	15	still	still	ADV
ajcp-1612	148	16	is	be	AUX
ajcp-1612	148	17	contradictory	contradictory	ADJ
ajcp-1612	148	18	to	to	ADP
ajcp-1612	148	19	its	its	PRON
ajcp-1612	148	20	nature	nature	NOUN
ajcp-1612	148	21	because	because	SCONJ
ajcp-1612	148	22	metformin	metformin	PROPN
ajcp-1612	148	23	excretes	excrete	NOUN
ajcp-1612	148	24	through	through	ADP
ajcp-1612	148	25	the	the	DET
ajcp-1612	148	26	renal	renal	ADJ
ajcp-1612	148	27	system	system	NOUN
ajcp-1612	148	28	and	and	CCONJ
ajcp-1612	148	29	the	the	DET
ajcp-1612	148	30	emergence	emergence	NOUN
ajcp-1612	148	31	of	of	ADP
ajcp-1612	148	32	lactic	lactic	ADJ
ajcp-1612	148	33	acidosis	acidosis	NOUN
ajcp-1612	148	34	,	,	PUNCT
ajcp-1612	148	35	which	which	PRON
ajcp-1612	148	36	is	be	AUX
ajcp-1612	148	37	one	one	NUM
ajcp-1612	148	38	of	of	ADP
ajcp-1612	148	39	its	its	PRON
ajcp-1612	148	40	most	most	ADV
ajcp-1612	148	41	serious	serious	ADJ
ajcp-1612	148	42	drawbacks	drawback	NOUN
ajcp-1612	148	43	but	but	CCONJ
ajcp-1612	148	44	only	only	ADV
ajcp-1612	148	45	occurs	occur	VERB
ajcp-1612	148	46	in	in	ADP
ajcp-1612	148	47	about	about	ADV
ajcp-1612	148	48	5	5	NUM
ajcp-1612	148	49	cases	case	NOUN
ajcp-1612	148	50	per	per	ADP
ajcp-1612	148	51	100,000	100,000	NUM
ajcp-1612	148	52	patient	patient	NOUN
ajcp-1612	148	53	-	-	PUNCT
ajcp-1612	148	54	years	year	NOUN
ajcp-1612	148	55	of	of	ADP
ajcp-1612	148	56	patients	patient	NOUN
ajcp-1612	148	57	on	on	ADP
ajcp-1612	148	58	average	average	ADJ
ajcp-1612	148	59	.	.	PUNCT
ajcp-1612	149	1	metformin	metformin	NOUN
ajcp-1612	149	2	can	can	AUX
ajcp-1612	149	3	be	be	AUX
ajcp-1612	149	4	used	use	VERB
ajcp-1612	149	5	to	to	PART
ajcp-1612	149	6	treat	treat	VERB
ajcp-1612	149	7	type	type	NOUN
ajcp-1612	149	8	2	2	NUM
ajcp-1612	149	9	diabetes	diabetes	NOUN
ajcp-1612	149	10	(	(	PUNCT
ajcp-1612	149	11	t2	t2	NOUN
ajcp-1612	149	12	dm	dm	PROPN
ajcp-1612	149	13	)	)	PUNCT
ajcp-1612	149	14	up	up	ADP
ajcp-1612	149	15	to	to	ADP
ajcp-1612	149	16	a	a	DET
ajcp-1612	149	17	gfr	gfr	NOUN
ajcp-1612	149	18	of	of	ADP
ajcp-1612	149	19	30	30	NUM
ajcp-1612	149	20	ml	ml	NOUN
ajcp-1612	149	21	/	/	SYM
ajcp-1612	149	22	min/1.73	min/1.73	NOUN
ajcp-1612	149	23	m2	m2	PROPN
ajcp-1612	149	24	,	,	PUNCT
ajcp-1612	149	25	with	with	ADP
ajcp-1612	149	26	a	a	DET
ajcp-1612	149	27	lower	low	ADJ
ajcp-1612	149	28	dose	dose	NOUN
ajcp-1612	149	29	indicated	indicate	VERB
ajcp-1612	149	30	at	at	ADP
ajcp-1612	149	31	45	45	NUM
ajcp-1612	149	32	ml	ml	NOUN
ajcp-1612	149	33	/	/	SYM
ajcp-1612	149	34	min/1.73	min/1.73	NOUN
ajcp-1612	150	1	m2	m2	PROPN
ajcp-1612	150	2	(	(	PUNCT
ajcp-1612	150	3	current	current	ADJ
ajcp-1612	150	4	uk	uk	PROPN
ajcp-1612	150	5	guidelines	guideline	NOUN
ajcp-1612	150	6	)	)	PUNCT
ajcp-1612	150	7	(	(	PUNCT
ajcp-1612	150	8	betônico	betônico	NOUN
ajcp-1612	150	9	et	et	PROPN
ajcp-1612	150	10	al	al	PROPN
ajcp-1612	150	11	.	.	PROPN
ajcp-1612	150	12	,	,	PUNCT
ajcp-1612	150	13	2016	2016	NUM
ajcp-1612	150	14	)	)	PUNCT
ajcp-1612	150	15	.	.	PUNCT
ajcp-1612	151	1	sulfonylureas	sulfonylureas	PROPN
ajcp-1612	151	2	(	(	PUNCT
ajcp-1612	151	3	sus	sus	NOUN
ajcp-1612	151	4	)	)	PUNCT
ajcp-1612	151	5	encourage	encourage	VERB
ajcp-1612	151	6	pancreatic	pancreatic	ADJ
ajcp-1612	151	7	b	b	NOUN
ajcp-1612	151	8	cells	cell	NOUN
ajcp-1612	151	9	to	to	PART
ajcp-1612	151	10	secrete	secrete	VERB
ajcp-1612	151	11	endogenous	endogenous	ADJ
ajcp-1612	151	12	insulin	insulin	NOUN
ajcp-1612	151	13	,	,	PUNCT
ajcp-1612	151	14	leading	lead	VERB
ajcp-1612	151	15	to	to	ADP
ajcp-1612	151	16	hypoglycemia	hypoglycemia	NOUN
ajcp-1612	151	17	,	,	PUNCT
ajcp-1612	151	18	alcohol	alcohol	NOUN
ajcp-1612	151	19	abuse	abuse	NOUN
ajcp-1612	151	20	,	,	PUNCT
ajcp-1612	151	21	hepatic	hepatic	ADJ
ajcp-1612	151	22	dysfunction	dysfunction	NOUN
ajcp-1612	151	23	,	,	PUNCT
ajcp-1612	151	24	heart	heart	NOUN
ajcp-1612	151	25	failure	failure	NOUN
ajcp-1612	151	26	,	,	PUNCT
ajcp-1612	151	27	malnutrition	malnutrition	NOUN
ajcp-1612	151	28	,	,	PUNCT
ajcp-1612	151	29	advanced	advanced	ADJ
ajcp-1612	151	30	age	age	NOUN
ajcp-1612	151	31	,	,	PUNCT
ajcp-1612	151	32	and	and	CCONJ
ajcp-1612	151	33	interactions	interaction	NOUN
ajcp-1612	151	34	with	with	ADP
ajcp-1612	151	35	other	other	ADJ
ajcp-1612	151	36	medications	medication	NOUN
ajcp-1612	151	37	that	that	PRON
ajcp-1612	151	38	displace	displace	VERB
ajcp-1612	151	39	sus	sus	NOUN
ajcp-1612	151	40	from	from	ADP
ajcp-1612	151	41	their	their	PRON
ajcp-1612	151	42	plasma	plasma	NOUN
ajcp-1612	151	43	protein	protein	NOUN
ajcp-1612	151	44	-	-	PUNCT
ajcp-1612	151	45	binding	bind	VERB
ajcp-1612	151	46	sites	site	NOUN
ajcp-1612	151	47	(	(	PUNCT
ajcp-1612	151	48	seino	seino	PROPN
ajcp-1612	151	49	et	et	PROPN
ajcp-1612	151	50	al	al	PROPN
ajcp-1612	151	51	.	.	PROPN
ajcp-1612	151	52	,	,	PUNCT
ajcp-1612	151	53	2016	2016	NUM
ajcp-1612	151	54	)	)	PUNCT
ajcp-1612	151	55	.	.	PUNCT
ajcp-1612	152	1	this	this	PRON
ajcp-1612	152	2	is	be	AUX
ajcp-1612	152	3	due	due	ADJ
ajcp-1612	152	4	to	to	ADP
ajcp-1612	152	5	accumulating	accumulate	VERB
ajcp-1612	152	6	one	one	NUM
ajcp-1612	152	7	or	or	CCONJ
ajcp-1612	152	8	more	more	ADJ
ajcp-1612	152	9	of	of	ADP
ajcp-1612	152	10	these	these	DET
ajcp-1612	152	11	medications	medication	NOUN
ajcp-1612	152	12	’	'	PUNCT
ajcp-1612	152	13	metabolites	metabolite	NOUN
ajcp-1612	152	14	,	,	PUNCT
ajcp-1612	152	15	increasing	increase	VERB
ajcp-1612	152	16	the	the	DET
ajcp-1612	152	17	risk	risk	NOUN
ajcp-1612	152	18	of	of	ADP
ajcp-1612	152	19	hypoglycemia	hypoglycemia	NOUN
ajcp-1612	152	20	.	.	PUNCT
ajcp-1612	153	1	other	other	ADJ
ajcp-1612	153	2	medications	medication	NOUN
ajcp-1612	153	3	help	help	NOUN
ajcp-1612	153	4	decrease	decrease	VERB
ajcp-1612	153	5	the	the	DET
ajcp-1612	153	6	incidence	incidence	NOUN
ajcp-1612	153	7	of	of	ADP
ajcp-1612	153	8	ckd	ckd	PROPN
ajcp-1612	153	9	in	in	ADP
ajcp-1612	153	10	diabetes	diabetes	NOUN
ajcp-1612	153	11	,	,	PUNCT
ajcp-1612	153	12	such	such	ADJ
ajcp-1612	153	13	as	as	ADP
ajcp-1612	153	14	glinides	glinide	NOUN
ajcp-1612	153	15	,	,	PUNCT
ajcp-1612	153	16	alpha	alpha	NOUN
ajcp-1612	153	17	-	-	PUNCT
ajcp-1612	153	18	glucosidase	glucosidase	ADJ
ajcp-1612	153	19	inhibitors	inhibitor	NOUN
ajcp-1612	153	20	,	,	PUNCT
ajcp-1612	153	21	glitazones	glitazone	NOUN
ajcp-1612	153	22	,	,	PUNCT
ajcp-1612	153	23	and	and	CCONJ
ajcp-1612	153	24	dipeptidyl	dipeptidyl	VERB
ajcp-1612	153	25	peptidase	peptidase	NOUN
ajcp-1612	153	26	4	4	NUM
ajcp-1612	153	27	inhibitors	inhibitor	NOUN
ajcp-1612	153	28	(	(	PUNCT
ajcp-1612	153	29	seino	seino	X
ajcp-1612	153	30	et	et	PROPN
ajcp-1612	153	31	al	al	PROPN
ajcp-1612	153	32	.	.	PROPN
ajcp-1612	153	33	,	,	PUNCT
ajcp-1612	153	34	2016	2016	NUM
ajcp-1612	153	35	)	)	PUNCT
ajcp-1612	153	36	.	.	PUNCT
ajcp-1612	154	1	insulin	insulin	NOUN
ajcp-1612	154	2	therapy	therapy	NOUN
ajcp-1612	154	3	the	the	DET
ajcp-1612	154	4	kidney	kidney	NOUN
ajcp-1612	154	5	is	be	AUX
ajcp-1612	154	6	crucial	crucial	ADJ
ajcp-1612	154	7	in	in	ADP
ajcp-1612	154	8	removing	remove	VERB
ajcp-1612	154	9	insulin	insulin	NOUN
ajcp-1612	154	10	from	from	ADP
ajcp-1612	154	11	the	the	DET
ajcp-1612	154	12	bloodstream	bloodstream	NOUN
ajcp-1612	154	13	through	through	ADP
ajcp-1612	154	14	two	two	NUM
ajcp-1612	154	15	different	different	ADJ
ajcp-1612	154	16	mechanisms	mechanism	NOUN
ajcp-1612	154	17	.	.	PUNCT
ajcp-1612	155	1	in	in	ADP
ajcp-1612	155	2	the	the	DET
ajcp-1612	155	3	initial	initial	ADJ
ajcp-1612	155	4	stage	stage	NOUN
ajcp-1612	155	5	,	,	PUNCT
ajcp-1612	155	6	insulin	insulin	NOUN
ajcp-1612	155	7	is	be	AUX
ajcp-1612	155	8	filtered	filter	VERB
ajcp-1612	155	9	by	by	ADP
ajcp-1612	155	10	the	the	DET
ajcp-1612	155	11	glomerulus	glomerulus	NOUN
ajcp-1612	155	12	and	and	CCONJ
ajcp-1612	155	13	then	then	ADV
ajcp-1612	155	14	taken	take	VERB
ajcp-1612	155	15	up	up	ADP
ajcp-1612	155	16	by	by	ADP
ajcp-1612	155	17	proximal	proximal	ADJ
ajcp-1612	155	18	tubular	tubular	ADJ
ajcp-1612	155	19	cells	cell	NOUN
ajcp-1612	155	20	via	via	ADP
ajcp-1612	155	21	endocytosis	endocytosis	NOUN
ajcp-1612	155	22	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	155	23	pa	pa	PROPN
ajcp-1612	155	24	ge	ge	PROPN
ajcp-1612	155	25	12	12	NUM
ajcp-1612	155	26	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	155	27	am	be	AUX
ajcp-1612	155	28	.	.	PUNCT
ajcp-1612	156	1	j.	j.	PROPN
ajcp-1612	156	2	chem	chem	PROPN
ajcp-1612	156	3	.	.	PUNCT
ajcp-1612	157	1	pharm	pharm	PROPN
ajcp-1612	157	2	.	.	PUNCT
ajcp-1612	158	1	2(2	2(2	NUM
ajcp-1612	158	2	)	)	PUNCT
ajcp-1612	158	3	9	9	NUM
ajcp-1612	158	4	-	-	SYM
ajcp-1612	158	5	14	14	NUM
ajcp-1612	158	6	,	,	PUNCT
ajcp-1612	158	7	2023	2023	NUM
ajcp-1612	158	8	(	(	PUNCT
ajcp-1612	158	9	peruchetti	peruchetti	PROPN
ajcp-1612	158	10	et	et	PROPN
ajcp-1612	158	11	al	al	PROPN
ajcp-1612	158	12	.	.	PROPN
ajcp-1612	158	13	,	,	PUNCT
ajcp-1612	158	14	2021	2021	NUM
ajcp-1612	158	15	)	)	PUNCT
ajcp-1612	158	16	.	.	PUNCT
ajcp-1612	159	1	the	the	DET
ajcp-1612	159	2	second	second	ADJ
ajcp-1612	159	3	process	process	NOUN
ajcp-1612	159	4	includes	include	VERB
ajcp-1612	159	5	insulin	insulin	NOUN
ajcp-1612	159	6	attaching	attach	VERB
ajcp-1612	159	7	to	to	ADP
ajcp-1612	159	8	the	the	DET
ajcp-1612	159	9	contra	contra	PROPN
ajcp-1612	159	10	luminal	luminal	ADJ
ajcp-1612	159	11	tubular	tubular	ADJ
ajcp-1612	159	12	membrane	membrane	NOUN
ajcp-1612	159	13	of	of	ADP
ajcp-1612	159	14	cells	cell	NOUN
ajcp-1612	159	15	and	and	CCONJ
ajcp-1612	159	16	diffusing	diffuse	VERB
ajcp-1612	159	17	through	through	ADP
ajcp-1612	159	18	peritubular	peritubular	ADJ
ajcp-1612	159	19	capillaries	capillary	NOUN
ajcp-1612	159	20	.	.	PUNCT
ajcp-1612	160	1	lysosomes	lysosome	NOUN
ajcp-1612	160	2	transport	transport	NOUN
ajcp-1612	160	3	insulin	insulin	NOUN
ajcp-1612	160	4	,	,	PUNCT
ajcp-1612	160	5	broken	break	VERB
ajcp-1612	160	6	down	down	ADP
ajcp-1612	160	7	into	into	ADP
ajcp-1612	160	8	amino	amino	ADJ
ajcp-1612	160	9	acids	acid	NOUN
ajcp-1612	160	10	and	and	CCONJ
ajcp-1612	160	11	diffused	diffuse	VERB
ajcp-1612	160	12	into	into	ADP
ajcp-1612	160	13	the	the	DET
ajcp-1612	160	14	peritubular	peritubular	ADJ
ajcp-1612	160	15	arteries	artery	NOUN
ajcp-1612	160	16	.	.	PUNCT
ajcp-1612	161	1	insulin	insulin	NOUN
ajcp-1612	161	2	clearance	clearance	NOUN
ajcp-1612	161	3	declines	decline	VERB
ajcp-1612	161	4	when	when	SCONJ
ajcp-1612	161	5	renal	renal	ADJ
ajcp-1612	161	6	failure	failure	NOUN
ajcp-1612	161	7	worsens	worsen	VERB
ajcp-1612	161	8	,	,	PUNCT
ajcp-1612	161	9	necessitating	necessitate	VERB
ajcp-1612	161	10	a	a	DET
ajcp-1612	161	11	dosage	dosage	NOUN
ajcp-1612	161	12	reduction	reduction	NOUN
ajcp-1612	161	13	to	to	PART
ajcp-1612	161	14	prevent	prevent	VERB
ajcp-1612	161	15	hypoglycemia	hypoglycemia	NOUN
ajcp-1612	161	16	(	(	PUNCT
ajcp-1612	161	17	peruchetti	peruchetti	PROPN
ajcp-1612	161	18	et	et	PROPN
ajcp-1612	161	19	al	al	PROPN
ajcp-1612	161	20	.	.	PROPN
ajcp-1612	161	21	,	,	PUNCT
ajcp-1612	161	22	2021	2021	NUM
ajcp-1612	161	23	)	)	PUNCT
ajcp-1612	161	24	.	.	PUNCT
ajcp-1612	162	1	this	this	DET
ajcp-1612	162	2	decrease	decrease	NOUN
ajcp-1612	162	3	in	in	ADP
ajcp-1612	162	4	insulin	insulin	NOUN
ajcp-1612	162	5	clearance	clearance	NOUN
ajcp-1612	162	6	is	be	AUX
ajcp-1612	162	7	initially	initially	ADV
ajcp-1612	162	8	offset	offset	VERB
ajcp-1612	162	9	by	by	ADP
ajcp-1612	162	10	a	a	DET
ajcp-1612	162	11	rise	rise	NOUN
ajcp-1612	162	12	in	in	ADP
ajcp-1612	162	13	proximal	proximal	ADJ
ajcp-1612	162	14	tubular	tubular	ADJ
ajcp-1612	162	15	cells	cell	NOUN
ajcp-1612	162	16	’	'	PUNCT
ajcp-1612	162	17	insulin	insulin	NOUN
ajcp-1612	162	18	absorption	absorption	NOUN
ajcp-1612	162	19	,	,	PUNCT
ajcp-1612	162	20	and	and	CCONJ
ajcp-1612	162	21	it	it	PRON
ajcp-1612	162	22	is	be	AUX
ajcp-1612	162	23	also	also	ADV
ajcp-1612	162	24	linked	link	VERB
ajcp-1612	162	25	to	to	ADP
ajcp-1612	162	26	an	an	DET
ajcp-1612	162	27	increase	increase	NOUN
ajcp-1612	162	28	in	in	ADP
ajcp-1612	162	29	insulin	insulin	NOUN
ajcp-1612	162	30	resistance	resistance	NOUN
ajcp-1612	162	31	.	.	PUNCT
ajcp-1612	163	1	muscle	muscle	NOUN
ajcp-1612	163	2	tissue	tissue	NOUN
ajcp-1612	163	3	is	be	AUX
ajcp-1612	163	4	the	the	DET
ajcp-1612	163	5	predominant	predominant	ADJ
ajcp-1612	163	6	source	source	NOUN
ajcp-1612	163	7	of	of	ADP
ajcp-1612	163	8	ir	ir	PROPN
ajcp-1612	163	9	in	in	ADP
ajcp-1612	163	10	ckd	ckd	PROPN
ajcp-1612	163	11	,	,	PUNCT
ajcp-1612	163	12	occurring	occur	VERB
ajcp-1612	163	13	mostly	mostly	ADV
ajcp-1612	163	14	at	at	ADP
ajcp-1612	163	15	the	the	DET
ajcp-1612	163	16	extremities	extremity	NOUN
ajcp-1612	163	17	.	.	PUNCT
ajcp-1612	164	1	in	in	ADP
ajcp-1612	164	2	individuals	individual	NOUN
ajcp-1612	164	3	with	with	ADP
ajcp-1612	164	4	esrd	esrd	PROPN
ajcp-1612	164	5	,	,	PUNCT
ajcp-1612	164	6	hepatic	hepatic	ADJ
ajcp-1612	164	7	glucose	glucose	NOUN
ajcp-1612	164	8	production	production	NOUN
ajcp-1612	164	9	is	be	AUX
ajcp-1612	164	10	not	not	PART
ajcp-1612	164	11	elevated	elevated	ADJ
ajcp-1612	164	12	and	and	CCONJ
ajcp-1612	164	13	repressed	repress	VERB
ajcp-1612	164	14	in	in	ADP
ajcp-1612	164	15	response	response	NOUN
ajcp-1612	164	16	to	to	ADP
ajcp-1612	164	17	insulin	insulin	NOUN
ajcp-1612	164	18	,	,	PUNCT
ajcp-1612	164	19	and	and	CCONJ
ajcp-1612	164	20	ir	ir	PROPN
ajcp-1612	164	21	may	may	AUX
ajcp-1612	164	22	not	not	PART
ajcp-1612	164	23	result	result	VERB
ajcp-1612	164	24	in	in	ADP
ajcp-1612	164	25	a	a	DET
ajcp-1612	164	26	proportional	proportional	ADJ
ajcp-1612	164	27	rise	rise	NOUN
ajcp-1612	164	28	in	in	ADP
ajcp-1612	164	29	insulin	insulin	NOUN
ajcp-1612	164	30	secretion	secretion	NOUN
ajcp-1612	164	31	(	(	PUNCT
ajcp-1612	164	32	gburek	gburek	NOUN
ajcp-1612	164	33	et	et	PROPN
ajcp-1612	164	34	al	al	PROPN
ajcp-1612	164	35	.	.	PROPN
ajcp-1612	164	36	,	,	PUNCT
ajcp-1612	164	37	2021	2021	NUM
ajcp-1612	164	38	)	)	PUNCT
ajcp-1612	164	39	.	.	PUNCT
ajcp-1612	165	1	lipid	lipid	NOUN
ajcp-1612	165	2	metabolism	metabolism	NOUN
ajcp-1612	165	3	dysregulation	dysregulation	NOUN
ajcp-1612	165	4	of	of	ADP
ajcp-1612	165	5	lipid	lipid	ADJ
ajcp-1612	165	6	metabolism	metabolism	NOUN
ajcp-1612	165	7	leads	lead	VERB
ajcp-1612	165	8	to	to	ADP
ajcp-1612	165	9	higher	high	ADJ
ajcp-1612	165	10	levels	level	NOUN
ajcp-1612	165	11	of	of	ADP
ajcp-1612	165	12	triglycerides	triglyceride	NOUN
ajcp-1612	165	13	,	,	PUNCT
ajcp-1612	165	14	oxidised	oxidise	VERB
ajcp-1612	165	15	lipoproteins	lipoprotein	NOUN
ajcp-1612	165	16	,	,	PUNCT
ajcp-1612	165	17	and	and	CCONJ
ajcp-1612	165	18	lower	low	ADJ
ajcp-1612	165	19	levels	level	NOUN
ajcp-1612	165	20	of	of	ADP
ajcp-1612	165	21	hdl	hdl	PROPN
ajcp-1612	165	22	cholesterol	cholesterol	PROPN
ajcp-1612	165	23	in	in	ADP
ajcp-1612	165	24	chronic	chronic	ADJ
ajcp-1612	165	25	renal	renal	ADJ
ajcp-1612	165	26	disease	disease	NOUN
ajcp-1612	165	27	and	and	CCONJ
ajcp-1612	165	28	esrd	esrd	PROPN
ajcp-1612	165	29	.	.	PUNCT
ajcp-1612	166	1	advanced	advanced	PROPN
ajcp-1612	166	2	ckd	ckd	PROPN
ajcp-1612	166	3	or	or	CCONJ
ajcp-1612	166	4	esrd	esrd	PROPN
ajcp-1612	166	5	patients	patient	NOUN
ajcp-1612	166	6	have	have	VERB
ajcp-1612	166	7	a	a	DET
ajcp-1612	166	8	distinctive	distinctive	ADJ
ajcp-1612	166	9	lipid	lipid	NOUN
ajcp-1612	166	10	pattern	pattern	NOUN
ajcp-1612	166	11	that	that	PRON
ajcp-1612	166	12	includes	include	VERB
ajcp-1612	166	13	hypertriglyceridemia	hypertriglyceridemia	NOUN
ajcp-1612	166	14	,	,	PUNCT
ajcp-1612	166	15	low	low	ADJ
ajcp-1612	166	16	hdl	hdl	PROPN
ajcp-1612	166	17	cholesterol	cholesterol	PROPN
ajcp-1612	166	18	,	,	PUNCT
ajcp-1612	166	19	and	and	CCONJ
ajcp-1612	166	20	normal	normal	ADJ
ajcp-1612	166	21	ldl	ldl	NOUN
ajcp-1612	166	22	cholesterol	cholesterol	NOUN
ajcp-1612	166	23	levels	level	NOUN
ajcp-1612	166	24	(	(	PUNCT
ajcp-1612	166	25	dincer	dincer	NOUN
ajcp-1612	166	26	et	et	PROPN
ajcp-1612	166	27	al	al	PROPN
ajcp-1612	166	28	.	.	PROPN
ajcp-1612	166	29	,	,	PUNCT
ajcp-1612	166	30	2019	2019	NUM
ajcp-1612	166	31	)	)	PUNCT
ajcp-1612	166	32	.	.	PUNCT
ajcp-1612	167	1	in	in	ADP
ajcp-1612	167	2	the	the	DET
ajcp-1612	167	3	general	general	ADJ
ajcp-1612	167	4	population	population	NOUN
ajcp-1612	167	5	,	,	PUNCT
ajcp-1612	167	6	there	there	PRON
ajcp-1612	167	7	is	be	VERB
ajcp-1612	167	8	a	a	DET
ajcp-1612	167	9	clear	clear	ADJ
ajcp-1612	167	10	correlation	correlation	NOUN
ajcp-1612	167	11	between	between	ADP
ajcp-1612	167	12	ldl	ldl	NOUN
ajcp-1612	167	13	cholesterol	cholesterol	NOUN
ajcp-1612	167	14	and	and	CCONJ
ajcp-1612	167	15	atherosclerotic	atherosclerotic	ADJ
ajcp-1612	167	16	events	event	NOUN
ajcp-1612	167	17	,	,	PUNCT
ajcp-1612	167	18	but	but	CCONJ
ajcp-1612	167	19	in	in	ADP
ajcp-1612	167	20	patients	patient	NOUN
ajcp-1612	167	21	with	with	ADP
ajcp-1612	167	22	esrd	esrd	PROPN
ajcp-1612	167	23	,	,	PUNCT
ajcp-1612	167	24	ldl	ldl	NOUN
ajcp-1612	167	25	cholesterol	cholesterol	NOUN
ajcp-1612	167	26	has	have	VERB
ajcp-1612	167	27	a	a	DET
ajcp-1612	167	28	flat	flat	ADJ
ajcp-1612	167	29	or	or	CCONJ
ajcp-1612	167	30	weakly	weakly	ADJ
ajcp-1612	167	31	positive	positive	ADJ
ajcp-1612	167	32	correlation	correlation	NOUN
ajcp-1612	167	33	with	with	ADP
ajcp-1612	167	34	mortality	mortality	NOUN
ajcp-1612	167	35	at	at	ADP
ajcp-1612	167	36	levels	level	NOUN
ajcp-1612	167	37	above	above	ADP
ajcp-1612	167	38	the	the	DET
ajcp-1612	167	39	average	average	NOUN
ajcp-1612	167	40	and	and	CCONJ
ajcp-1612	167	41	a	a	DET
ajcp-1612	167	42	negative	negative	ADJ
ajcp-1612	167	43	correlation	correlation	NOUN
ajcp-1612	167	44	with	with	ADP
ajcp-1612	167	45	these	these	DET
ajcp-1612	167	46	outcomes	outcome	NOUN
ajcp-1612	167	47	at	at	ADP
ajcp-1612	167	48	levels	level	NOUN
ajcp-1612	167	49	below	below	ADP
ajcp-1612	167	50	the	the	DET
ajcp-1612	167	51	average	average	NOUN
ajcp-1612	167	52	.	.	PUNCT
ajcp-1612	168	1	reducing	reduce	VERB
ajcp-1612	168	2	ldl	ldl	NOUN
ajcp-1612	168	3	cholesterol	cholesterol	NOUN
ajcp-1612	168	4	helps	helps	AUX
ajcp-1612	168	5	prevent	prevent	VERB
ajcp-1612	168	6	serious	serious	ADJ
ajcp-1612	168	7	atherosclerotic	atherosclerotic	ADJ
ajcp-1612	168	8	events	event	NOUN
ajcp-1612	168	9	in	in	ADP
ajcp-1612	168	10	people	people	NOUN
ajcp-1612	168	11	with	with	ADP
ajcp-1612	168	12	ckd	ckd	PROPN
ajcp-1612	168	13	and	and	CCONJ
ajcp-1612	168	14	kidney	kidney	NOUN
ajcp-1612	168	15	transplants	transplant	NOUN
ajcp-1612	168	16	but	but	CCONJ
ajcp-1612	168	17	not	not	PART
ajcp-1612	168	18	for	for	ADP
ajcp-1612	168	19	people	people	NOUN
ajcp-1612	168	20	who	who	PRON
ajcp-1612	168	21	need	need	VERB
ajcp-1612	168	22	dialysis	dialysis	NOUN
ajcp-1612	168	23	(	(	PUNCT
ajcp-1612	168	24	ferro	ferro	PROPN
ajcp-1612	168	25	et	et	PROPN
ajcp-1612	168	26	al	al	PROPN
ajcp-1612	168	27	.	.	PROPN
ajcp-1612	168	28	,	,	PUNCT
ajcp-1612	168	29	2018	2018	NUM
ajcp-1612	168	30	)	)	PUNCT
ajcp-1612	168	31	.	.	PUNCT
ajcp-1612	169	1	limitations	limitation	NOUN
ajcp-1612	169	2	and	and	CCONJ
ajcp-1612	169	3	strengths	strength	NOUN
ajcp-1612	169	4	1	1	NUM
ajcp-1612	169	5	.	.	PUNCT
ajcp-1612	170	1	the	the	DET
ajcp-1612	170	2	management	management	NOUN
ajcp-1612	170	3	and	and	CCONJ
ajcp-1612	170	4	treatments	treatment	NOUN
ajcp-1612	170	5	discussed	discuss	VERB
ajcp-1612	170	6	in	in	ADP
ajcp-1612	170	7	this	this	DET
ajcp-1612	170	8	review	review	NOUN
ajcp-1612	170	9	do	do	AUX
ajcp-1612	170	10	not	not	PART
ajcp-1612	170	11	guarantee	guarantee	VERB
ajcp-1612	170	12	the	the	DET
ajcp-1612	170	13	reversal	reversal	NOUN
ajcp-1612	170	14	of	of	ADP
ajcp-1612	170	15	the	the	DET
ajcp-1612	170	16	disease	disease	NOUN
ajcp-1612	170	17	.	.	PUNCT
ajcp-1612	171	1	2	2	X
ajcp-1612	171	2	.	.	X
ajcp-1612	171	3	several	several	ADJ
ajcp-1612	171	4	participants	participant	NOUN
ajcp-1612	171	5	were	be	AUX
ajcp-1612	171	6	not	not	PART
ajcp-1612	171	7	tested	test	VERB
ajcp-1612	171	8	in	in	ADP
ajcp-1612	171	9	this	this	DET
ajcp-1612	171	10	review	review	NOUN
ajcp-1612	171	11	;	;	PUNCT
ajcp-1612	171	12	the	the	DET
ajcp-1612	171	13	review	review	NOUN
ajcp-1612	171	14	is	be	AUX
ajcp-1612	171	15	based	base	VERB
ajcp-1612	171	16	on	on	ADP
ajcp-1612	171	17	factual	factual	ADJ
ajcp-1612	171	18	data	datum	NOUN
ajcp-1612	171	19	.	.	PUNCT
ajcp-1612	172	1	3	3	X
ajcp-1612	172	2	.	.	X
ajcp-1612	172	3	the	the	DET
ajcp-1612	172	4	most	most	ADV
ajcp-1612	172	5	coherent	coherent	ADJ
ajcp-1612	172	6	risk	risk	NOUN
ajcp-1612	172	7	factor	factor	NOUN
ajcp-1612	172	8	of	of	ADP
ajcp-1612	172	9	mortality	mortality	NOUN
ajcp-1612	172	10	due	due	ADP
ajcp-1612	172	11	to	to	ADP
ajcp-1612	172	12	ckd	ckd	PROPN
ajcp-1612	172	13	is	be	AUX
ajcp-1612	172	14	increasing	increase	VERB
ajcp-1612	172	15	age	age	NOUN
ajcp-1612	172	16	,	,	PUNCT
ajcp-1612	172	17	which	which	PRON
ajcp-1612	172	18	has	have	AUX
ajcp-1612	172	19	not	not	PART
ajcp-1612	172	20	been	be	AUX
ajcp-1612	172	21	extensively	extensively	ADV
ajcp-1612	172	22	discussed	discuss	VERB
ajcp-1612	172	23	.	.	PUNCT
ajcp-1612	173	1	4	4	X
ajcp-1612	173	2	.	.	X
ajcp-1612	173	3	the	the	DET
ajcp-1612	173	4	biggest	big	ADJ
ajcp-1612	173	5	strength	strength	NOUN
ajcp-1612	173	6	of	of	ADP
ajcp-1612	173	7	this	this	DET
ajcp-1612	173	8	review	review	NOUN
ajcp-1612	173	9	is	be	AUX
ajcp-1612	173	10	that	that	SCONJ
ajcp-1612	173	11	very	very	ADV
ajcp-1612	173	12	generalised	generalised	ADJ
ajcp-1612	173	13	terms	term	NOUN
ajcp-1612	173	14	have	have	AUX
ajcp-1612	173	15	been	be	AUX
ajcp-1612	173	16	used	use	VERB
ajcp-1612	173	17	in	in	ADP
ajcp-1612	173	18	searching	search	VERB
ajcp-1612	173	19	strategies	strategy	NOUN
ajcp-1612	173	20	to	to	PART
ajcp-1612	173	21	combat	combat	VERB
ajcp-1612	173	22	vast	vast	ADJ
ajcp-1612	173	23	unrelated	unrelated	ADJ
ajcp-1612	173	24	data	datum	NOUN
ajcp-1612	173	25	.	.	PUNCT
ajcp-1612	174	1	5	5	X
ajcp-1612	174	2	.	.	X
ajcp-1612	174	3	this	this	DET
ajcp-1612	174	4	review	review	NOUN
ajcp-1612	174	5	is	be	AUX
ajcp-1612	174	6	based	base	VERB
ajcp-1612	174	7	on	on	ADP
ajcp-1612	174	8	scientifically	scientifically	ADV
ajcp-1612	174	9	proven	prove	VERB
ajcp-1612	174	10	facts	fact	NOUN
ajcp-1612	174	11	.	.	PUNCT
ajcp-1612	175	1	conclusion	conclusion	NOUN
ajcp-1612	175	2	in	in	ADP
ajcp-1612	175	3	conclusion	conclusion	NOUN
ajcp-1612	175	4	of	of	ADP
ajcp-1612	175	5	this	this	DET
ajcp-1612	175	6	review	review	NOUN
ajcp-1612	175	7	,	,	PUNCT
ajcp-1612	175	8	diabetes	diabetes	NOUN
ajcp-1612	175	9	mellitus	mellitus	NOUN
ajcp-1612	175	10	is	be	AUX
ajcp-1612	175	11	the	the	DET
ajcp-1612	175	12	most	most	ADV
ajcp-1612	175	13	common	common	ADJ
ajcp-1612	175	14	and	and	CCONJ
ajcp-1612	175	15	biggest	big	ADJ
ajcp-1612	175	16	risk	risk	NOUN
ajcp-1612	175	17	factor	factor	NOUN
ajcp-1612	175	18	for	for	ADP
ajcp-1612	175	19	the	the	DET
ajcp-1612	175	20	occurrence	occurrence	NOUN
ajcp-1612	175	21	of	of	ADP
ajcp-1612	175	22	ckd	ckd	PROPN
ajcp-1612	175	23	and	and	CCONJ
ajcp-1612	175	24	esrd	esrd	PROPN
ajcp-1612	175	25	.	.	PUNCT
ajcp-1612	176	1	it	it	PRON
ajcp-1612	176	2	is	be	AUX
ajcp-1612	176	3	advised	advise	VERB
ajcp-1612	176	4	to	to	PART
ajcp-1612	176	5	maintain	maintain	VERB
ajcp-1612	176	6	and	and	CCONJ
ajcp-1612	176	7	focus	focus	VERB
ajcp-1612	176	8	on	on	ADP
ajcp-1612	176	9	the	the	DET
ajcp-1612	176	10	underlying	underlie	VERB
ajcp-1612	176	11	conditions	condition	NOUN
ajcp-1612	176	12	that	that	PRON
ajcp-1612	176	13	result	result	VERB
ajcp-1612	176	14	in	in	ADP
ajcp-1612	176	15	ckd	ckd	PROPN
ajcp-1612	176	16	over	over	ADP
ajcp-1612	176	17	time	time	NOUN
ajcp-1612	176	18	to	to	PART
ajcp-1612	176	19	prevent	prevent	VERB
ajcp-1612	176	20	the	the	DET
ajcp-1612	176	21	disease	disease	NOUN
ajcp-1612	176	22	.	.	PUNCT
ajcp-1612	177	1	these	these	DET
ajcp-1612	177	2	conditions	condition	NOUN
ajcp-1612	177	3	include	include	VERB
ajcp-1612	177	4	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	177	5	,	,	PUNCT
ajcp-1612	177	6	hypertension	hypertension	NOUN
ajcp-1612	177	7	,	,	PUNCT
ajcp-1612	177	8	microalbuminuria	microalbuminuria	ADJ
ajcp-1612	177	9	,	,	PUNCT
ajcp-1612	177	10	sedentary	sedentary	ADJ
ajcp-1612	177	11	lifestyle	lifestyle	NOUN
ajcp-1612	177	12	,	,	PUNCT
ajcp-1612	177	13	smoking	smoking	NOUN
ajcp-1612	177	14	,	,	PUNCT
ajcp-1612	177	15	etc	etc	X
ajcp-1612	177	16	.	.	X
ajcp-1612	178	1	these	these	DET
ajcp-1612	178	2	underlying	underlie	VERB
ajcp-1612	178	3	conditions	condition	NOUN
ajcp-1612	178	4	may	may	AUX
ajcp-1612	178	5	turn	turn	VERB
ajcp-1612	178	6	into	into	ADP
ajcp-1612	178	7	symptoms	symptom	NOUN
ajcp-1612	178	8	and	and	CCONJ
ajcp-1612	178	9	eventually	eventually	ADV
ajcp-1612	178	10	convert	convert	VERB
ajcp-1612	178	11	into	into	ADP
ajcp-1612	178	12	morbidity	morbidity	NOUN
ajcp-1612	178	13	.	.	PUNCT
ajcp-1612	179	1	changes	change	NOUN
ajcp-1612	179	2	in	in	ADP
ajcp-1612	179	3	lifestyle	lifestyle	NOUN
ajcp-1612	179	4	,	,	PUNCT
ajcp-1612	179	5	such	such	ADJ
ajcp-1612	179	6	as	as	ADP
ajcp-1612	179	7	healthy	healthy	ADJ
ajcp-1612	179	8	eating	eating	NOUN
ajcp-1612	179	9	,	,	PUNCT
ajcp-1612	179	10	regular	regular	ADJ
ajcp-1612	179	11	physical	physical	ADJ
ajcp-1612	179	12	activity	activity	NOUN
ajcp-1612	179	13	,	,	PUNCT
ajcp-1612	179	14	and	and	CCONJ
ajcp-1612	179	15	intake	intake	NOUN
ajcp-1612	179	16	of	of	ADP
ajcp-1612	179	17	advised	advised	ADJ
ajcp-1612	179	18	ml	ml	NOUN
ajcp-1612	179	19	of	of	ADP
ajcp-1612	179	20	water	water	NOUN
ajcp-1612	179	21	in	in	ADP
ajcp-1612	179	22	addition	addition	NOUN
ajcp-1612	179	23	to	to	ADP
ajcp-1612	179	24	some	some	DET
ajcp-1612	179	25	medications	medication	NOUN
ajcp-1612	179	26	and	and	CCONJ
ajcp-1612	179	27	therapies	therapy	NOUN
ajcp-1612	179	28	,	,	PUNCT
ajcp-1612	179	29	can	can	AUX
ajcp-1612	179	30	altogether	altogether	ADV
ajcp-1612	179	31	increase	increase	VERB
ajcp-1612	179	32	improvement	improvement	NOUN
ajcp-1612	179	33	rates	rate	NOUN
ajcp-1612	179	34	of	of	ADP
ajcp-1612	179	35	ckd	ckd	PROPN
ajcp-1612	179	36	incidence	incidence	NOUN
ajcp-1612	179	37	.	.	PUNCT
ajcp-1612	180	1	further	further	ADJ
ajcp-1612	180	2	future	future	ADJ
ajcp-1612	180	3	studies	study	NOUN
ajcp-1612	180	4	need	need	VERB
ajcp-1612	180	5	to	to	PART
ajcp-1612	180	6	be	be	AUX
ajcp-1612	180	7	done	do	VERB
ajcp-1612	180	8	to	to	PART
ajcp-1612	180	9	combat	combat	VERB
ajcp-1612	180	10	the	the	DET
ajcp-1612	180	11	disease	disease	NOUN
ajcp-1612	180	12	better	well	ADV
ajcp-1612	180	13	.	.	PUNCT
ajcp-1612	181	1	references	reference	NOUN
ajcp-1612	181	2	advani	advani	PROPN
ajcp-1612	181	3	,	,	PUNCT
ajcp-1612	181	4	a.	a.	NOUN
ajcp-1612	181	5	(	(	PUNCT
ajcp-1612	181	6	2020	2020	NUM
ajcp-1612	181	7	)	)	PUNCT
ajcp-1612	181	8	.	.	PUNCT
ajcp-1612	182	1	positioning	positioning	NOUN
ajcp-1612	182	2	time	time	NOUN
ajcp-1612	182	3	in	in	ADP
ajcp-1612	182	4	range	range	NOUN
ajcp-1612	182	5	in	in	ADP
ajcp-1612	182	6	diabetes	diabetes	NOUN
ajcp-1612	182	7	management	management	NOUN
ajcp-1612	182	8	.	.	PUNCT
ajcp-1612	183	1	diabetologia	diabetologia	NOUN
ajcp-1612	183	2	,	,	PUNCT
ajcp-1612	183	3	63(2	63(2	NUM
ajcp-1612	183	4	)	)	PUNCT
ajcp-1612	183	5	,	,	PUNCT
ajcp-1612	183	6	242	242	NUM
ajcp-1612	183	7	-	-	SYM
ajcp-1612	183	8	252	252	NUM
ajcp-1612	183	9	.	.	PUNCT
ajcp-1612	184	1	alkhatib	alkhatib	PROPN
ajcp-1612	184	2	,	,	PUNCT
ajcp-1612	184	3	l.	l.	PROPN
ajcp-1612	184	4	,	,	PUNCT
ajcp-1612	184	5	diaz	diaz	PROPN
ajcp-1612	184	6	,	,	PUNCT
ajcp-1612	184	7	l.	l.	PROPN
ajcp-1612	184	8	a.	a.	PROPN
ajcp-1612	184	9	v.	v.	PROPN
ajcp-1612	184	10	,	,	PUNCT
ajcp-1612	184	11	varma	varma	PROPN
ajcp-1612	184	12	,	,	PUNCT
ajcp-1612	184	13	s.	s.	PROPN
ajcp-1612	184	14	,	,	PUNCT
ajcp-1612	184	15	chowdhary	chowdhary	PROPN
ajcp-1612	184	16	,	,	PUNCT
ajcp-1612	184	17	a.	a.	NOUN
ajcp-1612	184	18	,	,	PUNCT
ajcp-1612	184	19	bapat	bapat	PROPN
ajcp-1612	184	20	,	,	PUNCT
ajcp-1612	184	21	p.	p.	PROPN
ajcp-1612	184	22	,	,	PUNCT
ajcp-1612	184	23	pan	pan	PROPN
ajcp-1612	184	24	,	,	PUNCT
ajcp-1612	184	25	h.	h.	PROPN
ajcp-1612	184	26	,	,	PUNCT
ajcp-1612	184	27	kukreja	kukreja	PROPN
ajcp-1612	184	28	,	,	PUNCT
ajcp-1612	184	29	g.	g.	PROPN
ajcp-1612	184	30	,	,	PUNCT
ajcp-1612	184	31	palabindela	palabindela	PROPN
ajcp-1612	184	32	,	,	PUNCT
ajcp-1612	184	33	p.	p.	PROPN
ajcp-1612	184	34	,	,	PUNCT
ajcp-1612	184	35	selvam	selvam	PROPN
ajcp-1612	184	36	,	,	PUNCT
ajcp-1612	184	37	s.	s.	PROPN
ajcp-1612	184	38	a.	a.	PROPN
ajcp-1612	184	39	,	,	PUNCT
ajcp-1612	184	40	&	&	CCONJ
ajcp-1612	184	41	kalra	kalra	PROPN
ajcp-1612	184	42	,	,	PUNCT
ajcp-1612	184	43	k.	k.	PROPN
ajcp-1612	184	44	(	(	PUNCT
ajcp-1612	184	45	2023	2023	NUM
ajcp-1612	184	46	)	)	PUNCT
ajcp-1612	184	47	.	.	PUNCT
ajcp-1612	185	1	lifestyle	lifestyle	PROPN
ajcp-1612	185	2	modifications	modification	NOUN
ajcp-1612	185	3	and	and	CCONJ
ajcp-1612	185	4	nutritional	nutritional	ADJ
ajcp-1612	185	5	and	and	CCONJ
ajcp-1612	185	6	therapeutic	therapeutic	ADJ
ajcp-1612	185	7	interventions	intervention	NOUN
ajcp-1612	185	8	in	in	ADP
ajcp-1612	185	9	delaying	delay	VERB
ajcp-1612	185	10	the	the	DET
ajcp-1612	185	11	progression	progression	NOUN
ajcp-1612	185	12	of	of	ADP
ajcp-1612	185	13	chronic	chronic	ADJ
ajcp-1612	185	14	kidney	kidney	NOUN
ajcp-1612	185	15	disease	disease	NOUN
ajcp-1612	185	16	:	:	PUNCT
ajcp-1612	185	17	a	a	DET
ajcp-1612	185	18	review	review	NOUN
ajcp-1612	185	19	.	.	PUNCT
ajcp-1612	186	1	cureus	cureus	NOUN
ajcp-1612	186	2	,	,	PUNCT
ajcp-1612	186	3	15(2	15(2	NUM
ajcp-1612	186	4	)	)	PUNCT
ajcp-1612	186	5	.	.	PUNCT
ajcp-1612	187	1	association	association	PROPN
ajcp-1612	187	2	,	,	PUNCT
ajcp-1612	187	3	a.	a.	PROPN
ajcp-1612	187	4	d.	d.	PROPN
ajcp-1612	187	5	(	(	PUNCT
ajcp-1612	187	6	2022	2022	NUM
ajcp-1612	187	7	)	)	PUNCT
ajcp-1612	187	8	.	.	PUNCT
ajcp-1612	188	1	statistics	statistic	NOUN
ajcp-1612	188	2	about	about	ADP
ajcp-1612	188	3	diabetes	diabetes	NOUN
ajcp-1612	188	4	.	.	PUNCT
ajcp-1612	189	1	american	american	ADJ
ajcp-1612	189	2	diabetes	diabetes	PROPN
ajcp-1612	189	3	association	association	PROPN
ajcp-1612	189	4	https://diabetes.org/about-us/	https://diabetes.org/about-us/	PROPN
ajcp-1612	189	5	statistics	statistic	NOUN
ajcp-1612	189	6	/	/	SYM
ajcp-1612	189	7	about	about	ADP
ajcp-1612	189	8	-	-	PUNCT
ajcp-1612	189	9	diabetes#:~:text	diabetes#:~:text	NUM
ajcp-1612	189	10	=	=	NOUN
ajcp-1612	189	11	prevalence%20in%20	prevalence%20in%20	X
ajcp-1612	189	12	seniors%3a%20the%20percentage	seniors%3a%20the%20percentage	NOUN
ajcp-1612	189	13	,	,	PUNCT
ajcp-1612	189	14	diagnosed%20	diagnosed%20	PROPN
ajcp-1612	189	15	with%20diabetes%20every%20year	with%20diabetes%20every%20year	PROPN
ajcp-1612	189	16	.	.	PROPN
ajcp-1612	189	17	beck	beck	PROPN
ajcp-1612	189	18	,	,	PUNCT
ajcp-1612	189	19	r.	r.	PROPN
ajcp-1612	189	20	w.	w.	PROPN
ajcp-1612	189	21	,	,	PUNCT
ajcp-1612	189	22	bergenstal	bergenstal	NOUN
ajcp-1612	189	23	,	,	PUNCT
ajcp-1612	189	24	r.	r.	PROPN
ajcp-1612	189	25	m.	m.	PROPN
ajcp-1612	189	26	,	,	PUNCT
ajcp-1612	189	27	cheng	cheng	PROPN
ajcp-1612	189	28	,	,	PUNCT
ajcp-1612	189	29	p.	p.	PROPN
ajcp-1612	189	30	,	,	PUNCT
ajcp-1612	189	31	kollman	kollman	PROPN
ajcp-1612	189	32	,	,	PUNCT
ajcp-1612	189	33	c.	c.	PROPN
ajcp-1612	189	34	,	,	PUNCT
ajcp-1612	189	35	carlson	carlson	PROPN
ajcp-1612	189	36	,	,	PUNCT
ajcp-1612	189	37	a.	a.	PROPN
ajcp-1612	189	38	l.	l.	PROPN
ajcp-1612	189	39	,	,	PUNCT
ajcp-1612	189	40	johnson	johnson	PROPN
ajcp-1612	189	41	,	,	PUNCT
ajcp-1612	189	42	m.	m.	PROPN
ajcp-1612	189	43	l.	l.	PROPN
ajcp-1612	189	44	,	,	PUNCT
ajcp-1612	189	45	&	&	CCONJ
ajcp-1612	189	46	rodbard	rodbard	NOUN
ajcp-1612	189	47	,	,	PUNCT
ajcp-1612	189	48	d.	d.	PROPN
ajcp-1612	189	49	(	(	PUNCT
ajcp-1612	189	50	2019	2019	NUM
ajcp-1612	189	51	)	)	PUNCT
ajcp-1612	189	52	.	.	PUNCT
ajcp-1612	190	1	the	the	DET
ajcp-1612	190	2	relationships	relationship	NOUN
ajcp-1612	190	3	between	between	ADP
ajcp-1612	190	4	time	time	NOUN
ajcp-1612	190	5	in	in	ADP
ajcp-1612	190	6	range	range	NOUN
ajcp-1612	190	7	,	,	PUNCT
ajcp-1612	190	8	hyperglycemia	hyperglycemia	NOUN
ajcp-1612	190	9	metrics	metric	NOUN
ajcp-1612	190	10	,	,	PUNCT
ajcp-1612	190	11	and	and	CCONJ
ajcp-1612	190	12	hba1c	hba1c	PROPN
ajcp-1612	190	13	.	.	PROPN
ajcp-1612	190	14	journal	journal	PROPN
ajcp-1612	190	15	of	of	ADP
ajcp-1612	190	16	diabetes	diabetes	NOUN
ajcp-1612	190	17	science	science	NOUN
ajcp-1612	190	18	and	and	CCONJ
ajcp-1612	190	19	technology	technology	NOUN
ajcp-1612	190	20	,	,	PUNCT
ajcp-1612	190	21	13(4	13(4	NUM
ajcp-1612	190	22	)	)	PUNCT
ajcp-1612	190	23	,	,	PUNCT
ajcp-1612	190	24	614	614	NUM
ajcp-1612	190	25	-	-	SYM
ajcp-1612	190	26	626	626	NUM
ajcp-1612	190	27	.	.	PUNCT
ajcp-1612	191	1	bello	bello	PROPN
ajcp-1612	191	2	,	,	PUNCT
ajcp-1612	191	3	a.	a.	PROPN
ajcp-1612	191	4	k.	k.	PROPN
ajcp-1612	191	5	,	,	PUNCT
ajcp-1612	191	6	nwankwo	nwankwo	PROPN
ajcp-1612	191	7	,	,	PUNCT
ajcp-1612	191	8	e.	e.	PROPN
ajcp-1612	191	9	,	,	PUNCT
ajcp-1612	191	10	&	&	CCONJ
ajcp-1612	191	11	el	el	PROPN
ajcp-1612	191	12	nahas	nahas	PROPN
ajcp-1612	191	13	,	,	PUNCT
ajcp-1612	191	14	a.	a.	NOUN
ajcp-1612	191	15	m.	m.	NOUN
ajcp-1612	191	16	(	(	PUNCT
ajcp-1612	191	17	2005	2005	NUM
ajcp-1612	191	18	)	)	PUNCT
ajcp-1612	191	19	.	.	PUNCT
ajcp-1612	192	1	prevention	prevention	NOUN
ajcp-1612	192	2	of	of	ADP
ajcp-1612	192	3	chronic	chronic	ADJ
ajcp-1612	192	4	kidney	kidney	NOUN
ajcp-1612	192	5	disease	disease	NOUN
ajcp-1612	192	6	:	:	PUNCT
ajcp-1612	192	7	a	a	DET
ajcp-1612	192	8	global	global	ADJ
ajcp-1612	192	9	challenge	challenge	NOUN
ajcp-1612	192	10	.	.	PUNCT
ajcp-1612	193	1	kidney	kidney	PROPN
ajcp-1612	193	2	international	international	PROPN
ajcp-1612	193	3	,	,	PUNCT
ajcp-1612	193	4	68	68	NUM
ajcp-1612	193	5	,	,	PUNCT
ajcp-1612	193	6	11	11	NUM
ajcp-1612	193	7	-	-	SYM
ajcp-1612	193	8	17	17	NUM
ajcp-1612	193	9	.	.	PUNCT
ajcp-1612	194	1	betônico	betônico	PROPN
ajcp-1612	194	2	,	,	PUNCT
ajcp-1612	194	3	c.	c.	PROPN
ajcp-1612	194	4	c.	c.	PROPN
ajcp-1612	194	5	,	,	PUNCT
ajcp-1612	194	6	titan	titan	NOUN
ajcp-1612	194	7	,	,	PUNCT
ajcp-1612	194	8	s.	s.	PROPN
ajcp-1612	194	9	m.	m.	PROPN
ajcp-1612	194	10	,	,	PUNCT
ajcp-1612	194	11	correa	correa	PROPN
ajcp-1612	194	12	-	-	PUNCT
ajcp-1612	194	13	giannella	giannella	PROPN
ajcp-1612	194	14	,	,	PUNCT
ajcp-1612	194	15	m.	m.	NOUN
ajcp-1612	194	16	l.	l.	PROPN
ajcp-1612	194	17	c.	c.	PROPN
ajcp-1612	194	18	,	,	PUNCT
ajcp-1612	194	19	nery	nery	PROPN
ajcp-1612	194	20	,	,	PUNCT
ajcp-1612	194	21	m.	m.	NOUN
ajcp-1612	194	22	,	,	PUNCT
ajcp-1612	194	23	&	&	CCONJ
ajcp-1612	194	24	queiroz	queiroz	ADV
ajcp-1612	194	25	,	,	PUNCT
ajcp-1612	194	26	m.	m.	NOUN
ajcp-1612	194	27	(	(	PUNCT
ajcp-1612	194	28	2016	2016	NUM
ajcp-1612	194	29	)	)	PUNCT
ajcp-1612	194	30	.	.	PUNCT
ajcp-1612	195	1	management	management	NOUN
ajcp-1612	195	2	of	of	ADP
ajcp-1612	195	3	diabetes	diabetes	NOUN
ajcp-1612	195	4	mellitus	mellitus	NOUN
ajcp-1612	195	5	in	in	ADP
ajcp-1612	195	6	individuals	individual	NOUN
ajcp-1612	195	7	with	with	ADP
ajcp-1612	195	8	chronic	chronic	ADJ
ajcp-1612	195	9	kidney	kidney	NOUN
ajcp-1612	195	10	disease	disease	NOUN
ajcp-1612	195	11	:	:	PUNCT
ajcp-1612	195	12	therapeutic	therapeutic	ADJ
ajcp-1612	195	13	perspectives	perspective	NOUN
ajcp-1612	195	14	and	and	CCONJ
ajcp-1612	195	15	glycemic	glycemic	ADJ
ajcp-1612	195	16	control	control	NOUN
ajcp-1612	195	17	.	.	PUNCT
ajcp-1612	196	1	clinics	clinic	NOUN
ajcp-1612	196	2	,	,	PUNCT
ajcp-1612	196	3	71	71	NUM
ajcp-1612	196	4	,	,	PUNCT
ajcp-1612	196	5	47	47	NUM
ajcp-1612	196	6	-	-	SYM
ajcp-1612	196	7	53	53	NUM
ajcp-1612	196	8	.	.	PUNCT
ajcp-1612	197	1	beulens	beulens	PROPN
ajcp-1612	197	2	,	,	PUNCT
ajcp-1612	197	3	j.	j.	PROPN
ajcp-1612	197	4	,	,	PUNCT
ajcp-1612	197	5	rutters	rutter	NOUN
ajcp-1612	197	6	,	,	PUNCT
ajcp-1612	197	7	f.	f.	PROPN
ajcp-1612	197	8	,	,	PUNCT
ajcp-1612	197	9	rydén	rydén	PROPN
ajcp-1612	197	10	,	,	PUNCT
ajcp-1612	197	11	l.	l.	PROPN
ajcp-1612	197	12	,	,	PUNCT
ajcp-1612	197	13	schnell	schnell	PROPN
ajcp-1612	197	14	,	,	PUNCT
ajcp-1612	197	15	o.	o.	PROPN
ajcp-1612	197	16	,	,	PUNCT
ajcp-1612	197	17	mellbin	mellbin	PROPN
ajcp-1612	197	18	,	,	PUNCT
ajcp-1612	197	19	l.	l.	PROPN
ajcp-1612	197	20	,	,	PUNCT
ajcp-1612	197	21	hart	hart	PROPN
ajcp-1612	197	22	,	,	PUNCT
ajcp-1612	197	23	h.	h.	PROPN
ajcp-1612	197	24	,	,	PUNCT
ajcp-1612	197	25	&	&	CCONJ
ajcp-1612	197	26	vos	vos	PROPN
ajcp-1612	197	27	,	,	PUNCT
ajcp-1612	197	28	r.	r.	PROPN
ajcp-1612	197	29	(	(	PUNCT
ajcp-1612	197	30	2020	2020	NUM
ajcp-1612	197	31	)	)	PUNCT
ajcp-1612	197	32	.	.	PUNCT
ajcp-1612	198	1	risk	risk	NOUN
ajcp-1612	198	2	and	and	CCONJ
ajcp-1612	198	3	management	management	NOUN
ajcp-1612	198	4	of	of	ADP
ajcp-1612	198	5	pre	pre	NOUN
ajcp-1612	198	6	-	-	NOUN
ajcp-1612	198	7	diabetes	diabetes	NOUN
ajcp-1612	198	8	.	.	PUNCT
ajcp-1612	199	1	european	european	ADJ
ajcp-1612	199	2	journal	journal	PROPN
ajcp-1612	199	3	of	of	ADP
ajcp-1612	199	4	preventive	preventive	ADJ
ajcp-1612	199	5	cardiology	cardiology	NOUN
ajcp-1612	199	6	,	,	PUNCT
ajcp-1612	199	7	26(2l	26(2l	NUM
ajcp-1612	199	8	)	)	PUNCT
ajcp-1612	199	9	,	,	PUNCT
ajcp-1612	199	10	47	47	NUM
ajcp-1612	199	11	-	-	SYM
ajcp-1612	199	12	54	54	NUM
ajcp-1612	199	13	.	.	PUNCT
ajcp-1612	200	1	https://doi	https://doi	PROPN
ajcp-1612	200	2	.	.	PUNCT
ajcp-1612	200	3	org/10.1177/2047487319880041	org/10.1177/2047487319880041	PROPN
ajcp-1612	200	4	chen	chen	PROPN
ajcp-1612	200	5	,	,	PUNCT
ajcp-1612	200	6	t.	t.	PROPN
ajcp-1612	200	7	k.	k.	PROPN
ajcp-1612	200	8	,	,	PUNCT
ajcp-1612	200	9	knicely	knicely	ADV
ajcp-1612	200	10	,	,	PUNCT
ajcp-1612	200	11	d.	d.	PROPN
ajcp-1612	200	12	h.	h.	PROPN
ajcp-1612	200	13	,	,	PUNCT
ajcp-1612	200	14	&	&	CCONJ
ajcp-1612	200	15	grams	grams	PROPN
ajcp-1612	200	16	,	,	PUNCT
ajcp-1612	200	17	m.	m.	PROPN
ajcp-1612	200	18	e.	e.	PROPN
ajcp-1612	200	19	(	(	PUNCT
ajcp-1612	200	20	2019	2019	NUM
ajcp-1612	200	21	)	)	PUNCT
ajcp-1612	200	22	.	.	PUNCT
ajcp-1612	201	1	chronic	chronic	ADJ
ajcp-1612	201	2	kidney	kidney	NOUN
ajcp-1612	201	3	disease	disease	NOUN
ajcp-1612	201	4	diagnosis	diagnosis	NOUN
ajcp-1612	201	5	and	and	CCONJ
ajcp-1612	201	6	management	management	NOUN
ajcp-1612	201	7	:	:	PUNCT
ajcp-1612	201	8	a	a	DET
ajcp-1612	201	9	review	review	NOUN
ajcp-1612	201	10	.	.	PUNCT
ajcp-1612	202	1	jama	jama	PROPN
ajcp-1612	202	2	,	,	PUNCT
ajcp-1612	202	3	322(13	322(13	NUM
ajcp-1612	202	4	)	)	PUNCT
ajcp-1612	202	5	,	,	PUNCT
ajcp-1612	202	6	1294	1294	NUM
ajcp-1612	202	7	-	-	SYM
ajcp-1612	202	8	1304	1304	NUM
ajcp-1612	202	9	.	.	PUNCT
ajcp-1612	203	1	cole	cole	PROPN
ajcp-1612	203	2	,	,	PUNCT
ajcp-1612	203	3	j.	j.	PROPN
ajcp-1612	203	4	b.	b.	PROPN
ajcp-1612	203	5	,	,	PUNCT
ajcp-1612	203	6	&	&	CCONJ
ajcp-1612	203	7	florez	florez	PROPN
ajcp-1612	203	8	,	,	PUNCT
ajcp-1612	203	9	j.	j.	PROPN
ajcp-1612	203	10	c.	c.	PROPN
ajcp-1612	203	11	(	(	PUNCT
ajcp-1612	203	12	2020	2020	NUM
ajcp-1612	203	13	)	)	PUNCT
ajcp-1612	203	14	.	.	PUNCT
ajcp-1612	204	1	genetics	genetic	NOUN
ajcp-1612	204	2	of	of	ADP
ajcp-1612	204	3	diabetes	diabetes	NOUN
ajcp-1612	204	4	mellitus	mellitus	NOUN
ajcp-1612	204	5	and	and	CCONJ
ajcp-1612	204	6	diabetes	diabetes	NOUN
ajcp-1612	204	7	complications	complication	NOUN
ajcp-1612	204	8	.	.	PUNCT
ajcp-1612	205	1	nature	nature	NOUN
ajcp-1612	205	2	reviews	review	VERB
ajcp-1612	205	3	nephrology	nephrology	NOUN
ajcp-1612	205	4	,	,	PUNCT
ajcp-1612	205	5	16(7	16(7	NUM
ajcp-1612	205	6	)	)	PUNCT
ajcp-1612	205	7	,	,	PUNCT
ajcp-1612	205	8	377	377	NUM
ajcp-1612	205	9	-	-	SYM
ajcp-1612	205	10	390	390	NUM
ajcp-1612	205	11	.	.	PUNCT
ajcp-1612	206	1	copur	copur	NOUN
ajcp-1612	206	2	,	,	PUNCT
ajcp-1612	206	3	s.	s.	PROPN
ajcp-1612	206	4	,	,	PUNCT
ajcp-1612	206	5	onal	onal	PROPN
ajcp-1612	206	6	,	,	PUNCT
ajcp-1612	206	7	e.	e.	PROPN
ajcp-1612	206	8	m.	m.	PROPN
ajcp-1612	206	9	,	,	PUNCT
ajcp-1612	206	10	afsar	afsar	PROPN
ajcp-1612	206	11	,	,	PUNCT
ajcp-1612	206	12	b.	b.	PROPN
ajcp-1612	206	13	,	,	PUNCT
ajcp-1612	206	14	ortiz	ortiz	PROPN
ajcp-1612	206	15	,	,	PUNCT
ajcp-1612	206	16	a.	a.	PROPN
ajcp-1612	206	17	,	,	PUNCT
ajcp-1612	206	18	van	van	PROPN
ajcp-1612	206	19	raalte	raalte	PROPN
ajcp-1612	206	20	,	,	PUNCT
ajcp-1612	206	21	d.	d.	PROPN
ajcp-1612	206	22	h.	h.	PROPN
ajcp-1612	206	23	,	,	PUNCT
ajcp-1612	206	24	cherney	cherney	PROPN
ajcp-1612	206	25	,	,	PUNCT
ajcp-1612	206	26	d.	d.	PROPN
ajcp-1612	206	27	z.	z.	PROPN
ajcp-1612	206	28	,	,	PUNCT
ajcp-1612	206	29	rossing	rosse	VERB
ajcp-1612	206	30	,	,	PUNCT
ajcp-1612	206	31	p.	p.	NOUN
ajcp-1612	206	32	,	,	PUNCT
ajcp-1612	206	33	&	&	CCONJ
ajcp-1612	206	34	kanbay	kanbay	PROPN
ajcp-1612	206	35	,	,	PUNCT
ajcp-1612	206	36	m.	m.	NOUN
ajcp-1612	206	37	(	(	PUNCT
ajcp-1612	206	38	2020	2020	NUM
ajcp-1612	206	39	)	)	PUNCT
ajcp-1612	206	40	.	.	PUNCT
ajcp-1612	207	1	diabetes	diabetes	NOUN
ajcp-1612	207	2	mellitus	mellitus	NOUN
ajcp-1612	207	3	in	in	ADP
ajcp-1612	207	4	chronic	chronic	ADJ
ajcp-1612	207	5	kidney	kidney	NOUN
ajcp-1612	207	6	disease	disease	NOUN
ajcp-1612	207	7	:	:	PUNCT
ajcp-1612	207	8	biomarkers	biomarker	NOUN
ajcp-1612	207	9	beyond	beyond	ADP
ajcp-1612	207	10	hba1c	hba1c	PROPN
ajcp-1612	207	11	to	to	PART
ajcp-1612	207	12	estimate	estimate	VERB
ajcp-1612	207	13	glycemic	glycemic	ADJ
ajcp-1612	207	14	control	control	NOUN
ajcp-1612	207	15	and	and	CCONJ
ajcp-1612	207	16	diabetes	diabetes	NOUN
ajcp-1612	207	17	-	-	PUNCT
ajcp-1612	207	18	dependent	dependent	ADJ
ajcp-1612	207	19	morbidity	morbidity	NOUN
ajcp-1612	207	20	and	and	CCONJ
ajcp-1612	207	21	mortality	mortality	NOUN
ajcp-1612	207	22	.	.	PUNCT
ajcp-1612	208	1	journal	journal	PROPN
ajcp-1612	208	2	of	of	ADP
ajcp-1612	208	3	diabetes	diabetes	NOUN
ajcp-1612	208	4	and	and	CCONJ
ajcp-1612	208	5	its	its	PRON
ajcp-1612	208	6	complications	complication	NOUN
ajcp-1612	208	7	,	,	PUNCT
ajcp-1612	208	8	34(11	34(11	NUM
ajcp-1612	208	9	)	)	PUNCT
ajcp-1612	208	10	,	,	PUNCT
ajcp-1612	208	11	107707	107707	NUM
ajcp-1612	208	12	.	.	PUNCT
ajcp-1612	209	1	dincer	dincer	NOUN
ajcp-1612	209	2	,	,	PUNCT
ajcp-1612	209	3	n.	n.	NOUN
ajcp-1612	209	4	,	,	PUNCT
ajcp-1612	209	5	dagel	dagel	NOUN
ajcp-1612	209	6	,	,	PUNCT
ajcp-1612	209	7	t.	t.	PROPN
ajcp-1612	209	8	,	,	PUNCT
ajcp-1612	209	9	afsar	afsar	PROPN
ajcp-1612	209	10	,	,	PUNCT
ajcp-1612	209	11	b.	b.	PROPN
ajcp-1612	209	12	,	,	PUNCT
ajcp-1612	209	13	covic	covic	PROPN
ajcp-1612	209	14	,	,	PUNCT
ajcp-1612	209	15	a.	a.	NOUN
ajcp-1612	209	16	,	,	PUNCT
ajcp-1612	209	17	ortiz	ortiz	PROPN
ajcp-1612	209	18	,	,	PUNCT
ajcp-1612	209	19	a.	a.	PROPN
ajcp-1612	209	20	,	,	PUNCT
ajcp-1612	209	21	&	&	CCONJ
ajcp-1612	209	22	kanbay	kanbay	PROPN
ajcp-1612	209	23	,	,	PUNCT
ajcp-1612	209	24	m.	m.	NOUN
ajcp-1612	209	25	(	(	PUNCT
ajcp-1612	209	26	2019	2019	NUM
ajcp-1612	209	27	)	)	PUNCT
ajcp-1612	209	28	.	.	PUNCT
ajcp-1612	210	1	the	the	DET
ajcp-1612	210	2	effect	effect	NOUN
ajcp-1612	210	3	of	of	ADP
ajcp-1612	210	4	chronic	chronic	ADJ
ajcp-1612	210	5	kidney	kidney	NOUN
ajcp-1612	210	6	disease	disease	NOUN
ajcp-1612	210	7	on	on	ADP
ajcp-1612	210	8	lipid	lipid	ADJ
ajcp-1612	210	9	metabolism	metabolism	NOUN
ajcp-1612	210	10	.	.	PUNCT
ajcp-1612	211	1	international	international	ADJ
ajcp-1612	211	2	urology	urology	NOUN
ajcp-1612	211	3	and	and	CCONJ
ajcp-1612	211	4	nephrology	nephrology	NOUN
ajcp-1612	211	5	,	,	PUNCT
ajcp-1612	211	6	51	51	NUM
ajcp-1612	211	7	,	,	PUNCT
ajcp-1612	211	8	265	265	NUM
ajcp-1612	211	9	-	-	SYM
ajcp-1612	211	10	277	277	NUM
ajcp-1612	211	11	.	.	PUNCT
ajcp-1612	212	1	eknoyan	eknoyan	PROPN
ajcp-1612	212	2	,	,	PUNCT
ajcp-1612	212	3	g.	g.	PROPN
ajcp-1612	212	4	,	,	PUNCT
ajcp-1612	212	5	&	&	CCONJ
ajcp-1612	212	6	nagy	nagy	PROPN
ajcp-1612	212	7	,	,	PUNCT
ajcp-1612	212	8	j.	j.	PROPN
ajcp-1612	212	9	(	(	PUNCT
ajcp-1612	212	10	2005	2005	NUM
ajcp-1612	212	11	)	)	PUNCT
ajcp-1612	212	12	.	.	PUNCT
ajcp-1612	213	1	a	a	DET
ajcp-1612	213	2	history	history	NOUN
ajcp-1612	213	3	of	of	ADP
ajcp-1612	213	4	diabetes	diabetes	NOUN
ajcp-1612	213	5	mellitus	mellitus	NOUN
ajcp-1612	213	6	or	or	CCONJ
ajcp-1612	213	7	how	how	SCONJ
ajcp-1612	213	8	a	a	DET
ajcp-1612	213	9	disease	disease	NOUN
ajcp-1612	213	10	of	of	ADP
ajcp-1612	213	11	the	the	DET
ajcp-1612	213	12	kidneys	kidney	NOUN
ajcp-1612	213	13	evolved	evolve	VERB
ajcp-1612	213	14	into	into	ADP
ajcp-1612	213	15	kidney	kidney	NOUN
ajcp-1612	213	16	disease	disease	NOUN
ajcp-1612	213	17	.	.	PUNCT
ajcp-1612	214	1	advances	advance	NOUN
ajcp-1612	214	2	in	in	ADP
ajcp-1612	214	3	chronic	chronic	ADJ
ajcp-1612	214	4	kidney	kidney	NOUN
ajcp-1612	214	5	disease	disease	NOUN
ajcp-1612	214	6	,	,	PUNCT
ajcp-1612	214	7	12(2	12(2	NUM
ajcp-1612	214	8	)	)	PUNCT
ajcp-1612	214	9	,	,	PUNCT
ajcp-1612	214	10	223	223	NUM
ajcp-1612	214	11	-	-	SYM
ajcp-1612	214	12	229	229	NUM
ajcp-1612	214	13	.	.	PUNCT
ajcp-1612	215	1	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	215	2	pa	pa	PROPN
ajcp-1612	215	3	ge	ge	PROPN
ajcp-1612	215	4	13	13	NUM
ajcp-1612	215	5	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	215	6	am	be	AUX
ajcp-1612	215	7	.	.	PUNCT
ajcp-1612	216	1	j.	j.	PROPN
ajcp-1612	216	2	chem	chem	PROPN
ajcp-1612	216	3	.	.	PUNCT
ajcp-1612	217	1	pharm	pharm	PROPN
ajcp-1612	217	2	.	.	PUNCT
ajcp-1612	218	1	2(2	2(2	NUM
ajcp-1612	218	2	)	)	PUNCT
ajcp-1612	218	3	9	9	NUM
ajcp-1612	218	4	-	-	SYM
ajcp-1612	218	5	14	14	NUM
ajcp-1612	218	6	,	,	PUNCT
ajcp-1612	218	7	2023	2023	NUM
ajcp-1612	218	8	erfanpoor	erfanpoor	NOUN
ajcp-1612	218	9	,	,	PUNCT
ajcp-1612	218	10	s.	s.	PROPN
ajcp-1612	218	11	,	,	PUNCT
ajcp-1612	218	12	etemad	etemad	PROPN
ajcp-1612	218	13	,	,	PUNCT
ajcp-1612	218	14	k.	k.	PROPN
ajcp-1612	218	15	,	,	PUNCT
ajcp-1612	218	16	kazempour	kazempour	NOUN
ajcp-1612	218	17	,	,	PUNCT
ajcp-1612	218	18	s.	s.	PROPN
ajcp-1612	218	19	,	,	PUNCT
ajcp-1612	218	20	hadaegh	hadaegh	VERB
ajcp-1612	218	21	,	,	PUNCT
ajcp-1612	218	22	f.	f.	PROPN
ajcp-1612	218	23	,	,	PUNCT
ajcp-1612	218	24	hasani	hasani	PROPN
ajcp-1612	218	25	,	,	PUNCT
ajcp-1612	218	26	j.	j.	PROPN
ajcp-1612	218	27	,	,	PUNCT
ajcp-1612	218	28	azizi	azizi	PROPN
ajcp-1612	218	29	,	,	PUNCT
ajcp-1612	218	30	f.	f.	PROPN
ajcp-1612	218	31	,	,	PUNCT
ajcp-1612	218	32	parizadeh	parizadeh	PROPN
ajcp-1612	218	33	,	,	PUNCT
ajcp-1612	218	34	d.	d.	PROPN
ajcp-1612	218	35	,	,	PUNCT
ajcp-1612	218	36	&	&	CCONJ
ajcp-1612	218	37	khalili	khalili	PROPN
ajcp-1612	218	38	,	,	PUNCT
ajcp-1612	218	39	d.	d.	PROPN
ajcp-1612	218	40	(	(	PUNCT
ajcp-1612	218	41	2021	2021	NUM
ajcp-1612	218	42	)	)	PUNCT
ajcp-1612	218	43	.	.	PUNCT
ajcp-1612	219	1	diabetes	diabetes	NOUN
ajcp-1612	219	2	,	,	PUNCT
ajcp-1612	219	3	hypertension	hypertension	NOUN
ajcp-1612	219	4	,	,	PUNCT
ajcp-1612	219	5	and	and	CCONJ
ajcp-1612	219	6	incidence	incidence	NOUN
ajcp-1612	219	7	of	of	ADP
ajcp-1612	219	8	chronic	chronic	ADJ
ajcp-1612	219	9	kidney	kidney	NOUN
ajcp-1612	219	10	disease	disease	NOUN
ajcp-1612	219	11	:	:	PUNCT
ajcp-1612	219	12	is	be	AUX
ajcp-1612	219	13	there	there	PRON
ajcp-1612	219	14	any	any	DET
ajcp-1612	219	15	multiplicative	multiplicative	ADJ
ajcp-1612	219	16	or	or	CCONJ
ajcp-1612	219	17	additive	additive	ADJ
ajcp-1612	219	18	interaction	interaction	NOUN
ajcp-1612	219	19	?	?	PUNCT
ajcp-1612	220	1	int	int	NOUN
ajcp-1612	220	2	.	.	PUNCT
ajcp-1612	221	1	j.	j.	PROPN
ajcp-1612	221	2	endocrinol	endocrinol	PROPN
ajcp-1612	221	3	metab	metab	PROPN
ajcp-1612	221	4	,	,	PUNCT
ajcp-1612	221	5	19(1	19(1	NUM
ajcp-1612	221	6	)	)	PUNCT
ajcp-1612	221	7	,	,	PUNCT
ajcp-1612	221	8	e101061	e101061	PROPN
ajcp-1612	221	9	.	.	PUNCT
ajcp-1612	221	10	https://doi.org/10.5812/ijem.101061	https://doi.org/10.5812/ijem.101061	PROPN
ajcp-1612	221	11	ferro	ferro	PROPN
ajcp-1612	221	12	,	,	PUNCT
ajcp-1612	221	13	c.	c.	PROPN
ajcp-1612	221	14	j.	j.	PROPN
ajcp-1612	221	15	,	,	PUNCT
ajcp-1612	221	16	mark	mark	PROPN
ajcp-1612	221	17	,	,	PUNCT
ajcp-1612	221	18	p.	p.	PROPN
ajcp-1612	221	19	b.	b.	PROPN
ajcp-1612	221	20	,	,	PUNCT
ajcp-1612	221	21	kanbay	kanbay	NOUN
ajcp-1612	221	22	,	,	PUNCT
ajcp-1612	221	23	m.	m.	NOUN
ajcp-1612	221	24	,	,	PUNCT
ajcp-1612	221	25	sarafidis	sarafidi	NOUN
ajcp-1612	221	26	,	,	PUNCT
ajcp-1612	221	27	p.	p.	PROPN
ajcp-1612	221	28	,	,	PUNCT
ajcp-1612	221	29	heine	heine	PROPN
ajcp-1612	221	30	,	,	PUNCT
ajcp-1612	221	31	g.	g.	PROPN
ajcp-1612	221	32	h.	h.	PROPN
ajcp-1612	221	33	,	,	PUNCT
ajcp-1612	221	34	rossignol	rossignol	NOUN
ajcp-1612	221	35	,	,	PUNCT
ajcp-1612	221	36	p.	p.	NOUN
ajcp-1612	221	37	,	,	PUNCT
ajcp-1612	221	38	massy	massy	ADJ
ajcp-1612	221	39	,	,	PUNCT
ajcp-1612	221	40	z.	z.	PROPN
ajcp-1612	221	41	a.	a.	PROPN
ajcp-1612	221	42	,	,	PUNCT
ajcp-1612	221	43	mallamaci	mallamaci	NOUN
ajcp-1612	221	44	,	,	PUNCT
ajcp-1612	221	45	f.	f.	PROPN
ajcp-1612	221	46	,	,	PUNCT
ajcp-1612	221	47	valdivielso	valdivielso	PROPN
ajcp-1612	221	48	,	,	PUNCT
ajcp-1612	221	49	j.	j.	PROPN
ajcp-1612	221	50	m.	m.	PROPN
ajcp-1612	221	51	,	,	PUNCT
ajcp-1612	221	52	malyszko	malyszko	PROPN
ajcp-1612	221	53	,	,	PUNCT
ajcp-1612	221	54	j.	j.	PROPN
ajcp-1612	221	55	,	,	PUNCT
ajcp-1612	221	56	verhaar	verhaar	NOUN
ajcp-1612	221	57	,	,	PUNCT
ajcp-1612	221	58	m.	m.	NOUN
ajcp-1612	221	59	c.	c.	PROPN
ajcp-1612	221	60	,	,	PUNCT
ajcp-1612	221	61	ekart	ekart	PROPN
ajcp-1612	221	62	,	,	PUNCT
ajcp-1612	221	63	r.	r.	PROPN
ajcp-1612	221	64	,	,	PUNCT
ajcp-1612	221	65	vanholder	vanholder	NOUN
ajcp-1612	221	66	,	,	PUNCT
ajcp-1612	221	67	r.	r.	PROPN
ajcp-1612	221	68	,	,	PUNCT
ajcp-1612	221	69	london	london	PROPN
ajcp-1612	221	70	,	,	PUNCT
ajcp-1612	221	71	g.	g.	PROPN
ajcp-1612	221	72	,	,	PUNCT
ajcp-1612	221	73	ortiz	ortiz	PROPN
ajcp-1612	221	74	,	,	PUNCT
ajcp-1612	221	75	a.	a.	PROPN
ajcp-1612	221	76	,	,	PUNCT
ajcp-1612	221	77	&	&	CCONJ
ajcp-1612	221	78	zoccali	zoccali	PROPN
ajcp-1612	221	79	,	,	PUNCT
ajcp-1612	221	80	c.	c.	PROPN
ajcp-1612	221	81	(	(	PUNCT
ajcp-1612	221	82	2018	2018	NUM
ajcp-1612	221	83	)	)	PUNCT
ajcp-1612	221	84	.	.	PUNCT
ajcp-1612	222	1	lipid	lipid	PROPN
ajcp-1612	222	2	management	management	NOUN
ajcp-1612	222	3	in	in	ADP
ajcp-1612	222	4	patients	patient	NOUN
ajcp-1612	222	5	with	with	ADP
ajcp-1612	222	6	chronic	chronic	ADJ
ajcp-1612	222	7	kidney	kidney	NOUN
ajcp-1612	222	8	disease	disease	NOUN
ajcp-1612	222	9	.	.	PUNCT
ajcp-1612	223	1	nature	nature	NOUN
ajcp-1612	223	2	reviews	review	VERB
ajcp-1612	223	3	nephrology	nephrology	NOUN
ajcp-1612	223	4	,	,	PUNCT
ajcp-1612	223	5	14(12	14(12	NUM
ajcp-1612	223	6	)	)	PUNCT
ajcp-1612	223	7	,	,	PUNCT
ajcp-1612	223	8	727749	727749	NUM
ajcp-1612	223	9	.	.	PUNCT
ajcp-1612	224	1	https://doi.org/10.1038/s41581-018-0072-9	https://doi.org/10.1038/s41581-018-0072-9	NOUN
ajcp-1612	224	2	gabbay	gabbay	NOUN
ajcp-1612	224	3	,	,	PUNCT
ajcp-1612	224	4	m.	m.	NOUN
ajcp-1612	224	5	a.	a.	PROPN
ajcp-1612	224	6	l.	l.	PROPN
ajcp-1612	224	7	,	,	PUNCT
ajcp-1612	224	8	rodacki	rodacki	NOUN
ajcp-1612	224	9	,	,	PUNCT
ajcp-1612	224	10	m.	m.	NOUN
ajcp-1612	224	11	,	,	PUNCT
ajcp-1612	224	12	calliari	calliari	PROPN
ajcp-1612	224	13	,	,	PUNCT
ajcp-1612	224	14	l.	l.	PROPN
ajcp-1612	224	15	e.	e.	PROPN
ajcp-1612	224	16	,	,	PUNCT
ajcp-1612	224	17	vianna	vianna	PROPN
ajcp-1612	224	18	,	,	PUNCT
ajcp-1612	224	19	a.	a.	PROPN
ajcp-1612	224	20	g.	g.	PROPN
ajcp-1612	224	21	d.	d.	PROPN
ajcp-1612	224	22	,	,	PUNCT
ajcp-1612	224	23	krakauer	krakauer	PROPN
ajcp-1612	224	24	,	,	PUNCT
ajcp-1612	224	25	m.	m.	NOUN
ajcp-1612	224	26	,	,	PUNCT
ajcp-1612	224	27	pinto	pinto	NOUN
ajcp-1612	224	28	,	,	PUNCT
ajcp-1612	224	29	m.	m.	NOUN
ajcp-1612	224	30	s.	s.	PROPN
ajcp-1612	224	31	,	,	PUNCT
ajcp-1612	224	32	reis	reis	NOUN
ajcp-1612	224	33	,	,	PUNCT
ajcp-1612	224	34	j.	j.	PROPN
ajcp-1612	224	35	s.	s.	PROPN
ajcp-1612	224	36	,	,	PUNCT
ajcp-1612	224	37	puñales	puñale	NOUN
ajcp-1612	224	38	,	,	PUNCT
ajcp-1612	224	39	m.	m.	NOUN
ajcp-1612	224	40	,	,	PUNCT
ajcp-1612	224	41	miranda	miranda	PROPN
ajcp-1612	224	42	,	,	PUNCT
ajcp-1612	224	43	l.	l.	PROPN
ajcp-1612	224	44	g.	g.	PROPN
ajcp-1612	224	45	,	,	PUNCT
ajcp-1612	224	46	ramalho	ramalho	PROPN
ajcp-1612	224	47	,	,	PUNCT
ajcp-1612	224	48	a.	a.	PROPN
ajcp-1612	224	49	c.	c.	PROPN
ajcp-1612	224	50	,	,	PUNCT
ajcp-1612	224	51	franco	franco	PROPN
ajcp-1612	224	52	,	,	PUNCT
ajcp-1612	224	53	d.	d.	PROPN
ajcp-1612	224	54	r.	r.	PROPN
ajcp-1612	224	55	,	,	PUNCT
ajcp-1612	224	56	&	&	CCONJ
ajcp-1612	224	57	pedrosa	pedrosa	PROPN
ajcp-1612	224	58	,	,	PUNCT
ajcp-1612	224	59	h.	h.	PROPN
ajcp-1612	224	60	p.	p.	PROPN
ajcp-1612	224	61	c.	c.	PROPN
ajcp-1612	224	62	(	(	PUNCT
ajcp-1612	224	63	2020	2020	NUM
ajcp-1612	224	64	)	)	PUNCT
ajcp-1612	224	65	.	.	PUNCT
ajcp-1612	225	1	time	time	NOUN
ajcp-1612	225	2	in	in	ADP
ajcp-1612	225	3	the	the	DET
ajcp-1612	225	4	range	range	NOUN
ajcp-1612	225	5	:	:	PUNCT
ajcp-1612	225	6	a	a	DET
ajcp-1612	225	7	new	new	ADJ
ajcp-1612	225	8	parameter	parameter	NOUN
ajcp-1612	225	9	to	to	PART
ajcp-1612	225	10	evaluate	evaluate	VERB
ajcp-1612	225	11	blood	blood	NOUN
ajcp-1612	225	12	glucose	glucose	NOUN
ajcp-1612	225	13	control	control	NOUN
ajcp-1612	225	14	in	in	ADP
ajcp-1612	225	15	patients	patient	NOUN
ajcp-1612	225	16	with	with	ADP
ajcp-1612	225	17	diabetes	diabetes	NOUN
ajcp-1612	225	18	.	.	PUNCT
ajcp-1612	226	1	diabetology	diabetology	PROPN
ajcp-1612	226	2	&	&	CCONJ
ajcp-1612	226	3	metabolic	metabolic	PROPN
ajcp-1612	226	4	syndrome	syndrome	PROPN
ajcp-1612	226	5	,	,	PUNCT
ajcp-1612	226	6	12(1	12(1	NUM
ajcp-1612	226	7	)	)	PUNCT
ajcp-1612	226	8	,	,	PUNCT
ajcp-1612	226	9	22	22	NUM
ajcp-1612	226	10	.	.	PUNCT
ajcp-1612	227	1	https://doi.org/10.1186/s13098-020-00529-z	https://doi.org/10.1186/s13098-020-00529-z	PROPN
ajcp-1612	227	2	gburek	gburek	PROPN
ajcp-1612	227	3	,	,	PUNCT
ajcp-1612	227	4	j.	j.	PROPN
ajcp-1612	227	5	,	,	PUNCT
ajcp-1612	227	6	konopska	konopska	PROPN
ajcp-1612	227	7	,	,	PUNCT
ajcp-1612	227	8	b.	b.	PROPN
ajcp-1612	227	9	,	,	PUNCT
ajcp-1612	227	10	&	&	CCONJ
ajcp-1612	227	11	gołąb	gołąb	PROPN
ajcp-1612	227	12	,	,	PUNCT
ajcp-1612	227	13	k.	k.	PROPN
ajcp-1612	227	14	(	(	PUNCT
ajcp-1612	227	15	2021	2021	NUM
ajcp-1612	227	16	)	)	PUNCT
ajcp-1612	227	17	.	.	PUNCT
ajcp-1612	228	1	renal	renal	ADJ
ajcp-1612	228	2	handling	handling	NOUN
ajcp-1612	228	3	of	of	ADP
ajcp-1612	228	4	albumin	albumin	NOUN
ajcp-1612	228	5	—	—	PUNCT
ajcp-1612	228	6	from	from	ADP
ajcp-1612	228	7	early	early	ADJ
ajcp-1612	228	8	findings	finding	NOUN
ajcp-1612	228	9	to	to	ADP
ajcp-1612	228	10	current	current	ADJ
ajcp-1612	228	11	concepts	concept	NOUN
ajcp-1612	228	12	.	.	PUNCT
ajcp-1612	229	1	international	international	ADJ
ajcp-1612	229	2	journal	journal	NOUN
ajcp-1612	229	3	of	of	ADP
ajcp-1612	229	4	molecular	molecular	ADJ
ajcp-1612	229	5	sciences	science	NOUN
ajcp-1612	229	6	,	,	PUNCT
ajcp-1612	229	7	22(11	22(11	NUM
ajcp-1612	229	8	)	)	PUNCT
ajcp-1612	229	9	,	,	PUNCT
ajcp-1612	229	10	5809	5809	NUM
ajcp-1612	229	11	.	.	PUNCT
ajcp-1612	230	1	goyal	goyal	PROPN
ajcp-1612	230	2	,	,	PUNCT
ajcp-1612	230	3	r.	r.	PROPN
ajcp-1612	230	4	,	,	PUNCT
ajcp-1612	230	5	&	&	CCONJ
ajcp-1612	230	6	jialal	jialal	PROPN
ajcp-1612	230	7	,	,	PUNCT
ajcp-1612	230	8	i.	i.	PROPN
ajcp-1612	230	9	(	(	PUNCT
ajcp-1612	230	10	2018	2018	NUM
ajcp-1612	230	11	)	)	PUNCT
ajcp-1612	230	12	.	.	PUNCT
ajcp-1612	231	1	diabetes	diabetes	NOUN
ajcp-1612	231	2	mellitus	mellitus	PROPN
ajcp-1612	231	3	type	type	VERB
ajcp-1612	231	4	2	2	NUM
ajcp-1612	231	5	.	.	PUNCT
ajcp-1612	232	1	hahr	hahr	PROPN
ajcp-1612	232	2	,	,	PUNCT
ajcp-1612	232	3	a.	a.	PROPN
ajcp-1612	232	4	j.	j.	PROPN
ajcp-1612	232	5	,	,	PUNCT
ajcp-1612	232	6	&	&	CCONJ
ajcp-1612	232	7	molitch	molitch	PROPN
ajcp-1612	232	8	,	,	PUNCT
ajcp-1612	232	9	m.	m.	PROPN
ajcp-1612	232	10	e.	e.	PROPN
ajcp-1612	232	11	(	(	PUNCT
ajcp-1612	232	12	2015	2015	NUM
ajcp-1612	232	13	)	)	PUNCT
ajcp-1612	232	14	.	.	PUNCT
ajcp-1612	233	1	management	management	NOUN
ajcp-1612	233	2	of	of	ADP
ajcp-1612	233	3	diabetes	diabetes	NOUN
ajcp-1612	233	4	mellitus	mellitus	NOUN
ajcp-1612	233	5	in	in	ADP
ajcp-1612	233	6	patients	patient	NOUN
ajcp-1612	233	7	with	with	ADP
ajcp-1612	233	8	chronic	chronic	ADJ
ajcp-1612	233	9	kidney	kidney	NOUN
ajcp-1612	233	10	disease	disease	NOUN
ajcp-1612	233	11	.	.	PUNCT
ajcp-1612	234	1	clinical	clinical	ADJ
ajcp-1612	234	2	diabetes	diabetes	NOUN
ajcp-1612	234	3	and	and	CCONJ
ajcp-1612	234	4	endocrinology	endocrinology	NOUN
ajcp-1612	234	5	,	,	PUNCT
ajcp-1612	234	6	1(1	1(1	NUM
ajcp-1612	234	7	)	)	PUNCT
ajcp-1612	234	8	,	,	PUNCT
ajcp-1612	234	9	1	1	NUM
ajcp-1612	234	10	-	-	SYM
ajcp-1612	234	11	9	9	NUM
ajcp-1612	234	12	.	.	PUNCT
ajcp-1612	235	1	hannan	hannan	PROPN
ajcp-1612	235	2	,	,	PUNCT
ajcp-1612	235	3	m.	m.	NOUN
ajcp-1612	235	4	,	,	PUNCT
ajcp-1612	235	5	ansari	ansari	PROPN
ajcp-1612	235	6	,	,	PUNCT
ajcp-1612	235	7	s.	s.	PROPN
ajcp-1612	235	8	,	,	PUNCT
ajcp-1612	235	9	meza	meza	PROPN
ajcp-1612	235	10	,	,	PUNCT
ajcp-1612	235	11	n.	n.	PROPN
ajcp-1612	235	12	,	,	PUNCT
ajcp-1612	235	13	anderson	anderson	PROPN
ajcp-1612	235	14	,	,	PUNCT
ajcp-1612	235	15	a.	a.	PROPN
ajcp-1612	235	16	h.	h.	PROPN
ajcp-1612	235	17	,	,	PUNCT
ajcp-1612	235	18	srivastava	srivastava	PROPN
ajcp-1612	235	19	,	,	PUNCT
ajcp-1612	235	20	a.	a.	NOUN
ajcp-1612	235	21	,	,	PUNCT
ajcp-1612	235	22	waikar	waikar	NOUN
ajcp-1612	235	23	,	,	PUNCT
ajcp-1612	235	24	s.	s.	PROPN
ajcp-1612	235	25	,	,	PUNCT
ajcp-1612	235	26	charleston	charleston	PROPN
ajcp-1612	235	27	,	,	PUNCT
ajcp-1612	235	28	j.	j.	PROPN
ajcp-1612	235	29	,	,	PUNCT
ajcp-1612	235	30	weir	weir	PROPN
ajcp-1612	235	31	,	,	PUNCT
ajcp-1612	235	32	m.	m.	PROPN
ajcp-1612	235	33	r.	r.	PROPN
ajcp-1612	235	34	,	,	PUNCT
ajcp-1612	235	35	taliercio	taliercio	PROPN
ajcp-1612	235	36	,	,	PUNCT
ajcp-1612	235	37	j.	j.	PROPN
ajcp-1612	235	38	,	,	PUNCT
ajcp-1612	235	39	&	&	CCONJ
ajcp-1612	235	40	horwitz	horwitz	PROPN
ajcp-1612	235	41	,	,	PUNCT
ajcp-1612	235	42	e.	e.	PROPN
ajcp-1612	235	43	(	(	PUNCT
ajcp-1612	235	44	2021	2021	NUM
ajcp-1612	235	45	)	)	PUNCT
ajcp-1612	235	46	.	.	PUNCT
ajcp-1612	236	1	risk	risk	NOUN
ajcp-1612	236	2	factors	factor	NOUN
ajcp-1612	236	3	for	for	ADP
ajcp-1612	236	4	ckd	ckd	NOUN
ajcp-1612	236	5	progression	progression	NOUN
ajcp-1612	236	6	:	:	PUNCT
ajcp-1612	236	7	an	an	DET
ajcp-1612	236	8	overview	overview	NOUN
ajcp-1612	236	9	of	of	ADP
ajcp-1612	236	10	findings	finding	NOUN
ajcp-1612	236	11	from	from	ADP
ajcp-1612	236	12	the	the	DET
ajcp-1612	236	13	cric	cric	PROPN
ajcp-1612	236	14	study	study	NOUN
ajcp-1612	236	15	.	.	PUNCT
ajcp-1612	237	1	clinical	clinical	ADJ
ajcp-1612	237	2	journal	journal	NOUN
ajcp-1612	237	3	of	of	ADP
ajcp-1612	237	4	the	the	DET
ajcp-1612	237	5	american	american	ADJ
ajcp-1612	237	6	society	society	NOUN
ajcp-1612	237	7	of	of	ADP
ajcp-1612	237	8	nephrology	nephrology	NOUN
ajcp-1612	237	9	,	,	PUNCT
ajcp-1612	237	10	16(4	16(4	NUM
ajcp-1612	237	11	)	)	PUNCT
ajcp-1612	237	12	,	,	PUNCT
ajcp-1612	237	13	648	648	NUM
ajcp-1612	237	14	-	-	SYM
ajcp-1612	237	15	659	659	NUM
ajcp-1612	237	16	.	.	PUNCT
ajcp-1612	238	1	hussain	hussain	PROPN
ajcp-1612	238	2	,	,	PUNCT
ajcp-1612	238	3	s.	s.	PROPN
ajcp-1612	238	4	,	,	PUNCT
ajcp-1612	238	5	habib	habib	PROPN
ajcp-1612	238	6	,	,	PUNCT
ajcp-1612	238	7	a.	a.	PROPN
ajcp-1612	238	8	,	,	PUNCT
ajcp-1612	238	9	hussain	hussain	PROPN
ajcp-1612	238	10	,	,	PUNCT
ajcp-1612	238	11	m.	m.	NOUN
ajcp-1612	238	12	s.	s.	PROPN
ajcp-1612	238	13	,	,	PUNCT
ajcp-1612	238	14	&	&	CCONJ
ajcp-1612	238	15	najmi	najmi	PROPN
ajcp-1612	238	16	,	,	PUNCT
ajcp-1612	238	17	a.	a.	PROPN
ajcp-1612	238	18	k.	k.	PROPN
ajcp-1612	238	19	(	(	PUNCT
ajcp-1612	238	20	2020	2020	NUM
ajcp-1612	238	21	)	)	PUNCT
ajcp-1612	238	22	.	.	PUNCT
ajcp-1612	239	1	potential	potential	ADJ
ajcp-1612	239	2	biomarkers	biomarker	NOUN
ajcp-1612	239	3	for	for	ADP
ajcp-1612	239	4	early	early	ADJ
ajcp-1612	239	5	detection	detection	NOUN
ajcp-1612	239	6	of	of	ADP
ajcp-1612	239	7	diabetic	diabetic	ADJ
ajcp-1612	239	8	kidney	kidney	NOUN
ajcp-1612	239	9	disease	disease	NOUN
ajcp-1612	239	10	.	.	PUNCT
ajcp-1612	240	1	diabetes	diabetes	NOUN
ajcp-1612	240	2	research	research	NOUN
ajcp-1612	240	3	and	and	CCONJ
ajcp-1612	240	4	clinical	clinical	ADJ
ajcp-1612	240	5	practice	practice	NOUN
ajcp-1612	240	6	,	,	PUNCT
ajcp-1612	240	7	161	161	NUM
ajcp-1612	240	8	,	,	PUNCT
ajcp-1612	240	9	108082	108082	NUM
ajcp-1612	240	10	.	.	PUNCT
ajcp-1612	241	1	https://doi.org/https://doi	https://doi.org/https://doi	X
ajcp-1612	241	2	.	.	X
ajcp-1612	241	3	org/10.1016	org/10.1016	PROPN
ajcp-1612	241	4	/	/	SYM
ajcp-1612	241	5	j.diabres.2020.108082	j.diabres.2020.108082	PROPN
ajcp-1612	241	6	idf	idf	PROPN
ajcp-1612	241	7	.	.	PUNCT
ajcp-1612	242	1	(	(	PUNCT
ajcp-1612	242	2	2021	2021	NUM
ajcp-1612	242	3	)	)	PUNCT
ajcp-1612	242	4	.	.	PUNCT
ajcp-1612	243	1	idf	idf	PROPN
ajcp-1612	243	2	diabetes	diabetes	NOUN
ajcp-1612	243	3	atlas	atlas	PROPN
ajcp-1612	243	4	2021	2021	NUM
ajcp-1612	243	5	.	.	PUNCT
ajcp-1612	244	1	https://	https://	PROPN
ajcp-1612	244	2	diabetesatlas.org/atlas/tenth-edition/	diabetesatlas.org/atlas/tenth-edition/	NOUN
ajcp-1612	244	3	kazancioğlu	kazancioğlu	PROPN
ajcp-1612	244	4	,	,	PUNCT
ajcp-1612	244	5	r.	r.	PROPN
ajcp-1612	244	6	(	(	PUNCT
ajcp-1612	244	7	2013	2013	NUM
ajcp-1612	244	8	)	)	PUNCT
ajcp-1612	244	9	.	.	PUNCT
ajcp-1612	245	1	risk	risk	NOUN
ajcp-1612	245	2	factors	factor	NOUN
ajcp-1612	245	3	for	for	ADP
ajcp-1612	245	4	chronic	chronic	ADJ
ajcp-1612	245	5	kidney	kidney	NOUN
ajcp-1612	245	6	disease	disease	NOUN
ajcp-1612	245	7	:	:	PUNCT
ajcp-1612	245	8	an	an	DET
ajcp-1612	245	9	update	update	NOUN
ajcp-1612	245	10	.	.	PUNCT
ajcp-1612	246	1	kidney	kidney	NOUN
ajcp-1612	246	2	international	international	ADJ
ajcp-1612	246	3	supplements	supplement	NOUN
ajcp-1612	246	4	,	,	PUNCT
ajcp-1612	246	5	3(4	3(4	NUM
ajcp-1612	246	6	)	)	PUNCT
ajcp-1612	246	7	,	,	PUNCT
ajcp-1612	246	8	368	368	NUM
ajcp-1612	246	9	-	-	SYM
ajcp-1612	246	10	371	371	NUM
ajcp-1612	246	11	.	.	PUNCT
ajcp-1612	247	1	kim	kim	PROPN
ajcp-1612	247	2	,	,	PUNCT
ajcp-1612	247	3	h.	h.	PROPN
ajcp-1612	247	4	,	,	PUNCT
ajcp-1612	247	5	park	park	PROPN
ajcp-1612	247	6	,	,	PUNCT
ajcp-1612	247	7	s.	s.	PROPN
ajcp-1612	247	8	,	,	PUNCT
ajcp-1612	247	9	kwon	kwon	PROPN
ajcp-1612	247	10	,	,	PUNCT
ajcp-1612	247	11	s.	s.	PROPN
ajcp-1612	247	12	h.	h.	PROPN
ajcp-1612	247	13	,	,	PUNCT
ajcp-1612	247	14	jeon	jeon	PROPN
ajcp-1612	247	15	,	,	PUNCT
ajcp-1612	247	16	j.	j.	PROPN
ajcp-1612	247	17	s.	s.	PROPN
ajcp-1612	247	18	,	,	PUNCT
ajcp-1612	247	19	han	han	PROPN
ajcp-1612	247	20	,	,	PUNCT
ajcp-1612	247	21	d.	d.	PROPN
ajcp-1612	247	22	c.	c.	PROPN
ajcp-1612	247	23	,	,	PUNCT
ajcp-1612	247	24	&	&	CCONJ
ajcp-1612	247	25	noh	noh	PROPN
ajcp-1612	247	26	,	,	PUNCT
ajcp-1612	247	27	h.	h.	PROPN
ajcp-1612	247	28	(	(	PUNCT
ajcp-1612	247	29	2020	2020	NUM
ajcp-1612	247	30	)	)	PUNCT
ajcp-1612	247	31	.	.	PUNCT
ajcp-1612	248	1	impaired	impair	VERB
ajcp-1612	248	2	fasting	fasting	NOUN
ajcp-1612	248	3	glucose	glucose	NOUN
ajcp-1612	248	4	and	and	CCONJ
ajcp-1612	248	5	development	development	NOUN
ajcp-1612	248	6	of	of	ADP
ajcp-1612	248	7	chronic	chronic	ADJ
ajcp-1612	248	8	kidney	kidney	NOUN
ajcp-1612	248	9	disease	disease	NOUN
ajcp-1612	248	10	in	in	ADP
ajcp-1612	248	11	a	a	DET
ajcp-1612	248	12	nondiabetic	nondiabetic	ADJ
ajcp-1612	248	13	population	population	NOUN
ajcp-1612	248	14	:	:	PUNCT
ajcp-1612	248	15	a	a	DET
ajcp-1612	248	16	mendelian	mendelian	ADJ
ajcp-1612	248	17	randomisation	randomisation	NOUN
ajcp-1612	248	18	study	study	NOUN
ajcp-1612	248	19	.	.	PUNCT
ajcp-1612	249	1	bmj	bmj	PROPN
ajcp-1612	249	2	open	open	ADJ
ajcp-1612	249	3	diabetes	diabetes	NOUN
ajcp-1612	249	4	research	research	NOUN
ajcp-1612	249	5	and	and	CCONJ
ajcp-1612	249	6	care	care	NOUN
ajcp-1612	249	7	,	,	PUNCT
ajcp-1612	249	8	8(1	8(1	NOUN
ajcp-1612	249	9	)	)	PUNCT
ajcp-1612	249	10	,	,	PUNCT
ajcp-1612	249	11	e001395	e001395	PROPN
ajcp-1612	249	12	.	.	PROPN
ajcp-1612	249	13	kovesdy	kovesdy	PROPN
ajcp-1612	249	14	,	,	PUNCT
ajcp-1612	249	15	c.	c.	PROPN
ajcp-1612	249	16	p.	p.	PROPN
ajcp-1612	249	17	(	(	PUNCT
ajcp-1612	249	18	2022	2022	NUM
ajcp-1612	249	19	)	)	PUNCT
ajcp-1612	249	20	.	.	PUNCT
ajcp-1612	250	1	epidemiology	epidemiology	NOUN
ajcp-1612	250	2	of	of	ADP
ajcp-1612	250	3	chronic	chronic	ADJ
ajcp-1612	250	4	kidney	kidney	NOUN
ajcp-1612	250	5	disease	disease	NOUN
ajcp-1612	250	6	:	:	PUNCT
ajcp-1612	250	7	an	an	DET
ajcp-1612	250	8	update	update	NOUN
ajcp-1612	250	9	2022	2022	NUM
ajcp-1612	250	10	.	.	PUNCT
ajcp-1612	251	1	kidney	kidney	PROPN
ajcp-1612	251	2	international	international	ADJ
ajcp-1612	251	3	supplements	supplement	NOUN
ajcp-1612	251	4	,	,	PUNCT
ajcp-1612	251	5	12(1	12(1	NUM
ajcp-1612	251	6	)	)	PUNCT
ajcp-1612	251	7	,	,	PUNCT
ajcp-1612	251	8	7	7	NUM
ajcp-1612	251	9	-	-	SYM
ajcp-1612	251	10	11	11	NUM
ajcp-1612	251	11	.	.	PUNCT
ajcp-1612	252	1	koye	koye	PROPN
ajcp-1612	252	2	,	,	PUNCT
ajcp-1612	252	3	d.	d.	PROPN
ajcp-1612	252	4	,	,	PUNCT
ajcp-1612	252	5	shaw	shaw	PROPN
ajcp-1612	252	6	,	,	PUNCT
ajcp-1612	252	7	j.	j.	PROPN
ajcp-1612	252	8	,	,	PUNCT
ajcp-1612	252	9	reid	reid	PROPN
ajcp-1612	252	10	,	,	PUNCT
ajcp-1612	252	11	c.	c.	PROPN
ajcp-1612	252	12	,	,	PUNCT
ajcp-1612	252	13	atkins	atkins	PROPN
ajcp-1612	252	14	,	,	PUNCT
ajcp-1612	252	15	r.	r.	PROPN
ajcp-1612	252	16	,	,	PUNCT
ajcp-1612	252	17	reutens	reuten	NOUN
ajcp-1612	252	18	,	,	PUNCT
ajcp-1612	252	19	a.	a.	NOUN
ajcp-1612	252	20	,	,	PUNCT
ajcp-1612	252	21	&	&	CCONJ
ajcp-1612	252	22	magliano	magliano	PROPN
ajcp-1612	252	23	,	,	PUNCT
ajcp-1612	252	24	d.	d.	PROPN
ajcp-1612	252	25	(	(	PUNCT
ajcp-1612	252	26	2017	2017	NUM
ajcp-1612	252	27	)	)	PUNCT
ajcp-1612	252	28	.	.	PUNCT
ajcp-1612	253	1	incidence	incidence	NOUN
ajcp-1612	253	2	of	of	ADP
ajcp-1612	253	3	chronic	chronic	ADJ
ajcp-1612	253	4	kidney	kidney	NOUN
ajcp-1612	253	5	disease	disease	NOUN
ajcp-1612	253	6	among	among	ADP
ajcp-1612	253	7	people	people	NOUN
ajcp-1612	253	8	with	with	ADP
ajcp-1612	253	9	diabetes	diabetes	NOUN
ajcp-1612	253	10	:	:	PUNCT
ajcp-1612	253	11	a	a	DET
ajcp-1612	253	12	systematic	systematic	ADJ
ajcp-1612	253	13	review	review	NOUN
ajcp-1612	253	14	of	of	ADP
ajcp-1612	253	15	observational	observational	ADJ
ajcp-1612	253	16	studies	study	NOUN
ajcp-1612	253	17	.	.	PUNCT
ajcp-1612	254	1	diabetic	diabetic	ADJ
ajcp-1612	254	2	medicine	medicine	NOUN
ajcp-1612	254	3	,	,	PUNCT
ajcp-1612	254	4	34(7	34(7	NUM
ajcp-1612	254	5	)	)	PUNCT
ajcp-1612	254	6	,	,	PUNCT
ajcp-1612	254	7	887	887	NUM
ajcp-1612	254	8	-	-	SYM
ajcp-1612	254	9	901	901	NUM
ajcp-1612	254	10	.	.	PUNCT
ajcp-1612	255	1	koye	koye	PROPN
ajcp-1612	255	2	,	,	PUNCT
ajcp-1612	255	3	d.	d.	PROPN
ajcp-1612	255	4	n.	n.	PROPN
ajcp-1612	255	5	,	,	PUNCT
ajcp-1612	255	6	magliano	magliano	PROPN
ajcp-1612	255	7	,	,	PUNCT
ajcp-1612	255	8	d.	d.	PROPN
ajcp-1612	255	9	j.	j.	PROPN
ajcp-1612	255	10	,	,	PUNCT
ajcp-1612	255	11	nelson	nelson	PROPN
ajcp-1612	255	12	,	,	PUNCT
ajcp-1612	255	13	r.	r.	PROPN
ajcp-1612	255	14	g.	g.	PROPN
ajcp-1612	255	15	,	,	PUNCT
ajcp-1612	255	16	&	&	CCONJ
ajcp-1612	255	17	pavkov	pavkov	PROPN
ajcp-1612	255	18	,	,	PUNCT
ajcp-1612	255	19	m.	m.	PROPN
ajcp-1612	255	20	e.	e.	PROPN
ajcp-1612	255	21	(	(	PUNCT
ajcp-1612	255	22	2018	2018	NUM
ajcp-1612	255	23	)	)	PUNCT
ajcp-1612	255	24	.	.	PUNCT
ajcp-1612	256	1	the	the	DET
ajcp-1612	256	2	global	global	ADJ
ajcp-1612	256	3	epidemiology	epidemiology	NOUN
ajcp-1612	256	4	of	of	ADP
ajcp-1612	256	5	diabetes	diabetes	NOUN
ajcp-1612	256	6	and	and	CCONJ
ajcp-1612	256	7	kidney	kidney	NOUN
ajcp-1612	256	8	disease	disease	NOUN
ajcp-1612	256	9	.	.	PUNCT
ajcp-1612	257	1	advances	advance	NOUN
ajcp-1612	257	2	in	in	ADP
ajcp-1612	257	3	chronic	chronic	ADJ
ajcp-1612	257	4	kidney	kidney	NOUN
ajcp-1612	257	5	disease	disease	NOUN
ajcp-1612	257	6	,	,	PUNCT
ajcp-1612	257	7	25(2	25(2	NUM
ajcp-1612	257	8	)	)	PUNCT
ajcp-1612	257	9	,	,	PUNCT
ajcp-1612	257	10	121	121	NUM
ajcp-1612	257	11	-	-	SYM
ajcp-1612	257	12	132	132	NUM
ajcp-1612	257	13	.	.	PUNCT
ajcp-1612	258	1	kurzhagen	kurzhagen	PROPN
ajcp-1612	258	2	,	,	PUNCT
ajcp-1612	258	3	j.	j.	PROPN
ajcp-1612	258	4	,	,	PUNCT
ajcp-1612	258	5	dellepiane	dellepiane	PROPN
ajcp-1612	258	6	,	,	PUNCT
ajcp-1612	258	7	s.	s.	PROPN
ajcp-1612	258	8	,	,	PUNCT
ajcp-1612	258	9	cantaluppi	cantaluppi	NOUN
ajcp-1612	258	10	,	,	PUNCT
ajcp-1612	258	11	v.	v.	PROPN
ajcp-1612	258	12	,	,	PUNCT
ajcp-1612	258	13	&	&	CCONJ
ajcp-1612	258	14	rabb	rabb	PROPN
ajcp-1612	258	15	,	,	PUNCT
ajcp-1612	258	16	h.	h.	PROPN
ajcp-1612	258	17	(	(	PUNCT
ajcp-1612	258	18	2020	2020	NUM
ajcp-1612	258	19	)	)	PUNCT
ajcp-1612	258	20	.	.	PUNCT
ajcp-1612	259	1	aki	aki	NOUN
ajcp-1612	259	2	:	:	PUNCT
ajcp-1612	259	3	an	an	DET
ajcp-1612	259	4	increasingly	increasingly	ADV
ajcp-1612	259	5	recognised	recognise	VERB
ajcp-1612	259	6	risk	risk	NOUN
ajcp-1612	259	7	factor	factor	NOUN
ajcp-1612	259	8	for	for	ADP
ajcp-1612	259	9	ckd	ckd	PROPN
ajcp-1612	259	10	development	development	NOUN
ajcp-1612	259	11	and	and	CCONJ
ajcp-1612	259	12	progression	progression	NOUN
ajcp-1612	259	13	.	.	PUNCT
ajcp-1612	260	1	journal	journal	NOUN
ajcp-1612	260	2	of	of	ADP
ajcp-1612	260	3	nephrology	nephrology	NOUN
ajcp-1612	260	4	,	,	PUNCT
ajcp-1612	260	5	33(6	33(6	NUM
ajcp-1612	260	6	)	)	PUNCT
ajcp-1612	260	7	,	,	PUNCT
ajcp-1612	260	8	1171	1171	NUM
ajcp-1612	260	9	-	-	SYM
ajcp-1612	260	10	1187	1187	NUM
ajcp-1612	260	11	.	.	PUNCT
ajcp-1612	261	1	lu	lu	PROPN
ajcp-1612	261	2	,	,	PUNCT
ajcp-1612	261	3	j.	j.	PROPN
ajcp-1612	261	4	,	,	PUNCT
ajcp-1612	261	5	ma	ma	PROPN
ajcp-1612	261	6	,	,	PUNCT
ajcp-1612	261	7	x.	x.	PROPN
ajcp-1612	261	8	,	,	PUNCT
ajcp-1612	261	9	zhang	zhang	PROPN
ajcp-1612	261	10	,	,	PUNCT
ajcp-1612	261	11	l.	l.	PROPN
ajcp-1612	261	12	,	,	PUNCT
ajcp-1612	261	13	mo	mo	PROPN
ajcp-1612	261	14	,	,	PUNCT
ajcp-1612	261	15	y.	y.	PROPN
ajcp-1612	261	16	,	,	PUNCT
ajcp-1612	261	17	lu	lu	PROPN
ajcp-1612	261	18	,	,	PUNCT
ajcp-1612	261	19	w.	w.	PROPN
ajcp-1612	261	20	,	,	PUNCT
ajcp-1612	261	21	zhu	zhu	PROPN
ajcp-1612	261	22	,	,	PUNCT
ajcp-1612	261	23	w.	w.	PROPN
ajcp-1612	261	24	,	,	PUNCT
ajcp-1612	261	25	bao	bao	PROPN
ajcp-1612	261	26	,	,	PUNCT
ajcp-1612	261	27	y.	y.	PROPN
ajcp-1612	261	28	,	,	PUNCT
ajcp-1612	261	29	jia	jia	PROPN
ajcp-1612	261	30	,	,	PUNCT
ajcp-1612	261	31	w.	w.	PROPN
ajcp-1612	261	32	,	,	PUNCT
ajcp-1612	261	33	&	&	CCONJ
ajcp-1612	261	34	zhou	zhou	PROPN
ajcp-1612	261	35	,	,	PUNCT
ajcp-1612	261	36	j.	j.	PROPN
ajcp-1612	261	37	(	(	PUNCT
ajcp-1612	261	38	2020	2020	NUM
ajcp-1612	261	39	)	)	PUNCT
ajcp-1612	261	40	.	.	PUNCT
ajcp-1612	262	1	glycemic	glycemic	ADJ
ajcp-1612	262	2	variability	variability	NOUN
ajcp-1612	262	3	modifies	modify	VERB
ajcp-1612	262	4	the	the	DET
ajcp-1612	262	5	relationship	relationship	NOUN
ajcp-1612	262	6	between	between	ADP
ajcp-1612	262	7	time	time	NOUN
ajcp-1612	262	8	in	in	ADP
ajcp-1612	262	9	range	range	NOUN
ajcp-1612	262	10	and	and	CCONJ
ajcp-1612	262	11	haemoglobin	haemoglobin	PROPN
ajcp-1612	262	12	a1c	a1c	PROPN
ajcp-1612	262	13	estimated	estimate	VERB
ajcp-1612	262	14	from	from	ADP
ajcp-1612	262	15	continuous	continuous	ADJ
ajcp-1612	262	16	glucose	glucose	NOUN
ajcp-1612	262	17	monitoring	monitoring	NOUN
ajcp-1612	262	18	:	:	PUNCT
ajcp-1612	262	19	a	a	DET
ajcp-1612	262	20	preliminary	preliminary	ADJ
ajcp-1612	262	21	study	study	NOUN
ajcp-1612	262	22	.	.	PUNCT
ajcp-1612	263	1	diabetes	diabetes	NOUN
ajcp-1612	263	2	research	research	NOUN
ajcp-1612	263	3	and	and	CCONJ
ajcp-1612	263	4	clinical	clinical	ADJ
ajcp-1612	263	5	practice	practice	NOUN
ajcp-1612	263	6	,	,	PUNCT
ajcp-1612	263	7	161	161	NUM
ajcp-1612	263	8	,	,	PUNCT
ajcp-1612	263	9	108032	108032	NUM
ajcp-1612	263	10	.	.	PUNCT
ajcp-1612	264	1	mayeda	mayeda	PROPN
ajcp-1612	264	2	,	,	PUNCT
ajcp-1612	264	3	l.	l.	PROPN
ajcp-1612	264	4	,	,	PUNCT
ajcp-1612	264	5	katz	katz	PROPN
ajcp-1612	264	6	,	,	PUNCT
ajcp-1612	264	7	r.	r.	PROPN
ajcp-1612	264	8	,	,	PUNCT
ajcp-1612	264	9	ahmad	ahmad	PROPN
ajcp-1612	264	10	,	,	PUNCT
ajcp-1612	264	11	i.	i.	PROPN
ajcp-1612	264	12	,	,	PUNCT
ajcp-1612	264	13	bansal	bansal	NOUN
ajcp-1612	264	14	,	,	PUNCT
ajcp-1612	264	15	n.	n.	NOUN
ajcp-1612	264	16	,	,	PUNCT
ajcp-1612	264	17	batacchi	batacchi	PROPN
ajcp-1612	264	18	,	,	PUNCT
ajcp-1612	264	19	z.	z.	PROPN
ajcp-1612	264	20	,	,	PUNCT
ajcp-1612	264	21	hirsch	hirsch	PROPN
ajcp-1612	264	22	,	,	PUNCT
ajcp-1612	264	23	i.	i.	PROPN
ajcp-1612	264	24	b.	b.	PROPN
ajcp-1612	264	25	,	,	PUNCT
ajcp-1612	264	26	robinson	robinson	PROPN
ajcp-1612	264	27	,	,	PUNCT
ajcp-1612	264	28	n.	n.	NOUN
ajcp-1612	264	29	,	,	PUNCT
ajcp-1612	264	30	trence	trence	NOUN
ajcp-1612	264	31	,	,	PUNCT
ajcp-1612	264	32	d.	d.	PROPN
ajcp-1612	264	33	l.	l.	PROPN
ajcp-1612	264	34	,	,	PUNCT
ajcp-1612	264	35	zelnick	zelnick	PROPN
ajcp-1612	264	36	,	,	PUNCT
ajcp-1612	264	37	l.	l.	PROPN
ajcp-1612	264	38	,	,	PUNCT
ajcp-1612	264	39	&	&	CCONJ
ajcp-1612	264	40	de	de	PROPN
ajcp-1612	264	41	boer	boer	PROPN
ajcp-1612	264	42	,	,	PUNCT
ajcp-1612	264	43	i.	i.	PROPN
ajcp-1612	264	44	h.	h.	PROPN
ajcp-1612	264	45	(	(	PUNCT
ajcp-1612	264	46	2020	2020	NUM
ajcp-1612	264	47	)	)	PUNCT
ajcp-1612	264	48	.	.	PUNCT
ajcp-1612	265	1	glucose	glucose	NOUN
ajcp-1612	265	2	time	time	NOUN
ajcp-1612	265	3	in	in	ADP
ajcp-1612	265	4	range	range	NOUN
ajcp-1612	265	5	and	and	CCONJ
ajcp-1612	265	6	peripheral	peripheral	ADJ
ajcp-1612	265	7	neuropathy	neuropathy	ADJ
ajcp-1612	265	8	in	in	ADP
ajcp-1612	265	9	type	type	NOUN
ajcp-1612	265	10	2	2	NUM
ajcp-1612	265	11	diabetes	diabetes	NOUN
ajcp-1612	265	12	mellitus	mellitus	NOUN
ajcp-1612	265	13	and	and	CCONJ
ajcp-1612	265	14	chronic	chronic	ADJ
ajcp-1612	265	15	kidney	kidney	NOUN
ajcp-1612	265	16	disease	disease	NOUN
ajcp-1612	265	17	.	.	PUNCT
ajcp-1612	266	1	bmj	bmj	PROPN
ajcp-1612	266	2	open	open	ADJ
ajcp-1612	266	3	diabetes	diabetes	NOUN
ajcp-1612	266	4	research	research	NOUN
ajcp-1612	266	5	and	and	CCONJ
ajcp-1612	266	6	care	care	NOUN
ajcp-1612	266	7	,	,	PUNCT
ajcp-1612	266	8	8(1	8(1	NOUN
ajcp-1612	266	9	)	)	PUNCT
ajcp-1612	266	10	,	,	PUNCT
ajcp-1612	266	11	e000991	e000991	PROPN
ajcp-1612	266	12	.	.	PUNCT
ajcp-1612	266	13	miller	miller	PROPN
ajcp-1612	266	14	,	,	PUNCT
ajcp-1612	266	15	w.	w.	PROPN
ajcp-1612	266	16	g.	g.	PROPN
ajcp-1612	266	17	,	,	PUNCT
ajcp-1612	266	18	&	&	CCONJ
ajcp-1612	266	19	jones	jones	PROPN
ajcp-1612	266	20	,	,	PUNCT
ajcp-1612	266	21	g.	g.	PROPN
ajcp-1612	266	22	r.	r.	PROPN
ajcp-1612	266	23	(	(	PUNCT
ajcp-1612	266	24	2018	2018	NUM
ajcp-1612	266	25	)	)	PUNCT
ajcp-1612	266	26	.	.	PUNCT
ajcp-1612	267	1	estimated	estimate	VERB
ajcp-1612	267	2	glomerular	glomerular	ADJ
ajcp-1612	267	3	filtration	filtration	NOUN
ajcp-1612	267	4	rate	rate	NOUN
ajcp-1612	267	5	;	;	PUNCT
ajcp-1612	267	6	laboratory	laboratory	NOUN
ajcp-1612	267	7	implementation	implementation	NOUN
ajcp-1612	267	8	and	and	CCONJ
ajcp-1612	267	9	current	current	ADJ
ajcp-1612	267	10	global	global	ADJ
ajcp-1612	267	11	status	status	NOUN
ajcp-1612	267	12	.	.	PUNCT
ajcp-1612	268	1	advances	advance	NOUN
ajcp-1612	268	2	in	in	ADP
ajcp-1612	268	3	chronic	chronic	ADJ
ajcp-1612	268	4	kidney	kidney	NOUN
ajcp-1612	268	5	disease	disease	NOUN
ajcp-1612	268	6	,	,	PUNCT
ajcp-1612	268	7	25(1	25(1	NUM
ajcp-1612	268	8	)	)	PUNCT
ajcp-1612	268	9	,	,	PUNCT
ajcp-1612	268	10	7	7	NUM
ajcp-1612	268	11	-	-	SYM
ajcp-1612	268	12	13	13	NUM
ajcp-1612	268	13	.	.	PUNCT
ajcp-1612	269	1	ohishi	ohishi	PROPN
ajcp-1612	269	2	,	,	PUNCT
ajcp-1612	269	3	m.	m.	NOUN
ajcp-1612	269	4	(	(	PUNCT
ajcp-1612	269	5	2018	2018	NUM
ajcp-1612	269	6	)	)	PUNCT
ajcp-1612	269	7	.	.	PUNCT
ajcp-1612	270	1	hypertension	hypertension	NOUN
ajcp-1612	270	2	with	with	ADP
ajcp-1612	270	3	diabetes	diabetes	NOUN
ajcp-1612	270	4	mellitus	mellitus	NOUN
ajcp-1612	270	5	:	:	PUNCT
ajcp-1612	270	6	physiology	physiology	NOUN
ajcp-1612	270	7	and	and	CCONJ
ajcp-1612	270	8	pathology	pathology	NOUN
ajcp-1612	270	9	.	.	PUNCT
ajcp-1612	271	1	hypertension	hypertension	NOUN
ajcp-1612	271	2	research	research	PROPN
ajcp-1612	271	3	,	,	PUNCT
ajcp-1612	271	4	41(6	41(6	NOUN
ajcp-1612	271	5	)	)	PUNCT
ajcp-1612	271	6	,	,	PUNCT
ajcp-1612	271	7	389	389	NUM
ajcp-1612	271	8	-	-	SYM
ajcp-1612	271	9	393	393	NUM
ajcp-1612	271	10	.	.	PUNCT
ajcp-1612	272	1	oshima	oshima	PROPN
ajcp-1612	272	2	,	,	PUNCT
ajcp-1612	272	3	m.	m.	NOUN
ajcp-1612	272	4	,	,	PUNCT
ajcp-1612	272	5	shimizu	shimizu	PROPN
ajcp-1612	272	6	,	,	PUNCT
ajcp-1612	272	7	m.	m.	NOUN
ajcp-1612	272	8	,	,	PUNCT
ajcp-1612	272	9	yamanouchi	yamanouchi	NOUN
ajcp-1612	272	10	,	,	PUNCT
ajcp-1612	272	11	m.	m.	NOUN
ajcp-1612	272	12	,	,	PUNCT
ajcp-1612	272	13	toyama	toyama	PROPN
ajcp-1612	272	14	,	,	PUNCT
ajcp-1612	272	15	t.	t.	PROPN
ajcp-1612	272	16	,	,	PUNCT
ajcp-1612	272	17	hara	hara	PROPN
ajcp-1612	272	18	,	,	PUNCT
ajcp-1612	272	19	a.	a.	NOUN
ajcp-1612	272	20	,	,	PUNCT
ajcp-1612	272	21	furuichi	furuichi	PROPN
ajcp-1612	272	22	,	,	PUNCT
ajcp-1612	272	23	k.	k.	PROPN
ajcp-1612	272	24	,	,	PUNCT
ajcp-1612	272	25	&	&	CCONJ
ajcp-1612	272	26	wada	wada	PROPN
ajcp-1612	272	27	,	,	PUNCT
ajcp-1612	272	28	t.	t.	PROPN
ajcp-1612	272	29	(	(	PUNCT
ajcp-1612	272	30	2021	2021	NUM
ajcp-1612	272	31	)	)	PUNCT
ajcp-1612	272	32	.	.	PUNCT
ajcp-1612	273	1	trajectories	trajectory	NOUN
ajcp-1612	273	2	of	of	ADP
ajcp-1612	273	3	kidney	kidney	NOUN
ajcp-1612	273	4	function	function	NOUN
ajcp-1612	273	5	in	in	ADP
ajcp-1612	273	6	diabetes	diabetes	NOUN
ajcp-1612	273	7	:	:	PUNCT
ajcp-1612	273	8	a	a	DET
ajcp-1612	273	9	clinicopathological	clinicopathological	ADJ
ajcp-1612	273	10	update	update	NOUN
ajcp-1612	273	11	.	.	PUNCT
ajcp-1612	274	1	nature	nature	NOUN
ajcp-1612	274	2	reviews	review	VERB
ajcp-1612	274	3	nephrology	nephrology	NOUN
ajcp-1612	274	4	,	,	PUNCT
ajcp-1612	274	5	17(11	17(11	NUM
ajcp-1612	274	6	)	)	PUNCT
ajcp-1612	274	7	,	,	PUNCT
ajcp-1612	274	8	740	740	NUM
ajcp-1612	274	9	-	-	SYM
ajcp-1612	274	10	750	750	NUM
ajcp-1612	274	11	.	.	PUNCT
ajcp-1612	275	1	parving	parve	VERB
ajcp-1612	275	2	,	,	PUNCT
ajcp-1612	275	3	h.-h	h.-h	NOUN
ajcp-1612	275	4	.	.	PUNCT
ajcp-1612	275	5	,	,	PUNCT
ajcp-1612	275	6	persson	persson	PROPN
ajcp-1612	275	7	,	,	PUNCT
ajcp-1612	275	8	f.	f.	PROPN
ajcp-1612	275	9	,	,	PUNCT
ajcp-1612	275	10	&	&	CCONJ
ajcp-1612	275	11	rossing	rosse	VERB
ajcp-1612	275	12	,	,	PUNCT
ajcp-1612	275	13	p.	p.	NOUN
ajcp-1612	275	14	(	(	PUNCT
ajcp-1612	275	15	2015	2015	NUM
ajcp-1612	275	16	)	)	PUNCT
ajcp-1612	275	17	.	.	PUNCT
ajcp-1612	276	1	microalbuminuria	microalbuminuria	NOUN
ajcp-1612	276	2	:	:	PUNCT
ajcp-1612	276	3	a	a	DET
ajcp-1612	276	4	parameter	parameter	NOUN
ajcp-1612	276	5	that	that	PRON
ajcp-1612	276	6	has	have	AUX
ajcp-1612	276	7	changed	change	VERB
ajcp-1612	276	8	diabetes	diabetes	NOUN
ajcp-1612	276	9	care	care	NOUN
ajcp-1612	276	10	.	.	PUNCT
ajcp-1612	277	1	diabetes	diabetes	NOUN
ajcp-1612	277	2	research	research	NOUN
ajcp-1612	277	3	and	and	CCONJ
ajcp-1612	277	4	clinical	clinical	ADJ
ajcp-1612	277	5	practice	practice	NOUN
ajcp-1612	277	6	,	,	PUNCT
ajcp-1612	277	7	107(1	107(1	NUM
ajcp-1612	277	8	)	)	PUNCT
ajcp-1612	277	9	,	,	PUNCT
ajcp-1612	277	10	1	1	NUM
ajcp-1612	277	11	-	-	SYM
ajcp-1612	277	12	8	8	NUM
ajcp-1612	277	13	.	.	PUNCT
ajcp-1612	278	1	persson	persson	PROPN
ajcp-1612	278	2	,	,	PUNCT
ajcp-1612	278	3	f.	f.	PROPN
ajcp-1612	278	4	,	,	PUNCT
ajcp-1612	278	5	&	&	CCONJ
ajcp-1612	278	6	rossing	rosse	VERB
ajcp-1612	278	7	,	,	PUNCT
ajcp-1612	278	8	p.	p.	NOUN
ajcp-1612	278	9	(	(	PUNCT
ajcp-1612	278	10	2018	2018	NUM
ajcp-1612	278	11	)	)	PUNCT
ajcp-1612	278	12	.	.	PUNCT
ajcp-1612	279	1	diagnosis	diagnosis	NOUN
ajcp-1612	279	2	of	of	ADP
ajcp-1612	279	3	diabetic	diabetic	ADJ
ajcp-1612	279	4	kidney	kidney	NOUN
ajcp-1612	279	5	disease	disease	NOUN
ajcp-1612	279	6	:	:	PUNCT
ajcp-1612	279	7	state	state	NOUN
ajcp-1612	279	8	of	of	ADP
ajcp-1612	279	9	the	the	DET
ajcp-1612	279	10	art	art	NOUN
ajcp-1612	279	11	and	and	CCONJ
ajcp-1612	279	12	future	future	ADJ
ajcp-1612	279	13	perspective	perspective	NOUN
ajcp-1612	279	14	.	.	PUNCT
ajcp-1612	280	1	kidney	kidney	NOUN
ajcp-1612	280	2	international	international	ADJ
ajcp-1612	280	3	supplements	supplement	NOUN
ajcp-1612	280	4	,	,	PUNCT
ajcp-1612	280	5	8(1	8(1	NOUN
ajcp-1612	280	6	)	)	PUNCT
ajcp-1612	280	7	,	,	PUNCT
ajcp-1612	280	8	2	2	NUM
ajcp-1612	280	9	-	-	SYM
ajcp-1612	280	10	7	7	NUM
ajcp-1612	280	11	.	.	PUNCT
ajcp-1612	281	1	peruchetti	peruchetti	PROPN
ajcp-1612	281	2	,	,	PUNCT
ajcp-1612	281	3	d.	d.	PROPN
ajcp-1612	281	4	b.	b.	PROPN
ajcp-1612	281	5	,	,	PUNCT
ajcp-1612	281	6	barahuna	barahuna	NOUN
ajcp-1612	281	7	-	-	PUNCT
ajcp-1612	281	8	filho	filho	NOUN
ajcp-1612	281	9	,	,	PUNCT
ajcp-1612	281	10	p.	p.	PROPN
ajcp-1612	281	11	f.	f.	PROPN
ajcp-1612	281	12	,	,	PUNCT
ajcp-1612	281	13	silva	silva	NOUN
ajcp-1612	281	14	-	-	PUNCT
ajcp-1612	281	15	aguiar	aguiar	NOUN
ajcp-1612	281	16	,	,	PUNCT
ajcp-1612	281	17	r.	r.	PROPN
ajcp-1612	281	18	p.	p.	PROPN
ajcp-1612	281	19	,	,	PUNCT
ajcp-1612	281	20	abreu	abreu	PROPN
ajcp-1612	281	21	,	,	PUNCT
ajcp-1612	281	22	t.	t.	PROPN
ajcp-1612	281	23	p.	p.	PROPN
ajcp-1612	281	24	,	,	PUNCT
ajcp-1612	281	25	takiya	takiya	PROPN
ajcp-1612	281	26	,	,	PUNCT
ajcp-1612	281	27	c.	c.	PROPN
ajcp-1612	281	28	m.	m.	PROPN
ajcp-1612	281	29	,	,	PUNCT
ajcp-1612	281	30	cheng	cheng	PROPN
ajcp-1612	281	31	,	,	PUNCT
ajcp-1612	281	32	j.	j.	PROPN
ajcp-1612	281	33	,	,	PUNCT
ajcp-1612	281	34	pinheiro	pinheiro	PROPN
ajcp-1612	281	35	,	,	PUNCT
ajcp-1612	281	36	a.	a.	PROPN
ajcp-1612	281	37	a.	a.	PROPN
ajcp-1612	281	38	s.	s.	PROPN
ajcp-1612	281	39	,	,	PUNCT
ajcp-1612	281	40	cebotaru	cebotaru	NOUN
ajcp-1612	281	41	,	,	PUNCT
ajcp-1612	281	42	l.	l.	PROPN
ajcp-1612	281	43	,	,	PUNCT
ajcp-1612	281	44	guggino	guggino	PROPN
ajcp-1612	281	45	,	,	PUNCT
ajcp-1612	281	46	w.	w.	PROPN
ajcp-1612	281	47	b.	b.	PROPN
ajcp-1612	281	48	,	,	PUNCT
ajcp-1612	281	49	&	&	CCONJ
ajcp-1612	281	50	carusoneves	carusoneves	PROPN
ajcp-1612	281	51	,	,	PUNCT
ajcp-1612	281	52	c.	c.	NOUN
ajcp-1612	281	53	(	(	PUNCT
ajcp-1612	281	54	2021	2021	NUM
ajcp-1612	281	55	)	)	PUNCT
ajcp-1612	281	56	.	.	PUNCT
ajcp-1612	282	1	megalin	megalin	NOUN
ajcp-1612	282	2	-	-	PUNCT
ajcp-1612	282	3	mediated	mediate	VERB
ajcp-1612	282	4	albumin	albumin	ADJ
ajcp-1612	282	5	endocytosis	endocytosis	NOUN
ajcp-1612	282	6	in	in	ADP
ajcp-1612	282	7	renal	renal	ADJ
ajcp-1612	282	8	proximal	proximal	ADJ
ajcp-1612	282	9	tubules	tubule	NOUN
ajcp-1612	282	10	is	be	AUX
ajcp-1612	282	11	involved	involve	VERB
ajcp-1612	282	12	in	in	ADP
ajcp-1612	282	13	the	the	DET
ajcp-1612	282	14	antiproteinuric	antiproteinuric	ADJ
ajcp-1612	282	15	effect	effect	NOUN
ajcp-1612	282	16	of	of	ADP
ajcp-1612	282	17	angiotensin	angiotensin	PROPN
ajcp-1612	282	18	ii	ii	PROPN
ajcp-1612	282	19	type	type	NOUN
ajcp-1612	282	20	1	1	NUM
ajcp-1612	282	21	receptor	receptor	NOUN
ajcp-1612	282	22	blocker	blocker	NOUN
ajcp-1612	282	23	in	in	ADP
ajcp-1612	282	24	a	a	DET
ajcp-1612	282	25	subclinical	subclinical	ADJ
ajcp-1612	282	26	acute	acute	NOUN
ajcp-1612	282	27	kidney	kidney	PROPN
ajcp-1612	282	28	injury	injury	NOUN
ajcp-1612	282	29	animal	animal	NOUN
ajcp-1612	282	30	model	model	NOUN
ajcp-1612	282	31	.	.	PUNCT
ajcp-1612	283	1	biochimica	biochimica	PROPN
ajcp-1612	283	2	et	et	PROPN
ajcp-1612	283	3	biophysica	biophysica	PROPN
ajcp-1612	283	4	acta	acta	PROPN
ajcp-1612	283	5	(	(	PUNCT
ajcp-1612	283	6	bba)general	bba)general	ADJ
ajcp-1612	283	7	subjects	subject	NOUN
ajcp-1612	283	8	,	,	PUNCT
ajcp-1612	283	9	1865(9	1865(9	NUM
ajcp-1612	283	10	)	)	PUNCT
ajcp-1612	283	11	,	,	PUNCT
ajcp-1612	283	12	129950	129950	NUM
ajcp-1612	283	13	.	.	PUNCT
ajcp-1612	284	1	porta	porta	PROPN
ajcp-1612	284	2	,	,	PUNCT
ajcp-1612	284	3	m.	m.	NOUN
ajcp-1612	284	4	(	(	PUNCT
ajcp-1612	284	5	2020	2020	NUM
ajcp-1612	284	6	)	)	PUNCT
ajcp-1612	284	7	.	.	PUNCT
ajcp-1612	285	1	diabetes	diabetes	NOUN
ajcp-1612	285	2	in	in	ADP
ajcp-1612	285	3	ancient	ancient	ADJ
ajcp-1612	285	4	times	time	NOUN
ajcp-1612	285	5	:	:	PUNCT
ajcp-1612	285	6	the	the	DET
ajcp-1612	285	7	long	long	ADJ
ajcp-1612	285	8	and	and	CCONJ
ajcp-1612	285	9	winding	wind	VERB
ajcp-1612	285	10	road	road	NOUN
ajcp-1612	285	11	to	to	ADP
ajcp-1612	285	12	insulin	insulin	NOUN
ajcp-1612	285	13	.	.	PUNCT
ajcp-1612	286	1	in	in	ADP
ajcp-1612	286	2	unveiling	unveil	VERB
ajcp-1612	286	3	diabetes	diabetes	NOUN
ajcp-1612	286	4	-	-	PUNCT
ajcp-1612	286	5	historical	historical	ADJ
ajcp-1612	286	6	milestones	milestone	NOUN
ajcp-1612	286	7	in	in	ADP
ajcp-1612	286	8	diabetology	diabetology	NOUN
ajcp-1612	286	9	29	29	NUM
ajcp-1612	286	10	,	,	PUNCT
ajcp-1612	286	11	1	1	NUM
ajcp-1612	286	12	-	-	SYM
ajcp-1612	286	13	13	13	NUM
ajcp-1612	286	14	.	.	PUNCT
ajcp-1612	287	1	karger	karger	NOUN
ajcp-1612	287	2	publishers	publisher	NOUN
ajcp-1612	287	3	.	.	PUNCT
ajcp-1612	288	1	prasad	prasad	PROPN
ajcp-1612	288	2	,	,	PUNCT
ajcp-1612	288	3	r.	r.	PROPN
ajcp-1612	288	4	m.	m.	PROPN
ajcp-1612	288	5	,	,	PUNCT
ajcp-1612	288	6	&	&	CCONJ
ajcp-1612	288	7	tikaria	tikaria	PROPN
ajcp-1612	288	8	,	,	PUNCT
ajcp-1612	288	9	r.	r.	PROPN
ajcp-1612	288	10	(	(	PUNCT
ajcp-1612	288	11	2022	2022	NUM
ajcp-1612	288	12	)	)	PUNCT
ajcp-1612	288	13	.	.	PUNCT
ajcp-1612	289	1	microalbuminuria	microalbuminuria	PROPN
ajcp-1612	289	2	.	.	PUNCT
ajcp-1612	289	3	statpearls	statpearls	PROPN
ajcp-1612	289	4	publishing	publishing	NOUN
ajcp-1612	289	5	,	,	PUNCT
ajcp-1612	289	6	treasure	treasure	NOUN
ajcp-1612	289	7	island	island	NOUN
ajcp-1612	289	8	(	(	PUNCT
ajcp-1612	289	9	fl	fl	NOUN
ajcp-1612	289	10	)	)	PUNCT
ajcp-1612	289	11	.	.	PUNCT
ajcp-1612	290	1	http://	http://	PROPN
ajcp-1612	290	2	europepmc.org/abstract/med/33085402	europepmc.org/abstract/med/33085402	PROPN
ajcp-1612	290	3	prevention	prevention	NOUN
ajcp-1612	290	4	,	,	PUNCT
ajcp-1612	290	5	c.	c.	PROPN
ajcp-1612	290	6	f.	f.	PROPN
ajcp-1612	290	7	d.	d.	PROPN
ajcp-1612	290	8	c.	c.	PROPN
ajcp-1612	290	9	a.	a.	PROPN
ajcp-1612	290	10	(	(	PUNCT
ajcp-1612	290	11	2020	2020	NUM
ajcp-1612	290	12	)	)	PUNCT
ajcp-1612	290	13	.	.	PUNCT
ajcp-1612	291	1	world	world	NOUN
ajcp-1612	291	2	diabetes	diabetes	PROPN
ajcp-1612	291	3	day	day	NOUN
ajcp-1612	291	4	.	.	PUNCT
ajcp-1612	292	1	https://www.cdc.gov/globalhealth/infographics/	https://www.cdc.gov/globalhealth/infographics/	PROPN
ajcp-1612	292	2	diabetes	diabetes	NOUN
ajcp-1612	292	3	/	/	SYM
ajcp-1612	292	4	world	world	NOUN
ajcp-1612	292	5	-	-	PUNCT
ajcp-1612	292	6	diabetes	diabetes	NOUN
ajcp-1612	292	7	-	-	PUNCT
ajcp-1612	292	8	day.html#:~:text	day.html#:~:text	NOUN
ajcp-1612	292	9	=	=	NOUN
ajcp-1612	292	10	today%20	today%20	NOUN
ajcp-1612	292	11	415%20million%20people%20worldwide	415%20million%20people%20worldwide	NOUN
ajcp-1612	292	12	,	,	PUNCT
ajcp-1612	292	13	a%20	a%20	PROPN
ajcp-1612	292	14	billion%20will%20have%20diabetes	billion%20will%20have%20diabetes	PROPN
ajcp-1612	292	15	.	.	PROPN
ajcp-1612	292	16	raja	raja	PROPN
ajcp-1612	292	17	,	,	PUNCT
ajcp-1612	292	18	p.	p.	PROPN
ajcp-1612	292	19	,	,	PUNCT
ajcp-1612	292	20	maxwell	maxwell	PROPN
ajcp-1612	292	21	,	,	PUNCT
ajcp-1612	292	22	a.	a.	NOUN
ajcp-1612	292	23	p.	p.	PROPN
ajcp-1612	292	24	,	,	PUNCT
ajcp-1612	292	25	&	&	CCONJ
ajcp-1612	292	26	brazil	brazil	PROPN
ajcp-1612	292	27	,	,	PUNCT
ajcp-1612	292	28	d.	d.	PROPN
ajcp-1612	292	29	p.	p.	PROPN
ajcp-1612	292	30	(	(	PUNCT
ajcp-1612	292	31	2021	2021	NUM
ajcp-1612	292	32	)	)	PUNCT
ajcp-1612	292	33	.	.	PUNCT
ajcp-1612	293	1	the	the	DET
ajcp-1612	293	2	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	293	3	pa	pa	PROPN
ajcp-1612	293	4	ge	ge	PROPN
ajcp-1612	293	5	14	14	NUM
ajcp-1612	293	6	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN
ajcp-1612	293	7	am	be	AUX
ajcp-1612	293	8	.	.	PUNCT
ajcp-1612	294	1	j.	j.	PROPN
ajcp-1612	294	2	chem	chem	PROPN
ajcp-1612	294	3	.	.	PUNCT
ajcp-1612	295	1	pharm	pharm	PROPN
ajcp-1612	295	2	.	.	PUNCT
ajcp-1612	296	1	2(2	2(2	NUM
ajcp-1612	296	2	)	)	PUNCT
ajcp-1612	296	3	9	9	NUM
ajcp-1612	296	4	-	-	SYM
ajcp-1612	296	5	14	14	NUM
ajcp-1612	296	6	,	,	PUNCT
ajcp-1612	296	7	2023	2023	NUM
ajcp-1612	296	8	potential	potential	NOUN
ajcp-1612	296	9	of	of	ADP
ajcp-1612	296	10	albuminuria	albuminuria	NOUN
ajcp-1612	296	11	as	as	ADP
ajcp-1612	296	12	a	a	DET
ajcp-1612	296	13	biomarker	biomarker	NOUN
ajcp-1612	296	14	of	of	ADP
ajcp-1612	296	15	diabetic	diabetic	ADJ
ajcp-1612	296	16	complications	complication	NOUN
ajcp-1612	296	17	.	.	PUNCT
ajcp-1612	297	1	cardiovascular	cardiovascular	ADJ
ajcp-1612	297	2	drugs	drug	NOUN
ajcp-1612	297	3	and	and	CCONJ
ajcp-1612	297	4	therapy	therapy	NOUN
ajcp-1612	297	5	,	,	PUNCT
ajcp-1612	297	6	35	35	NUM
ajcp-1612	297	7	,	,	PUNCT
ajcp-1612	297	8	455466	455466	NUM
ajcp-1612	297	9	.	.	PUNCT
ajcp-1612	298	1	rodrigues	rodrigues	PROPN
ajcp-1612	298	2	,	,	PUNCT
ajcp-1612	298	3	b.	b.	PROPN
ajcp-1612	298	4	t.	t.	PROPN
ajcp-1612	298	5	,	,	PUNCT
ajcp-1612	298	6	vangaveti	vangaveti	PROPN
ajcp-1612	298	7	,	,	PUNCT
ajcp-1612	298	8	v.	v.	ADP
ajcp-1612	298	9	n.	n.	NOUN
ajcp-1612	298	10	,	,	PUNCT
ajcp-1612	298	11	urkude	urkude	NOUN
ajcp-1612	298	12	,	,	PUNCT
ajcp-1612	298	13	r.	r.	PROPN
ajcp-1612	298	14	,	,	PUNCT
ajcp-1612	298	15	biros	biros	PROPN
ajcp-1612	298	16	,	,	PUNCT
ajcp-1612	298	17	e.	e.	PROPN
ajcp-1612	298	18	,	,	PUNCT
ajcp-1612	298	19	&	&	CCONJ
ajcp-1612	298	20	malabu	malabu	NOUN
ajcp-1612	298	21	,	,	PUNCT
ajcp-1612	298	22	u.	u.	PROPN
ajcp-1612	298	23	h.	h.	PROPN
ajcp-1612	298	24	(	(	PUNCT
ajcp-1612	298	25	2022	2022	NUM
ajcp-1612	298	26	)	)	PUNCT
ajcp-1612	298	27	.	.	PUNCT
ajcp-1612	299	1	prevalence	prevalence	NOUN
ajcp-1612	299	2	and	and	CCONJ
ajcp-1612	299	3	risk	risk	NOUN
ajcp-1612	299	4	factors	factor	NOUN
ajcp-1612	299	5	of	of	ADP
ajcp-1612	299	6	lower	low	ADJ
ajcp-1612	299	7	limb	limb	NOUN
ajcp-1612	299	8	amputations	amputation	NOUN
ajcp-1612	299	9	in	in	ADP
ajcp-1612	299	10	patients	patient	NOUN
ajcp-1612	299	11	with	with	ADP
ajcp-1612	299	12	diabetic	diabetic	ADJ
ajcp-1612	299	13	foot	foot	NOUN
ajcp-1612	299	14	ulcers	ulcer	NOUN
ajcp-1612	299	15	:	:	PUNCT
ajcp-1612	299	16	a	a	DET
ajcp-1612	299	17	systematic	systematic	ADJ
ajcp-1612	299	18	review	review	NOUN
ajcp-1612	299	19	and	and	CCONJ
ajcp-1612	299	20	meta	meta	ADJ
ajcp-1612	299	21	-	-	PUNCT
ajcp-1612	299	22	analysis	analysis	NOUN
ajcp-1612	299	23	.	.	PUNCT
ajcp-1612	300	1	diabetes	diabetes	NOUN
ajcp-1612	300	2	&	&	CCONJ
ajcp-1612	300	3	metabolic	metabolic	PROPN
ajcp-1612	300	4	syndrome	syndrome	PROPN
ajcp-1612	300	5	:	:	PUNCT
ajcp-1612	300	6	clinical	clinical	ADJ
ajcp-1612	300	7	research	research	NOUN
ajcp-1612	300	8	&	&	CCONJ
ajcp-1612	300	9	reviews	review	NOUN
ajcp-1612	300	10	,	,	PUNCT
ajcp-1612	300	11	102397	102397	NUM
ajcp-1612	300	12	.	.	PUNCT
ajcp-1612	301	1	romagnani	romagnani	PROPN
ajcp-1612	301	2	,	,	PUNCT
ajcp-1612	301	3	p.	p.	NOUN
ajcp-1612	301	4	,	,	PUNCT
ajcp-1612	301	5	remuzzi	remuzzi	NOUN
ajcp-1612	301	6	,	,	PUNCT
ajcp-1612	301	7	g.	g.	PROPN
ajcp-1612	301	8	,	,	PUNCT
ajcp-1612	301	9	glassock	glassock	PROPN
ajcp-1612	301	10	,	,	PUNCT
ajcp-1612	301	11	r.	r.	PROPN
ajcp-1612	301	12	,	,	PUNCT
ajcp-1612	301	13	levin	levin	PROPN
ajcp-1612	301	14	,	,	PUNCT
ajcp-1612	301	15	a.	a.	PROPN
ajcp-1612	301	16	,	,	PUNCT
ajcp-1612	301	17	jager	jager	PROPN
ajcp-1612	301	18	,	,	PUNCT
ajcp-1612	301	19	k.	k.	PROPN
ajcp-1612	301	20	j.	j.	PROPN
ajcp-1612	301	21	,	,	PUNCT
ajcp-1612	301	22	tonelli	tonelli	PROPN
ajcp-1612	301	23	,	,	PUNCT
ajcp-1612	301	24	m.	m.	NOUN
ajcp-1612	301	25	,	,	PUNCT
ajcp-1612	301	26	massy	massy	ADJ
ajcp-1612	301	27	,	,	PUNCT
ajcp-1612	301	28	z.	z.	PROPN
ajcp-1612	301	29	,	,	PUNCT
ajcp-1612	301	30	wanner	wanner	NOUN
ajcp-1612	301	31	,	,	PUNCT
ajcp-1612	301	32	c.	c.	PROPN
ajcp-1612	301	33	,	,	PUNCT
ajcp-1612	301	34	&	&	CCONJ
ajcp-1612	301	35	anders	ander	NOUN
ajcp-1612	301	36	,	,	PUNCT
ajcp-1612	301	37	h.-j	h.-j	PROPN
ajcp-1612	301	38	.	.	PUNCT
ajcp-1612	302	1	(	(	PUNCT
ajcp-1612	302	2	2017	2017	NUM
ajcp-1612	302	3	)	)	PUNCT
ajcp-1612	302	4	.	.	PUNCT
ajcp-1612	303	1	chronic	chronic	ADJ
ajcp-1612	303	2	kidney	kidney	NOUN
ajcp-1612	303	3	disease	disease	NOUN
ajcp-1612	303	4	.	.	PUNCT
ajcp-1612	304	1	nature	nature	NOUN
ajcp-1612	304	2	reviews	review	NOUN
ajcp-1612	304	3	disease	disease	NOUN
ajcp-1612	304	4	primers	primer	NOUN
ajcp-1612	304	5	,	,	PUNCT
ajcp-1612	304	6	3(1	3(1	NUM
ajcp-1612	304	7	)	)	PUNCT
ajcp-1612	304	8	,	,	PUNCT
ajcp-1612	304	9	1	1	NUM
ajcp-1612	304	10	-	-	SYM
ajcp-1612	304	11	24	24	NUM
ajcp-1612	304	12	.	.	PUNCT
ajcp-1612	305	1	sagoo	sagoo	PROPN
ajcp-1612	305	2	,	,	PUNCT
ajcp-1612	305	3	m.	m.	PROPN
ajcp-1612	305	4	k.	k.	PROPN
ajcp-1612	305	5	,	,	PUNCT
ajcp-1612	305	6	&	&	CCONJ
ajcp-1612	305	7	gnudi	gnudi	PROPN
ajcp-1612	305	8	,	,	PUNCT
ajcp-1612	305	9	l.	l.	PROPN
ajcp-1612	305	10	(	(	PUNCT
ajcp-1612	305	11	2020	2020	NUM
ajcp-1612	305	12	)	)	PUNCT
ajcp-1612	305	13	.	.	PUNCT
ajcp-1612	306	1	diabetic	diabetic	ADJ
ajcp-1612	306	2	nephropathy	nephropathy	NOUN
ajcp-1612	306	3	:	:	PUNCT
ajcp-1612	306	4	an	an	DET
ajcp-1612	306	5	overview	overview	NOUN
ajcp-1612	306	6	.	.	PUNCT
ajcp-1612	307	1	diabetic	diabetic	ADJ
ajcp-1612	307	2	nephropathy	nephropathy	NOUN
ajcp-1612	307	3	:	:	PUNCT
ajcp-1612	307	4	methods	method	NOUN
ajcp-1612	307	5	and	and	CCONJ
ajcp-1612	307	6	protocols	protocol	NOUN
ajcp-1612	307	7	,	,	PUNCT
ajcp-1612	307	8	3	3	NUM
ajcp-1612	307	9	-	-	SYM
ajcp-1612	307	10	7	7	NUM
ajcp-1612	307	11	.	.	PUNCT
ajcp-1612	308	1	seino	seino	PROPN
ajcp-1612	308	2	,	,	PUNCT
ajcp-1612	308	3	y.	y.	PROPN
ajcp-1612	308	4	,	,	PUNCT
ajcp-1612	308	5	kuwata	kuwata	PROPN
ajcp-1612	308	6	,	,	PUNCT
ajcp-1612	308	7	h.	h.	PROPN
ajcp-1612	308	8	,	,	PUNCT
ajcp-1612	308	9	&	&	CCONJ
ajcp-1612	308	10	yabe	yabe	PROPN
ajcp-1612	308	11	,	,	PUNCT
ajcp-1612	308	12	d.	d.	PROPN
ajcp-1612	308	13	(	(	PUNCT
ajcp-1612	308	14	2016	2016	NUM
ajcp-1612	308	15	)	)	PUNCT
ajcp-1612	308	16	.	.	PUNCT
ajcp-1612	309	1	incretin‐	incretin‐	PROPN
ajcp-1612	309	2	based	base	VERB
ajcp-1612	309	3	drugs	drug	NOUN
ajcp-1612	309	4	for	for	ADP
ajcp-1612	309	5	type	type	NOUN
ajcp-1612	309	6	2	2	NUM
ajcp-1612	309	7	diabetes	diabetes	NOUN
ajcp-1612	309	8	:	:	PUNCT
ajcp-1612	309	9	focus	focus	VERB
ajcp-1612	309	10	on	on	ADP
ajcp-1612	309	11	east	east	ADJ
ajcp-1612	309	12	asian	asian	ADJ
ajcp-1612	309	13	perspectives	perspective	NOUN
ajcp-1612	309	14	.	.	PUNCT
ajcp-1612	310	1	journal	journal	NOUN
ajcp-1612	310	2	of	of	ADP
ajcp-1612	310	3	diabetes	diabetes	NOUN
ajcp-1612	310	4	investigation	investigation	NOUN
ajcp-1612	310	5	,	,	PUNCT
ajcp-1612	310	6	7	7	NUM
ajcp-1612	310	7	,	,	PUNCT
ajcp-1612	310	8	102	102	NUM
ajcp-1612	310	9	-	-	SYM
ajcp-1612	310	10	109	109	NUM
ajcp-1612	310	11	.	.	PUNCT
ajcp-1612	311	1	shah	shah	PROPN
ajcp-1612	311	2	,	,	PUNCT
ajcp-1612	311	3	v.	v.	ADP
ajcp-1612	311	4	n.	n.	NOUN
ajcp-1612	311	5	,	,	PUNCT
ajcp-1612	311	6	snell	snell	NOUN
ajcp-1612	311	7	-	-	PUNCT
ajcp-1612	311	8	bergeon	bergeon	PROPN
ajcp-1612	311	9	,	,	PUNCT
ajcp-1612	311	10	j.	j.	PROPN
ajcp-1612	311	11	k.	k.	PROPN
ajcp-1612	311	12	,	,	PUNCT
ajcp-1612	311	13	demmitt	demmitt	PROPN
ajcp-1612	311	14	,	,	PUNCT
ajcp-1612	311	15	j.	j.	PROPN
ajcp-1612	311	16	k.	k.	PROPN
ajcp-1612	311	17	,	,	PUNCT
ajcp-1612	311	18	joshee	joshee	PROPN
ajcp-1612	311	19	,	,	PUNCT
ajcp-1612	311	20	p.	p.	NOUN
ajcp-1612	311	21	,	,	PUNCT
ajcp-1612	311	22	garcetti	garcetti	NOUN
ajcp-1612	311	23	,	,	PUNCT
ajcp-1612	311	24	r.	r.	PROPN
ajcp-1612	311	25	,	,	PUNCT
ajcp-1612	311	26	pyle	pyle	PROPN
ajcp-1612	311	27	,	,	PUNCT
ajcp-1612	311	28	l.	l.	PROPN
ajcp-1612	311	29	,	,	PUNCT
ajcp-1612	311	30	&	&	CCONJ
ajcp-1612	311	31	polsky	polsky	PROPN
ajcp-1612	311	32	,	,	PUNCT
ajcp-1612	311	33	s.	s.	PROPN
ajcp-1612	311	34	(	(	PUNCT
ajcp-1612	311	35	2021	2021	NUM
ajcp-1612	311	36	)	)	PUNCT
ajcp-1612	311	37	.	.	PUNCT
ajcp-1612	312	1	relationship	relationship	NOUN
ajcp-1612	312	2	between	between	ADP
ajcp-1612	312	3	time	time	NOUN
ajcp-1612	312	4	-	-	PUNCT
ajcp-1612	312	5	in	in	ADP
ajcp-1612	312	6	-	-	PUNCT
ajcp-1612	312	7	range	range	NOUN
ajcp-1612	312	8	,	,	PUNCT
ajcp-1612	312	9	hba1c	hba1c	PROPN
ajcp-1612	312	10	,	,	PUNCT
ajcp-1612	312	11	and	and	CCONJ
ajcp-1612	312	12	the	the	DET
ajcp-1612	312	13	glucose	glucose	NOUN
ajcp-1612	312	14	management	management	NOUN
ajcp-1612	312	15	indicator	indicator	NOUN
ajcp-1612	312	16	in	in	ADP
ajcp-1612	312	17	pregnancies	pregnancy	NOUN
ajcp-1612	312	18	complicated	complicate	VERB
ajcp-1612	312	19	by	by	ADP
ajcp-1612	312	20	type	type	NOUN
ajcp-1612	312	21	1	1	NUM
ajcp-1612	312	22	diabetes	diabetes	NOUN
ajcp-1612	312	23	.	.	PUNCT
ajcp-1612	313	1	diabetes	diabetes	NOUN
ajcp-1612	313	2	technol	technol	NOUN
ajcp-1612	313	3	ther	ther	ADV
ajcp-1612	313	4	,	,	PUNCT
ajcp-1612	313	5	23(12	23(12	NUM
ajcp-1612	313	6	)	)	PUNCT
ajcp-1612	313	7	,	,	PUNCT
ajcp-1612	313	8	783790	783790	NUM
ajcp-1612	313	9	.	.	PUNCT
ajcp-1612	314	1	https://doi.org/10.1089/dia.2021.0093	https://doi.org/10.1089/dia.2021.0093	PROPN
ajcp-1612	314	2	sutherland	sutherland	PROPN
ajcp-1612	314	3	,	,	PUNCT
ajcp-1612	314	4	d.	d.	PROPN
ajcp-1612	314	5	e.	e.	PROPN
ajcp-1612	314	6	,	,	PUNCT
ajcp-1612	314	7	&	&	CCONJ
ajcp-1612	314	8	gruessner	gruessner	PROPN
ajcp-1612	314	9	,	,	PUNCT
ajcp-1612	314	10	r.	r.	PROPN
ajcp-1612	314	11	w.	w.	PROPN
ajcp-1612	314	12	(	(	PUNCT
ajcp-1612	314	13	2020	2020	NUM
ajcp-1612	314	14	)	)	PUNCT
ajcp-1612	314	15	.	.	PUNCT
ajcp-1612	315	1	history	history	NOUN
ajcp-1612	315	2	of	of	ADP
ajcp-1612	315	3	pancreas	pancreas	NOUN
ajcp-1612	315	4	transplantation	transplantation	NOUN
ajcp-1612	315	5	.	.	PUNCT
ajcp-1612	316	1	in	in	ADP
ajcp-1612	316	2	transplantation	transplantation	NOUN
ajcp-1612	316	3	,	,	PUNCT
ajcp-1612	316	4	bioengineering	bioengineering	NOUN
ajcp-1612	316	5	,	,	PUNCT
ajcp-1612	316	6	and	and	CCONJ
ajcp-1612	316	7	regeneration	regeneration	NOUN
ajcp-1612	316	8	of	of	ADP
ajcp-1612	316	9	the	the	DET
ajcp-1612	316	10	endocrine	endocrine	ADJ
ajcp-1612	316	11	pancreas	pancreas	NOUN
ajcp-1612	316	12	5	5	NUM
ajcp-1612	316	13	-	-	SYM
ajcp-1612	316	14	27	27	NUM
ajcp-1612	316	15	.	.	PUNCT
ajcp-1612	317	1	elsevier	elsevier	NOUN
ajcp-1612	317	2	.	.	PUNCT
ajcp-1612	318	1	tong	tong	PROPN
ajcp-1612	318	2	,	,	PUNCT
ajcp-1612	318	3	l.	l.	PROPN
ajcp-1612	318	4	,	,	PUNCT
ajcp-1612	318	5	&	&	CCONJ
ajcp-1612	318	6	adler	adler	PROPN
ajcp-1612	318	7	,	,	PUNCT
ajcp-1612	318	8	s.	s.	PROPN
ajcp-1612	318	9	g.	g.	PROPN
ajcp-1612	318	10	(	(	PUNCT
ajcp-1612	318	11	2018	2018	NUM
ajcp-1612	318	12	)	)	PUNCT
ajcp-1612	318	13	.	.	PUNCT
ajcp-1612	319	1	diabetic	diabetic	ADJ
ajcp-1612	319	2	kidney	kidney	NOUN
ajcp-1612	319	3	disease	disease	NOUN
ajcp-1612	319	4	.	.	PUNCT
ajcp-1612	320	1	clinical	clinical	ADJ
ajcp-1612	320	2	journal	journal	NOUN
ajcp-1612	320	3	of	of	ADP
ajcp-1612	320	4	the	the	DET
ajcp-1612	320	5	american	american	ADJ
ajcp-1612	320	6	society	society	NOUN
ajcp-1612	320	7	of	of	ADP
ajcp-1612	320	8	nephrology	nephrology	NOUN
ajcp-1612	320	9	,	,	PUNCT
ajcp-1612	320	10	13(2	13(2	PROPN
ajcp-1612	320	11	)	)	PUNCT
ajcp-1612	320	12	,	,	PUNCT
ajcp-1612	320	13	335	335	NUM
ajcp-1612	320	14	-	-	SYM
ajcp-1612	320	15	338	338	NUM
ajcp-1612	320	16	.	.	PUNCT
ajcp-1612	321	1	vigersky	vigersky	ADJ
ajcp-1612	321	2	,	,	PUNCT
ajcp-1612	321	3	r.	r.	PROPN
ajcp-1612	321	4	a.	a.	PROPN
ajcp-1612	321	5	,	,	PUNCT
ajcp-1612	321	6	&	&	CCONJ
ajcp-1612	321	7	mcmahon	mcmahon	PROPN
ajcp-1612	321	8	,	,	PUNCT
ajcp-1612	321	9	c.	c.	PROPN
ajcp-1612	321	10	(	(	PUNCT
ajcp-1612	321	11	2019	2019	NUM
ajcp-1612	321	12	)	)	PUNCT
ajcp-1612	321	13	.	.	PUNCT
ajcp-1612	322	1	the	the	DET
ajcp-1612	322	2	relationship	relationship	NOUN
ajcp-1612	322	3	of	of	ADP
ajcp-1612	322	4	haemoglobin	haemoglobin	PROPN
ajcp-1612	322	5	a1c	a1c	PROPN
ajcp-1612	322	6	to	to	ADP
ajcp-1612	322	7	time	time	NOUN
ajcp-1612	322	8	-	-	PUNCT
ajcp-1612	322	9	in	in	ADP
ajcp-1612	322	10	-	-	PUNCT
ajcp-1612	322	11	range	range	NOUN
ajcp-1612	322	12	in	in	ADP
ajcp-1612	322	13	patients	patient	NOUN
ajcp-1612	322	14	with	with	ADP
ajcp-1612	322	15	diabetes	diabetes	NOUN
ajcp-1612	322	16	.	.	PUNCT
ajcp-1612	323	1	diabetes	diabetes	NOUN
ajcp-1612	323	2	technology	technology	PROPN
ajcp-1612	323	3	&	&	CCONJ
ajcp-1612	323	4	therapeutics	therapeutic	NOUN
ajcp-1612	323	5	,	,	PUNCT
ajcp-1612	323	6	21(2	21(2	NUM
ajcp-1612	323	7	)	)	PUNCT
ajcp-1612	323	8	,	,	PUNCT
ajcp-1612	323	9	81	81	NUM
ajcp-1612	323	10	-	-	SYM
ajcp-1612	323	11	85	85	NUM
ajcp-1612	323	12	.	.	PUNCT
ajcp-1612	324	1	webster	webster	PROPN
ajcp-1612	324	2	,	,	PUNCT
ajcp-1612	324	3	a.	a.	PROPN
ajcp-1612	324	4	c.	c.	PROPN
ajcp-1612	324	5	,	,	PUNCT
ajcp-1612	324	6	nagler	nagler	NOUN
ajcp-1612	324	7	,	,	PUNCT
ajcp-1612	324	8	e.	e.	PROPN
ajcp-1612	324	9	v.	v.	PROPN
ajcp-1612	324	10	,	,	PUNCT
ajcp-1612	324	11	morton	morton	PROPN
ajcp-1612	324	12	,	,	PUNCT
ajcp-1612	324	13	r.	r.	PROPN
ajcp-1612	324	14	l.	l.	PROPN
ajcp-1612	324	15	,	,	PUNCT
ajcp-1612	324	16	&	&	CCONJ
ajcp-1612	324	17	masson	masson	PROPN
ajcp-1612	324	18	,	,	PUNCT
ajcp-1612	324	19	p.	p.	NOUN
ajcp-1612	324	20	(	(	PUNCT
ajcp-1612	324	21	2017	2017	NUM
ajcp-1612	324	22	)	)	PUNCT
ajcp-1612	324	23	.	.	PUNCT
ajcp-1612	325	1	chronic	chronic	ADJ
ajcp-1612	325	2	kidney	kidney	NOUN
ajcp-1612	325	3	disease	disease	NOUN
ajcp-1612	325	4	.	.	PUNCT
ajcp-1612	326	1	the	the	DET
ajcp-1612	326	2	lancet	lancet	PROPN
ajcp-1612	326	3	,	,	PUNCT
ajcp-1612	326	4	389(10075	389(10075	NUM
ajcp-1612	326	5	)	)	PUNCT
ajcp-1612	326	6	,	,	PUNCT
ajcp-1612	326	7	1238	1238	NUM
ajcp-1612	326	8	-	-	SYM
ajcp-1612	326	9	1252	1252	NUM
ajcp-1612	326	10	.	.	PUNCT
ajcp-1612	327	1	williams	williams	PROPN
ajcp-1612	327	2	,	,	PUNCT
ajcp-1612	327	3	j.	j.	PROPN
ajcp-1612	327	4	k.	k.	PROPN
ajcp-1612	327	5	y.	y.	PROPN
ajcp-1612	327	6	(	(	PUNCT
ajcp-1612	327	7	2017	2017	NUM
ajcp-1612	327	8	)	)	PUNCT
ajcp-1612	327	9	.	.	PUNCT
ajcp-1612	328	1	management	management	NOUN
ajcp-1612	328	2	strategies	strategy	NOUN
ajcp-1612	328	3	for	for	ADP
ajcp-1612	328	4	diabetic	diabetic	ADJ
ajcp-1612	328	5	kidney	kidney	NOUN
ajcp-1612	328	6	disease	disease	NOUN
ajcp-1612	328	7	and	and	CCONJ
ajcp-1612	328	8	chronic	chronic	ADJ
ajcp-1612	328	9	kidney	kidney	NOUN
ajcp-1612	328	10	disease	disease	NOUN
ajcp-1612	328	11	in	in	ADP
ajcp-1612	328	12	diabetes	diabetes	NOUN
ajcp-1612	328	13	.	.	PUNCT
ajcp-1612	329	1	nursing	nursing	NOUN
ajcp-1612	329	2	clinics	clinic	NOUN
ajcp-1612	329	3	,	,	PUNCT
ajcp-1612	329	4	52(4	52(4	NUM
ajcp-1612	329	5	)	)	PUNCT
ajcp-1612	329	6	,	,	PUNCT
ajcp-1612	329	7	575	575	NUM
ajcp-1612	329	8	-	-	SYM
ajcp-1612	329	9	587	587	NUM
ajcp-1612	329	10	.	.	PUNCT
ajcp-1612	330	1	winocour	winocour	ADJ
ajcp-1612	330	2	,	,	PUNCT
ajcp-1612	330	3	p.	p.	NOUN
ajcp-1612	330	4	(	(	PUNCT
ajcp-1612	330	5	2018	2018	NUM
ajcp-1612	330	6	)	)	PUNCT
ajcp-1612	330	7	.	.	PUNCT
ajcp-1612	331	1	diabetes	diabetes	NOUN
ajcp-1612	331	2	and	and	CCONJ
ajcp-1612	331	3	chronic	chronic	ADJ
ajcp-1612	331	4	kidney	kidney	NOUN
ajcp-1612	331	5	disease	disease	NOUN
ajcp-1612	331	6	:	:	PUNCT
ajcp-1612	331	7	an	an	DET
ajcp-1612	331	8	increasingly	increasingly	ADV
ajcp-1612	331	9	common	common	ADJ
ajcp-1612	331	10	multi‐morbid	multi‐morbid	NOUN
ajcp-1612	331	11	disease	disease	NOUN
ajcp-1612	331	12	needing	need	VERB
ajcp-1612	331	13	a	a	DET
ajcp-1612	331	14	paradigm	paradigm	NOUN
ajcp-1612	331	15	shift	shift	NOUN
ajcp-1612	331	16	in	in	ADP
ajcp-1612	331	17	care	care	NOUN
ajcp-1612	331	18	.	.	PUNCT
ajcp-1612	332	1	diabetic	diabetic	ADJ
ajcp-1612	332	2	medicine	medicine	NOUN
ajcp-1612	332	3	,	,	PUNCT
ajcp-1612	332	4	35(3	35(3	NUM
ajcp-1612	332	5	)	)	PUNCT
ajcp-1612	332	6	,	,	PUNCT
ajcp-1612	332	7	300	300	NUM
ajcp-1612	332	8	-	-	SYM
ajcp-1612	332	9	305	305	NUM
ajcp-1612	332	10	.	.	PUNCT
ajcp-1612	333	1	wright	wright	PROPN
ajcp-1612	333	2	,	,	PUNCT
ajcp-1612	333	3	e.	e.	PROPN
ajcp-1612	333	4	e.	e.	PROPN
ajcp-1612	333	5	,	,	PUNCT
ajcp-1612	333	6	jr	jr	PROPN
ajcp-1612	333	7	.	.	PROPN
ajcp-1612	333	8	,	,	PUNCT
ajcp-1612	333	9	morgan	morgan	PROPN
ajcp-1612	333	10	,	,	PUNCT
ajcp-1612	333	11	k.	k.	PROPN
ajcp-1612	333	12	,	,	PUNCT
ajcp-1612	333	13	fu	fu	PROPN
ajcp-1612	333	14	,	,	PUNCT
ajcp-1612	333	15	d.	d.	PROPN
ajcp-1612	333	16	k.	k.	PROPN
ajcp-1612	333	17	,	,	PUNCT
ajcp-1612	333	18	wilkins	wilkins	PROPN
ajcp-1612	333	19	,	,	PUNCT
ajcp-1612	333	20	n.	n.	NOUN
ajcp-1612	333	21	,	,	PUNCT
ajcp-1612	333	22	&	&	CCONJ
ajcp-1612	333	23	guffey	guffey	PROPN
ajcp-1612	333	24	,	,	PUNCT
ajcp-1612	333	25	w.	w.	PROPN
ajcp-1612	333	26	j.	j.	PROPN
ajcp-1612	333	27	(	(	PUNCT
ajcp-1612	333	28	2020	2020	NUM
ajcp-1612	333	29	)	)	PUNCT
ajcp-1612	333	30	.	.	PUNCT
ajcp-1612	334	1	time	time	NOUN
ajcp-1612	334	2	in	in	ADP
ajcp-1612	334	3	range	range	NOUN
ajcp-1612	334	4	:	:	PUNCT
ajcp-1612	334	5	how	how	SCONJ
ajcp-1612	334	6	to	to	PART
ajcp-1612	334	7	measure	measure	VERB
ajcp-1612	334	8	it	it	PRON
ajcp-1612	334	9	,	,	PUNCT
ajcp-1612	334	10	how	how	SCONJ
ajcp-1612	334	11	to	to	PART
ajcp-1612	334	12	report	report	VERB
ajcp-1612	334	13	it	it	PRON
ajcp-1612	334	14	,	,	PUNCT
ajcp-1612	334	15	and	and	CCONJ
ajcp-1612	334	16	its	its	PRON
ajcp-1612	334	17	practical	practical	ADJ
ajcp-1612	334	18	application	application	NOUN
ajcp-1612	334	19	in	in	ADP
ajcp-1612	334	20	clinical	clinical	ADJ
ajcp-1612	334	21	decision	decision	NOUN
ajcp-1612	334	22	-	-	PUNCT
ajcp-1612	334	23	making	making	NOUN
ajcp-1612	334	24	.	.	PUNCT
ajcp-1612	335	1	clin	clin	PROPN
ajcp-1612	335	2	diabetes	diabetes	PROPN
ajcp-1612	335	3	,	,	PUNCT
ajcp-1612	335	4	38(5	38(5	NUM
ajcp-1612	335	5	)	)	PUNCT
ajcp-1612	335	6	,	,	PUNCT
ajcp-1612	335	7	439448	439448	NUM
ajcp-1612	335	8	.	.	PUNCT
ajcp-1612	336	1	https://doi.org/10.2337/cd20-0042	https://doi.org/10.2337/cd20-0042	PROPN
ajcp-1612	336	2	yoo	yoo	PROPN
ajcp-1612	336	3	,	,	PUNCT
ajcp-1612	336	4	j.	j.	PROPN
ajcp-1612	336	5	h.	h.	PROPN
ajcp-1612	336	6	,	,	PUNCT
ajcp-1612	336	7	&	&	CCONJ
ajcp-1612	336	8	kim	kim	PROPN
ajcp-1612	336	9	,	,	PUNCT
ajcp-1612	336	10	j.	j.	PROPN
ajcp-1612	336	11	h.	h.	PROPN
ajcp-1612	336	12	(	(	PUNCT
ajcp-1612	336	13	2020	2020	NUM
ajcp-1612	336	14	)	)	PUNCT
ajcp-1612	336	15	.	.	PUNCT
ajcp-1612	337	1	time	time	NOUN
ajcp-1612	337	2	in	in	ADP
ajcp-1612	337	3	the	the	DET
ajcp-1612	337	4	range	range	NOUN
ajcp-1612	337	5	from	from	ADP
ajcp-1612	337	6	continuous	continuous	ADJ
ajcp-1612	337	7	glucose	glucose	NOUN
ajcp-1612	337	8	monitoring	monitoring	NOUN
ajcp-1612	337	9	:	:	PUNCT
ajcp-1612	337	10	a	a	DET
ajcp-1612	337	11	novel	novel	ADJ
ajcp-1612	337	12	metric	metric	NOUN
ajcp-1612	337	13	for	for	ADP
ajcp-1612	337	14	glycemic	glycemic	ADJ
ajcp-1612	337	15	control	control	NOUN
ajcp-1612	337	16	.	.	PUNCT
ajcp-1612	338	1	diabetes	diabetes	NOUN
ajcp-1612	338	2	&	&	CCONJ
ajcp-1612	338	3	metabolism	metabolism	NOUN
ajcp-1612	338	4	journal	journal	NOUN
ajcp-1612	338	5	,	,	PUNCT
ajcp-1612	338	6	44(6	44(6	PROPN
ajcp-1612	338	7	)	)	PUNCT
ajcp-1612	338	8	,	,	PUNCT
ajcp-1612	338	9	828	828	NUM
ajcp-1612	338	10	-	-	SYM
ajcp-1612	338	11	839	839	NUM
ajcp-1612	338	12	.	.	PUNCT
ajcp-1612	339	1	yu	yu	PROPN
ajcp-1612	339	2	,	,	PUNCT
ajcp-1612	339	3	e.	e.	PROPN
ajcp-1612	339	4	s.	s.	PROPN
ajcp-1612	339	5	,	,	PUNCT
ajcp-1612	339	6	hong	hong	PROPN
ajcp-1612	339	7	,	,	PUNCT
ajcp-1612	339	8	k.	k.	PROPN
ajcp-1612	339	9	,	,	PUNCT
ajcp-1612	339	10	&	&	CCONJ
ajcp-1612	339	11	chun	chun	PROPN
ajcp-1612	339	12	,	,	PUNCT
ajcp-1612	339	13	b.	b.	PROPN
ajcp-1612	339	14	c.	c.	PROPN
ajcp-1612	339	15	(	(	PUNCT
ajcp-1612	339	16	2020	2020	NUM
ajcp-1612	339	17	)	)	PUNCT
ajcp-1612	339	18	.	.	PUNCT
ajcp-1612	340	1	incidence	incidence	NOUN
ajcp-1612	340	2	and	and	CCONJ
ajcp-1612	340	3	risk	risk	NOUN
ajcp-1612	340	4	factors	factor	NOUN
ajcp-1612	340	5	of	of	ADP
ajcp-1612	340	6	vascular	vascular	ADJ
ajcp-1612	340	7	complications	complication	NOUN
ajcp-1612	340	8	in	in	ADP
ajcp-1612	340	9	people	people	NOUN
ajcp-1612	340	10	with	with	ADP
ajcp-1612	340	11	impaired	impaired	ADJ
ajcp-1612	340	12	fasting	fasting	NOUN
ajcp-1612	340	13	glucose	glucose	NOUN
ajcp-1612	340	14	:	:	PUNCT
ajcp-1612	340	15	a	a	DET
ajcp-1612	340	16	national	national	ADJ
ajcp-1612	340	17	cohort	cohort	NOUN
ajcp-1612	340	18	study	study	NOUN
ajcp-1612	340	19	in	in	ADP
ajcp-1612	340	20	korea	korea	PROPN
ajcp-1612	340	21	.	.	PUNCT
ajcp-1612	341	1	scientific	scientific	ADJ
ajcp-1612	341	2	reports	report	NOUN
ajcp-1612	341	3	,	,	PUNCT
ajcp-1612	341	4	10(1	10(1	NUM
ajcp-1612	341	5	)	)	PUNCT
ajcp-1612	341	6	,	,	PUNCT
ajcp-1612	341	7	19504	19504	NUM
ajcp-1612	341	8	.	.	PUNCT
ajcp-1612	342	1	https://doi	https://doi	X
ajcp-1612	342	2	.	.	PUNCT
ajcp-1612	343	1	org/10.1038	org/10.1038	PROPN
ajcp-1612	343	2	/	/	SYM
ajcp-1612	343	3	s41598	s41598	PROPN
ajcp-1612	343	4	-	-	PUNCT
ajcp-1612	343	5	020	020	NUM
ajcp-1612	343	6	-	-	PUNCT
ajcp-1612	343	7	76661	76661	NUM
ajcp-1612	343	8	-	-	SYM
ajcp-1612	343	9	7	7	NUM
ajcp-1612	343	10	https://journals.e-palli.com/home/index.php/ajcp	https://journals.e-palli.com/home/index.php/ajcp	PROPN